Stability of drugs and pesticides of forensic toxicological interest and their metabolites in biological samples by Alfazil, Abdulkareem  Abdulwahab
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Alfazil, Abdulkareem Abdulwahab (2009) Stability of drugs and 
pesticides of forensic toxicological interest and their metabolites in 
biological samples. PhD thesis 
 
http://theses.gla.ac.uk/1309/ 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given. 
 
  
                             
 
 
 
 
 
 
STABILITY OF DRUGS AND PESTICIDES OF FORENSIC 
TOXICOLOGICAL INTEREST AND THEIR METABOLITES 
IN BIOLOGICAL SAMPLES 
 
 
Thesis submitted in Accordance with Requirements of the University 
of Glasgow for the Degree of Doctor of Philosophy 
by 
Abdulkareem Abdulwahab Alfazil 
    
 
Department of Forensic Medicine and Science 
May 2009 
 
© Abdulkareem A. Alfazil
 ii 
Acknowledgement 
Initially I would like to thank Almighty God for helping and guiding me 
throughout my life and specifically for accomplishing this thesis. 
A special thanks to Dr Robert Anderson for his support and guidance throughout 
this research. 
Many thanks to Dr Hazel Torrance and Dr Fiona Wiely for their help and advice 
during my study. 
I would also like to thank all of staff and students in department of forensic 
medicine and science for the good study environment they provided. 
A massive thanks to my parents, my brothers and my sisters for their 
encouragement and support. 
Finally I would like to thank my government, particularly ministry of interior for 
supporting me financially and sponsorship my PhD study. 
 
 
 iii 
Table of Contents 
 
Acknowledgement......................................................................... ii 
List of Tables ............................................................................. viii 
List of Figures .............................................................................xii 
Summary .................................................................................. xiv 
Abbreviations............................................................................ xvii 
1 Introduction ........................................................................... 1 
1.1.1 Toxicology................................................................... 1 
1.1.2. Forensic toxicology: an introduction.......................................... 2 
1.1.2.1. Post-mortem forensic toxicology............................................ 2 
1.1.2.2. Human performance toxicology ............................................. 3 
1.1.2.3. Forensic drug testing ......................................................... 4 
1.2 Drugs and poisons – trends ..................................................... 4 
1.3 Pharmacology .................................................................... 7 
1.3.1 Pharmacodynamics......................................................... 7 
1.3.2 Pharmacokinetics .......................................................... 8 
1.4. Samples used.................................................................... 12 
1.5 Forensic toxicology problems .................................................... 14 
1.6 Aims .............................................................................. 15 
2 Stability of Drugs and Poisons: Literature Review............................16 
2.1 Introduction ..................................................................... 16 
2.2 Drugs.............................................................................. 17 
2.3 Pesticides ........................................................................ 25 
2.3.1 Organophosphates......................................................... 25 
2.4 Stabilisation of samples........................................................ 26 
2.4.1 Additives.................................................................... 26 
2.4.2 Filter paper ................................................................ 28 
2.4.3 Freezing .................................................................... 29 
2.4.4 Acidification ............................................................... 29 
2.4.5 Antioxidants................................................................ 30 
3 General Experimental Procedures Used in this Project .....................46 
3.1 Extraction........................................................................ 46 
3.1.1 Solid phase extraction.................................................... 46 
3.2 Derivatization ................................................................... 49 
 iv 
3.2.1 Silylation.................................................................... 49 
3.3 Gas Chromatography/Mass Spectrometry (GC/MS) ........................ 51 
3.4 Liquid chromatography - tandem mass spectrometry (LC/MS/MS)...... 53 
3.5 Method validation .............................................................. 55 
3.5.1 Linearity .................................................................... 55 
3.5.2 Limit of Detection and Lower Limit of Quantitation................. 55 
3.5.3 Recovery.................................................................... 56 
3.5.4 Precision.................................................................... 56 
3.6 Statistical evaluation of stability of substances during storage ......... 57 
4 Stability of Benzodiazepines in Whole Blood under Different Storage 
Conditions..................................................................................58 
4.1 Introduction ..................................................................... 58 
4.2 Benzodiazepines included in the present study............................ 59 
4.3 Aims .............................................................................. 60 
4.4 Experimental Section .......................................................... 61 
4.4.1 Chemical and material: .................................................. 61 
4.4.2 Solutions: ................................................................... 61 
4.4.3 Preparation of blood samples: .......................................... 62 
4.4.4 Sample storage and time for analysis .................................. 63 
4.4.5 Analytical method......................................................... 64 
4.5 Results............................................................................ 68 
4.5.1 Validation results.......................................................... 68 
4.5.2 Stability results ............................................................ 70 
4.5.3 Summary of benzodiazepine stability in blood samples ............. 86 
4.6 Discussion ........................................................................ 87 
4.7 Conclusions ...................................................................... 90 
5 Stability of Opiate Glucuronides in Blood and Urine .........................91 
5.1 Introduction ..................................................................... 91 
5.2 Aims .............................................................................. 95 
5.3 Experimental Section .......................................................... 95 
5.3.1 Chemical and material: .................................................. 95 
5.3.2 Solutions: ................................................................... 95 
5.3.3 Preparation of blood and urine samples: .............................. 96 
5.3.4 Sample storage and times of analysis .................................. 97 
5.3.5 Analysis ..................................................................... 98 
5.3.6 Instrumentation ........................................................... 98 
 v 
5.4 Stability results ................................................................100 
5.4.1 Stability of M3G in blood and urine....................................100 
5.4.2 Stability of M6G in blood and urine....................................103 
5.4.3 Stability of C6G in blood and urine ....................................106 
5.4.4 Summary of M3G, M6G, and C6G stability in blood and urine 
samples.. .............................................................................109 
5.5 Discussion .......................................................................110 
5.6 Conclusion ......................................................................113 
6 Stability of Cocaine and Benzodiazepines in Dried Blood Spots ......... 114 
6.1 Introduction ....................................................................114 
6.2 Experimental Section .........................................................118 
6.2.1 Chemical and material: .................................................118 
6.2.2 Solutions: ..................................................................118 
6.2.3 Preparation of DBS samples:............................................119 
6.2.4 Extraction procedure ....................................................120 
6.2.5 Instrumentation ..........................................................123 
Internal standards .....................................................................124 
6.3 Validation of analytical method .............................................125 
6.4 Results...........................................................................125 
6.4.1 Method validation results ...............................................125 
6.4.2 Stability results ...........................................................128 
6.5 Discussion .......................................................................137 
6.6 Conclusion ......................................................................141 
7 Correction for Loss of Benzodiazepines During Storage................... 142 
7.1 Introduction: degradation of drugs .........................................142 
7.2 Experimental Section .........................................................145 
7.2.1 Chemicals and Materials ................................................145 
7.2.1 Solutions ...................................................................145 
7.3 Optimisation of Analytical Method for Diazepam, Temazepam, and 
MACB.....................................................................................147 
7.3.1 Optimization of Mobile Phase ..........................................147 
7.3.2 Optimisation of Extraction Method ....................................150 
7.3.3 Validation of Analytical Method........................................155 
7.4 Validation Results .............................................................156 
7.4.1 Validation Results in Blood .............................................156 
7.4.2 Validation Results in Urine..............................................158 
 vi 
7.5 Degradation Study: Diazepam and Temazepam...........................160 
7.5.1 Introduction...............................................................160 
7.5.2 Stability Study in Blood and Urine .....................................160 
7.5.3 Extraction Procedure ....................................................160 
7.5.4 Instrumentation ..........................................................161 
7.5.5 Results of Diazepam and Temazepam Degradation .................162 
7.6 Degradation Study: Chlordiazepoxide and Oxazepam....................168 
7.6.1 Introduction...............................................................168 
7.6.2 Stability Study in Blood and Urine .....................................168 
7.6.3 Analytical method........................................................168 
7.6.4 Results of Chlordiazepoxide and Oxazepam Degradation Study...170 
7.7 Further Degradation of MACB to ACB and AB..............................176 
7.7.1 Stability Study in Blood..................................................176 
7.7.2 Results of MACB Degradation ...........................................177 
7.8 Effect of Cosmetics on Benzodiazepine Degradation.....................178 
7.8.1 Introduction...............................................................178 
7.8.2 Chemicals and Materials ................................................180 
7.8.3 Experimental section ....................................................180 
7.8.4 Results .....................................................................181 
7.9 Case Samples ...................................................................184 
7.9.1 In Blood ....................................................................184 
7.9.2 In Urine ....................................................................185 
7.10 Summary of benzodiazepines degradation in blood and urine under 
different storage conditions..........................................................186 
7.11 Discussion and Conclusions...................................................187 
8 Stability of Organophosphorus Pesticides During Storage in Preserved 
Blood and Dried Blood Spots ......................................................... 194 
8.1 Introduction ....................................................................194 
8.2 Experimental section..........................................................197 
8.2.1 Chemicals and materials ................................................197 
8.2.2 Solutions ...................................................................198 
8.2.3 Instrumentation (GC-MS) ................................................198 
8.2.4 Identification of retention times and fragmentation ...............199 
8.2.5 Optimisation of derivatisation..........................................200 
8.2.6 Optimisation of extraction method....................................203 
8.2.7 Method validation ........................................................207 
 vii 
8.2.8 Stability study ............................................................210 
8.3 Results...........................................................................211 
8.3.1 Dichlorvos .................................................................211 
8.3.2 Chlorpyrifos ...............................................................213 
8.3.3 Diazinon ...................................................................215 
8.3.4 Parathion ..................................................................217 
8.3.5 Paraoxon...................................................................219 
8.3.6 Summary of pesticides stability using different preservative 
methods. .............................................................................221 
8.4 Discussion .......................................................................222 
8.5 Conclusions .....................................................................225 
9 Conclusions and Future Work................................................... 226 
10 References ......................................................................... 230 
11 Appendices: ........................................................................ 257 
11.1 Conference Papers and Journal Publication in Support of this Thesis. 257 
12 Specimen Chromatograms....................................................... 262 
 viii 
List of Tables 
Table  2-1: Summary of drugs and pesticides stability ............................... 31 
Table  4-1: Validation of analytical method............................................ 64 
Table  4-2: Optimum tuning parameters................................................ 67 
Table  4-3 : Linearity, LOD, and LLOQ of drugs in 1 ml of blood.................... 68 
Table  4-4: Mean recoveries of analytes. ............................................... 69 
Table  4-5: Interday and intraday precision results. .................................. 69 
Table  4-6: Stability of alprazolam 50 ng/ml under different storage conditions.71 
Table  4-7: Stability of alprazolam 400 ng/ml under different storage conditions.
............................................................................................... 72 
Table  4-8: Stability of lorazepam 50 ng/ml under different storage conditions. 75 
Table  4-9: Stability of lorazepam 400 ng/ml under different storage conditions.
............................................................................................... 76 
Table  4-10: Stability of oxazepam 50 ng/ml under different conditions.......... 79 
Table  4-11: Stability of oxazepam 400 ng/ml under different storage conditions.
............................................................................................... 80 
Table  4-12: Stability of estazolam 50 ng/ml  under different storage conditions.
............................................................................................... 83 
Table  4-13: Stability of estazolam 400 ng/ml under different storage conditions.
............................................................................................... 84 
Table  4-14: Summary of benzodiazepine stability in blood under varied storage 
conditions................................................................................... 86 
Table  5-1: Optimum tuning parameters................................................ 99 
Table  5-2: M3G stability in blood at 100 ng/ml ......................................101 
Table  5-3: M3G stability in urine at 100 ng/ml ......................................102 
Table  5-4: M6G stability in blood at 100 ng/ml ......................................104 
Table  5-5: M6G stability in urine at 100 ng/ml ......................................105 
Table  5-6: C6G stability in blood at 100 ng/ml ......................................107 
Table  5-7: C6G stability in urine at 100 ng/ml.......................................108 
Table  5-8: Summary of stability of M3G, M6G, and C6G in blood and urine 
samples for 1 year under different storage conditions .............................109 
Table  6-1: Recovery of (50 ng/spot) drugs from DBS using three different 
solvents and buffer:......................................................................121 
Table  6-2: Optimum tuning parameters...............................................124 
Table  6-3: Linear correlation coefficients, LODs and LLOQs of drugs in DBS....125 
 ix 
Table  6-4: Recoveries of analytes from DBSs.........................................126 
Table  6-5: Inter-day and intra-day precision results. ...............................127 
Table  6-6: Stability of cocaine in dried blood spots stored in filter paper ......129 
Table  6-7: Stability of flunitrazepam in dried blood spots stored in filter paper.
..............................................................................................130 
Table  6-8: Stability of temazepam in dried blood spots stored in filter paper..131 
Table  6-9: Stability of oxazepam in dried blood spots stored in filter paper....132 
Table  6-10: Stability of lorazepam in dried blood spots stored in filter paper..133 
Table  6-11: Stability of nitrazepam in dried blood spots stored in filter paper 134 
Table  6-12: Stability of diazepam in dried blood spots stored in filter paper...135 
Table  6-13: Summary of the stability of cocaine and benzodiazepines in DBS 
stored under different storage conditions for 1 year ...............................136 
Table  6-14: Comparison of stability of lorazepam and oxazepam in liquid blood 
and DBS for 1 year under different storage temperatures .........................140 
Table  7-1: Optimum tuning parameters for diazepam, temazepam and MACB. 147 
Table  7-2: Comparison of effect of 5mM ammonium acetate and 3mM ammonium 
formate on analyte response. ..........................................................148 
Table  7-3: Effect of formic acid on analyte response...............................149 
Table  7-4: SPE method for extraction of benzodiazepines from blood...........150 
Table  7-5: Average recoveries (%) of diazepam, temazepam, and MACB using SPE 
procedure..................................................................................151 
Table  7-6: Average recoveries (%) of diazepam, temazepam, and MACB after 
modifying washing step..................................................................152 
Table  7-7 : Average recoveries (%) of diazepam, temazepam, and MACB using 
buffers of different pH. .................................................................154 
Table  7-8: Average recoveries (%) of diazepam, temazepam, and MACB using 
different elution solvents ...............................................................155 
Table  7-9: Linearcorrelation coefficients, LODs, and LLOQs of drugs in blood .156 
Table  7-10: Recoveries of analytes from blood ......................................157 
 7-11: Interday and intraday precision results in blood..............................157 
Table  7-12: Linearity, LOD and LLOQ of drugs in urine.............................158 
Table  7-13: Recovery of analytes from urine.........................................158 
 7-14: Interday and intraday precision results in urine ..............................159 
Table  7-15: SPE extraction procedure.................................................161 
Table  7-16: Optimum tuning parameter for chlordiazepoxide, oxazepam and ACB
..............................................................................................169 
 x 
Table  7-17: Optimum tuning parameter for 2-aminobenzophenone (AB). .......176 
Table  7-18: Decomposition of diazepam by cosmetic materials ..................181 
Table  7-19: Decomposition of temazepam by cosmetic materials ................182 
Table  7-20: Decomposition of chlordiazepoxide by cosmetic materials .........182 
Table  7-21: Decomposition of oxazepam by cosmetic materials ..................183 
Table  7-22: Benzodiazepines and their degradation products in blood case 
samples ....................................................................................184 
Table  7-23: Benzodiazepines and their degradation products in urine case 
samples (not matched to the blood samples in Table 7-22) .......................185 
Table  7-24: Summary of degradation of diazepam, temazepam, chlodiazepoxide, 
and oxazepam in blood and urine samples under different storage conditions .186 
Table  8-1: Retention times and fragment ions of OPs, DAPs and internal 
standards. .................................................................................199 
Table  8-2: Relative peak areas for OPs, DAPs and IS at different reagent 
compositions*. ............................................................................201 
Table  8-3: Peak area at different incubation times.................................202 
Table  8-4: Procedures for three extraction methods used for comparison ......203 
Table  8-5: Mean recoveries for analytes, using three different methods........204 
Table  8-6: Average recoveries obtained for OPs and DAPs using different elution 
solvents ....................................................................................205 
Table  8-7: Optimised extraction and derivatisation method for OPs and DAPs. 206 
Table  8-8: Linear correlation coefficients, LODs and LLOQs of DAPs and OPs in 
blood. ......................................................................................207 
Table  8-9: Recoveries of DAPs and OPs. ..............................................208 
Table  8-10: Intraday and interday precision results.................................209 
Table  8-11: Stability of dichlorvos in blood samples preserved with 2% (w/v) NaF
..............................................................................................211 
Table  8-12: Stability of dichlorvos in dried blood spots stored on filter paper .212 
Table  8-13: Stability of chlorpyrifos in blood samples preserved with 2% (w/v) 
NaF. ........................................................................................213 
Table  8-14: Stability of chlorpyrifos in dried blood spots stored on filter paper.
..............................................................................................214 
Table  8-15: Stability of diazinon in blood samples preserved with 2% (w/v) NaF.
..............................................................................................215 
Table  8-16: Stability of diazinon in dried blood spots stored on filter paper ...216 
Table  8-17: Stability of parathion in blood samples stored with 2% (w/v) NaF. 217 
 xi 
Table  8-18: Stability of parathion in dried blood spots stored on filter paper. .218 
Table  8-19: Stability of paraoxon in blood sample preserved with 2% (w/v) NaF.
..............................................................................................219 
Table  8-20: Stability of paraoxon in dried blood spot stored on filter paper. ..220 
Table  8-21: Summary of pesticides stability in DBS or using 2% (W/V) NAF .....221 
 
 xii 
List of Figures 
Figure  1-1: Ebers papyrus ................................................................. 1 
Figure  1-3: Phase I reactions ............................................................ 10 
Figure  1-4: Phase II reactions............................................................ 11 
Figure  4-1: Chemical structures of benzodiazepines included in this study. ..... 60 
Figure  4-2: Prepared samples were stored under different conditions............ 63 
Figure  4-3: Stability of unpreserved alprazolam at varying storage temperature. 
LC: Low concentration, HC: High concentration and RT: Room temperature.... 73 
Figure  4-4: Stability of preserved alprazolam at varying storage temperature. LC: 
Low concentration, HC: High concentration and RT: Room temperature......... 73 
Figure  4-5: Stability of unpreserved lorazepam at varying storage temperature. 
LC: Low concentration, HC: High concentration and RT: Room temperature.... 77 
Figure  4-6: Stability of preserved lorazepam at varying storage temperature. LC: 
Low concentration, HC: High concentration and RT: Room temperature......... 77 
Figure  4-7: Stability of unpreserved oxazepam at varying storage temperature. 
LC: Low concentration, HC: High concentration and RT: Room temperature.... 81 
Figure  4-8: Stability of preserved oxazepam at varying storage temperature. LC: 
Low concentration, HC: High concentration and RT: Room temperature......... 81 
Figure  4-9: Stability of unpreserved estazolam at varying storage temperature. 
LC: Low concentration, HC: High concentration and RT: Room temperature.... 85 
Figure  4-10: Stability of preserved estazolam at varying storage temperature. 
LC: Low concentration, HC: High concentration and RT: Room temperature.... 85 
Figure  5-1: Chemical structures of morphine and codeine and their glucuronide 
metabolites................................................................................. 94 
Figure  6-1: Chemical structure of cocaine............................................116 
Figure  6-2: Chemical structures of benzodiazepines used in this study..........117 
Figure  6-3: 100µl aliquots of spiked blood were spotted on sheets of paper 903® 
to produce 100 spots in total. ..........................................................120 
Figure  6-4: Stability of benzodiazepines and cocaine in DBS for one year. Initial 
concentrations were 100 ng/spot. .....................................................139 
Figure  7-1: Analysis of cyclohexane wash by LC-MS/MS ............................153 
Figure  7-2: Degradation of diazepam in blood at 80 °C.............................163 
Figure  7-3: Degradation of diazepam in blood at pH 2 .............................163 
Figure  7-4: Degradation of diazepam in blood at pH 12 ............................163 
Figure  7-5: Degradation of diazepam in urine at 80 °C .............................164 
 xiii 
Figure  7-6: Degradation of diazepam in urine at pH 2 ..............................164 
Figure  7-7: Degradation of diazepam in urine at pH 12 ............................164 
Figure  7-8: Degradation of temazepam in blood at 80 °C ..........................166 
Figure  7-9: Degradation of temazepam in blood at pH 2 ...........................166 
Figure  7-10: Degradation of temazepam in blood at pH 12 ........................166 
Figure  7-11: Degradation of temazepam in urine at 80 °C .........................167 
Figure  7-12: Degradation of temazepam in urine at pH 2 ..........................167 
Figure  7-13: Degradation of temazepam in urine at pH 12.........................167 
Figure  7-14: Degradation of chlordiazepoxide in blood at 80 °C ..................171 
Figure  7-15: Degradation of chlordiazepoxide in blood at pH 2 ...................171 
Figure  7-16: Degradation of chlordiazepoxide in blood at pH 12..................171 
Figure  7-17: Degradation of chlordiazepoxide in urine at 80 °C...................172 
Figure  7-18: Degradation of chlordiazepoxide in urine at pH 2 ...................172 
Figure  7-19: Degradation of chlordiazepoxide in urine at pH 12 ..................172 
Figure  7-20: Degradation of oxazepam in blood at 80 °C...........................174 
Figure  7-21: Degradation of oxazepam in blood at pH 2 ...........................174 
Figure  7-22: Degradation of oxazepam in blood at pH 12 ..........................174 
Figure  7-23: Degradation of oxazepam in urine at 80 °C ...........................175 
Figure  7-24: Degradation of oxazepam in urine at pH 2 ............................175 
Figure  7-25: Degradation of oxazepam in urine at pH 12...........................175 
Figure  7-26: Degradation of MACB in blood at 80 °C ................................177 
Figure  7-27: Hydrolysis of diazepam and temazepam ..............................190 
Figure  7-28: Hydrolysis of oxazepam ..................................................190 
Figure  7-29: Hydrolysis of chlordiazepoxide..........................................191 
Figure  8-1: Chemical structures of organophosphates (OPs).......................196 
Figure  8-2: Chemical structures of dialkylphosphates (DAPs)......................197 
 
 
 
 
 
 
 
 
 xiv 
Summary 
Loss of analyte from biological samples during the post-mortem interval or 
during storage has potentially serious implications in forensic toxicology and 
represents a challenge for the forensic toxicologist, especially in the 
interpretation of case results. The initial aim of the studies in this thesis was to 
evaluate the stability of some important drugs and compounds in blood under 
different storage conditions in order to optimize the preservation of these 
compounds. A second aim was to evaluate a new method of stabilizing these 
compounds in blood by storing them as dried blood spots on filter paper. The 
third aim was to investigate methods by which corrections could be made for 
analyte losses based on quantification of their degradation products, which 
would serve as markers of the former presence of the compounds even if they 
were no longer detectable. 
The background to toxicology and its classification systems is reviewed along 
with the most common areas of application, including forensic toxicology. 
Details are given of the most commonly-used matrices and of current problems 
facing forensic toxicologists, particularly the problem of analyte instability. The 
literature concerning stability of drugs and pesticides in biological samples are 
reviewed and discussed as well as methods applied to enhance and stabilize 
analytes for long storage periods. Background is provided on methodologies used 
in the work reported in this thesis, including extraction techniques and 
instrumental analysis by LC-MS/MS and GC/MS. Also, because of its importance 
in forensic toxicology at present validation procedures and requirements are also 
discussed.  
An initial study was made of drug stability during storage in blood samples for 1 
year under conventional laboratory conditions using selected drugs from the 
benzodiazepine group, alprazolam, lorazepam, oxazepam and estazolam. Blank 
blood containing these drugs at low and high concentrations was stored in tubes 
at -20° C, 4°C and room temperature. Half of the tubes contained fluoride-
oxalate preservative. Blood samples were analysed on the first (day zero), 
second and fourth days, and after one week, two weeks, one month, two 
months, three months, six months and one year using a method which was 
developed and validated for this study based on solid phase extraction (SPE) and 
 xv 
liquid chromatography-tandem mass spectrometry (LC-MS/MS).  Alprazolam and 
estazolam were stable at -20° C and 4° C, but decreased by almost 10% at room 
temperature (RT) at both concentrations. Lorazepam and oxazepam were stable 
at -20°C but were poorly stable at 4° C and decreased by 100% at RT by the end 
of the 1 year period. Sodium fluoride stabilised the drugs by approximately 13% 
compared to unpreserved samples. The long-term stability of alprazolam and 
estazolam is attributed to the presence of the trizolo ring in their structures 
which makes the compounds more resistant to hydrolysis, the most prominent 
degradation reaction affecting benzodiazepines. 
 
A similar study was performed on the stability of morphine-3- and 6-glucuronide 
and codeine-6-glucuronide in blood and urine under the same storage conditions. 
These compounds were stable at -20° C, losing less than 7% but losses were 
higher at 4° C, up to 18% in blood and 28% in urine, and at room temperature up 
to 54% in blood and 78% in urine after 1 year. Sodium fluoride did not have a 
significant effect (<10% increase in stability). 
 
An investigation was carried out on stabilisation of hydrolytically-labile 
benzodiazepines and cocaine in blood during storage as dried blood spots (DBS) 
on filter paper.  An analytical method was developed and validated for this study 
based on SPE and LC-MS/MS analysis. The drugs selected were flunitrazepam, 
temazepam, oxazepam, lorazepam, nitrazepam, diazepam and cocaine.  Blood 
spots (100 µl blood) on Guthrie card 903 containing the drugs at 1000 ng/ml 
were dried overnight at RT.  Spots were cut out and extracted with buffer (pH 
6), which was analysed with the validated method.  DBS were stored in duplicate 
at RT, 4°C and -20°C for up to one year.  Degradation of the drugs in DBS in all 
storage conditions was less than for the corresponding liquid blood samples 
stored under similar conditions. More than 80% of each analyte could be 
recovered from DBS after one month while 15 % cocaine and 74 % of the 
benzodiazepines were recovered after 1 year under all conditions. 
 
The degradation of diazepam, temazepam, chlorodiazepoxide and oxazepam by 
hydrolysis was studied over a 1 month period under conditions designed to 
accelerate the reaction (80 °C, pH 2 and 12) and the hydrolysis products 2-
methylamino 5-chlorobenzophenone (MACB) and 2-amino 5-chlorobenzophenone 
(ACB) were analysed by a method based on SPE and LC-MS/MS which was 
 xvi 
developed and validated for this study. MACB and ACB in whole blood and urine 
were evaluated as indicators of the original drug concentrations. Blank blood 
and urine containing these compounds at 1000 ng/ml stored at high temperature 
(80°C) and under acidic (pH 2) and basic (pH 12) conditions at room temperature 
for one month. The samples were analyzed in duplicate at days 1, 2, 4, 7, 14 and 
30. MACB and ACB were the main hydrolysis products and their concentrations 
increased as degradation of the drugs proceeded. They could be detected when 
the starting materials had completely disappeared.  However, MACB and ACB 
were found to be further degraded under some of the conditions used and a 
further study was made of the conversion of MACB to ACB. It was concluded that 
the drugs studied were more sensitive to alkaline pH than to acidic pH or high 
temperature and that MACB and ACB can be used to confirm the original 
presence of these drugs in samples, especially when they have decomposed due 
to poor or prolonged storage conditions.  
 
A final study was made of organophosphates (OPs) and their dialkylphosphate 
(DAP) hydrolysis products. A new method was developed and validated for 
analysis of OPs and DAPs in blood samples based on SPE and GCMS after 
derivatization with N-tert-butyldimethylsilyl-N-methyltrifluroacetamide. The 
influence of sodium fluoride preservative and storage as DBS on filter paper on 
the stability of OPs in blood was assessed over a 3 day period at RT. With 
preservative, DAPs concentrations increased as degradation of the OPs 
proceeded and they could be detected when the parent compounds had 
completely disappeared. OPs in DBS showed good stability in comparison to 
liquid blood samples containing NAF and the parent compounds were detected at 
the end of the observation period. 
It was concluded that careful attention should be given to the storage of samples 
to avoid loss of analyte and erroneous interpretation of results.  DBS could be an 
effective and inexpensive way of increasing analyte retention but routine use of 
preservatives without evaluation of their effects is discouraged, as these may 
accelerate loss of analyte. 
 
 
  
 xvii 
Abbreviations 
AB             2-Aminobenzophenone 
ACB           2-Amino-5-chlorobenzophenone 
ADB           2-Amino-2`, 5-dichlorobenzophenone 
AEME         Anhydroecgonine Methyl Ester  
ANB           2-Amino-5-nitrobenzophenone 
APCI           Atmospheric Pressure Chemical Ionization 
API             Atmospheric Pressure Ionization 
BBB            Blood Brain Barrier  
BZE            Benzoylecgonine  
C6G            Codeine-6-glucuronide   
CI               Cemichal Ionization 
CNS            Central Nervous System 
DAP            Dialkylphosphate 
DBS             Dried Blood Spot 
DEP             Diethylphosphate 
DETP           Diethylthiophosphate 
DFSA           Drug Facilitated Sexual Assault 
DI               Deionized Water 
DMP            Dimethylphosphate 
DNA            Deoxyribonuclic Acid 
EI               Electron Impact 
EME           Anhydroecgonine Methyl Ester  
 xviii 
ESI             Electrospray Ionization 
HPLC          High Pressure Liquid Chromatography 
GABA         Gamma-aminobutyric Acid 
GC             Gas Chromatography 
GCMS         Gas Chromatography Mass spectrometry 
LC              Liquid Chromatography 
LCMSMS      Liquid Chromatography Tandem Spectrometry 
LLE             Liquid-Liquid Extraction 
LOD            Limit of Detection 
LLOQ          Lower Limit of Quantitation 
M3G            Morphine-3-glucuronide     
M6G            Morphine-6-glucuronide     
MACB         2-Methyl-5-chlorobenzophenone 
MBSTFA      N-tert-Butyl-Dimethylsilyl-N-Methyl-Trifluoracetamide         
MS              Mass Spectrometry 
NaF            Sodium Flouride 
NaN3          Sodium Azide 
NP             Normal Phase 
OP             Organophosphate 
P               Propability Value 
pH             Negative log of the hydrogen ion concentration 
Pka            pH at which 50% of anlyte is ionized and 50% is non-ionized 
 xix 
R2             Linear Correlation Coefficient 
RF             Radiofrequency  
RP             Reversed Phase  
RSD           Relative Standard Deviation 
RT             Room Temperature 
SAX           Strong Anion Exchange 
SCX           Strong Cation Exchnage 
SD             Standard Deviation 
SIM            Selected ion monitorng            
SOD           Sodium Metabisulfite 
SPE            Solid phas Extraction 
TBDMCS     Tert-Butyl-Dimethylchlorosilane 
 
 
 
 
 
 
 
 1 
1 Introduction 
1.1.1      Toxicology 
           
Figure  1-1: Ebers papyrus 
  
Toxicology is the study of the effects of poisons on living organisms. A poison or 
toxicant is any substance that causes illness or death when taken into the body.1  
Toxicology has a long history. The following are some of the prominent events in 
history. Even primitive man who was aware of the toxicity of plants and animals 
used poisons as a weapon, for suicide and for political assassination. The Ebers 
papyrus shown in Figure 1-1, written in 1500 BC, is one of the oldest preserved 
medical documents anywhere. It contains information about aconite, which was 
used by the Chinese as an arrow poison. Later, Socrates was condemned to 
commit suicide by drinking conium (hemlock), which was the poison of the 
Greeks, while Hindus used opium as both a poison and an antidote.2  
 
The Romanian king Mithridates was so afraid of poisoning that he ingested a 
mixture of more than 36 antidotes in order to protect himself against it. 
However, his plan backfired when he was unable to commit suicide after being 
captured by his enemies because of the powerful antidotes he used.1,2  
 
Paracelsus (1493-1541) was the first to discover the relationship between a dose 
and the body’s reaction to it, which is now known as the dose-response 
relationship and most of pharmacology, toxicology and therapeutics are based on 
this. Paracelsus said that “all substances are poisons; there is none which is not 
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a poison. The right dose differentiates a poison from a remedy.” We now 
understand that any compound when taken in a large enough dosage may cause 
a harmful effect. Even water, which is known as a very safe compound and the 
single largest constituent of the body, can cause a lethal electrolyte imbalance 
if a person swallows enough of it. However, small amounts of toxic substances 
such as cyanide and arsenic when ingested from food or inhaled from the air will 
not cause fatal toxicity.1  
 
There are many types of toxic substances, which are illustrated in Figure 1-2. 
Toxicology can be categorized in three branches: environmental, clinical and 
forensic. Environmental toxicology is concerned with the harmful effect of 
industrial chemicals released into the atmosphere. Clinical toxicology is 
concerned with the adverse effects of drugs that are given intentionally for 
therapeutic purposes. Details about forensic toxicology are provided in the next 
section. 
 
1.1.2. Forensic toxicology: an introduction 
Forensic toxicology is the use of analytical chemistry, pharmacology, and 
toxicology to aid the medicolegal investigation of the effects of a poison. Orfila 
(1787-1853) is considered to be the first toxicologist who used chemical analysis 
of autopsy specimens to prove the presence of a poison. Therefore the forensic 
toxicologist should improve and develop methods to determine toxic compounds, 
decide which specimens are suitable for analysis, apply these methods to the 
samples and interpret the results obtained. Forensic toxicology can be divided 
into three subfields, which are discussed in the following sections.3,4 
1.1.2.1. Post-mortem forensic toxicology 
Many forensic toxicology cases are investigations of deaths by poisoning. Many of 
these cases deal with children who accidentally ingested a poisonous substance 
that was not safely stored, such as household materials, drugs, pesticides and 
detergents. Sometimes adults are also accidentally poisoned when a toxic 
substance is mislabelled or when a worker is exposed to a toxic substance due to 
lack of workplace safety. Concurrent use of two or more drugs may lead to drug 
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interactions when one drug elevates the concentration of another beyond the 
therapeutic level.3 
Death can also result if a person ingests an illicit or controlled substance while 
seeking euphoria. People who use drugs in this way build up a tolerance to it, so 
they increase the dose to reach the desired effect, and death can occur as a 
result of toxicity.5  
In addition, a person who is depressed or has another psychological disorder may 
commit suicide by ingesting a toxic substance, traditionally poisons such as 
cyanide, arsenic, or carbon monoxide. Recent research shows that most suicides 
today use prescribed medicine in high doses or a mixture of prescribed drugs.5  
Death due to the ingestion of poison administered by another person is called 
homicide, and it is rarely seen by forensic toxicologists today; however, it has 
been reported in post-mortem cases.3  
The forensic toxicologist plays a very important role in post-mortem cases 
confirming the presence or absence of a toxic compound and selecting a suitable 
specimen in which to quantify the amount of poison in order to interpret the 
cause of death.3,4  
1.1.2.2. Human performance toxicology 
This field is related to psychology and is concerned with drugs that can alter 
human behaviour by stimulating or inhibiting performance. Most toxicologists in 
this field are interested in drugs that impair performance including stimulants, 
because chronic use of stimulants results in deficiency of motor and cognitive 
performance. Such impairment will lead to the inhibition of a person’s ability to 
perform skills requiring full attention such as operating machinery in industry or 
driving a vehicle. Besides illicit drugs such as opiates, cannabis and 
hallucinogens, legal drugs like antidepressants and benzodiazepines that exert 
an inhibitory effect on the central nervous system (CNS) have been reported in 
previous studies as the cause of automobile accidents.6,7 Moreover, researchers 
have reported that benzodiazepines are used by rapists to facilitate sexual 
assault, especially when the victim takes them with alcohol, which enhances 
their effect.8 Alcohol is the most common compound impairing human 
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performance, and its use is reported in connection with many driving accidents. 
Therefore many countries have prohibited its use by drivers and those operating 
machines.4  
1.1.2.3. Forensic drug testing 
Drug abuse has increased as a result of social or personal problems such as 
feelings of failure in education, on the job, or in family life, which may lead to 
depression and dysphoria and cause a person to seek euphoria by using drugs. 
Other factors include the availability of free time, ease of obtaining drugs, as 
well as curiosity to learn more and experience new feelings.9  Since drug abuse 
may affect the combat readiness of the armed forces, cause accidents in the 
industrial and transportation sectors, and are used as performance 
enhancements in sports, drug testing is increasingly used in the military, 
criminal justice, public sector, and sports.4,10  
 
 
1.2 Drugs and poisons – trends 
 
 
Drugs are chemical substances that alter bodily functions by interacting with a 
biological target.11 Toxicity of drugs may occur as a result of overdose, drug 
interactions, and genetic problems.2 Even over-the-counter (OTC) drugs are not 
Toxicants 
Drugs  Food 
additives 
Natural 
plants and 
animals 
Industrial 
chemicals 
Household 
Supplies 
 
Figure  1-2: Poison classification1  
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safe when used inappropriately. For example, the most commonly used drug 
worldwide is paracetamol, an analgesic. A high dose of paracetamol taken 
accidentally or in order to commit suicide will cause hepatotoxicity (liver 
damage).12 Thalidomide can interfere with the development of a foetus or cause 
birth defects if it is taken during pregnancy as a sedative or to treat morning 
sickness.13,14 Genetic factors also play a role in drug toxicity, especially for those 
having glucose-6-phosphate degydrogenase deficiency.15 Anti-malarial drugs such 
as primaquine will induce haemolytic anaemia in those who take them. In 
addition, poor metabolism of the antihypertensive drug debrisoquine may cause 
severe hypotension.16  
Drug abuse has increased for the reasons mentioned earlier. Despite their 
harmful effects, alcohol and nicotine are still accepted in most societies and are 
legal in most countries. The following are descriptions of the psychoactive drugs 
most commonly abused. 
Stimulant drugs such as cocaine and amphetamines improve the mood, leading 
to pleasant feelings (euphoria) and give one a sense of increased energy and 
enhanced physical performance. Stimulant drugs are highly addictive. Khat, 
widely used in some African and Middle Eastern countries, has the same effect as 
amphetamines.4  
Depressant drugs such as alcohol, barbiturates, chloral hydrate, antipsychotic 
agents and benzodiazepines cause sedation, drowsiness, and euphoria.4  
Hallucinogens include lysergic acid diethylamide (LSD), phencyclidine (PCP), and 
mescaline. This group of drugs has the ability to induce unpleasant effects like 
panic, fright, and hallucinations.4 
Opioids such as heroin, morphine, pethidine, and codeine are often misused 
because they produce an intense sense of euphoria. 4  
Cannabis, more often called marijuana in the United States of America, refers to 
several variations of Cannabis sativa L. that contain the psychoactive drug delta-
9-tetrahydrocannbinol (THC). Cannabis has both a depressant and a 
hallucinogenic effect. 4  
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Food toxicity may occur because of additives added intentionally or as a result 
of contamination. The additives usually include flavouring agents, sweeteners, 
colouring agents, stabilizers, and preservatives. For example, tartrazine (E102) 
is a dye added to juice, foods, and pharmaceutical preparations to give them an 
orange colour. The toxic effects attributed to tartrazine include hyperkinetic 
behaviour in children, skin rash (urticria), and asthma in people who are 
hypersensitive to this material.17 The sweetening agent saccharin was banned 
from United States because of its carcinogenic effect.1,18 Clostridium botulinum 
is a bacterium that produces the toxin botulin, the causative agent in botulism, 
which is a toxic syndrome characterized by weakness and difficulty breathing 
that can lead to death.19 Furthermore, aflatoxins are any of the various related 
mycotoxins produced by a species of Aspergillus, commonly A. flavus, found as a 
contaminant in mouldy grains and meals, as in rice and peanut meal, and 
suspected of causing liver cancer in humans and other animals.20 Oil mixtures 
containing rapeseed oil denatured with aniline were clearly linked by 
epidemiological and analytic chemical studies to the toxic oil syndrome that hit 
Spain in the spring and summer of 1981, in which 20,000 people became acutely 
ill, 12,000 were hospitalized, and more than 350 died in the first year of the 
epidemic.21  
Pesticides are compounds used to kill certain organisms. They are used in 
herbicides, fungicides, insecticides, and rodenticides. Improper use of 
agricultural sprays containing these compounds or ingestion of food 
contaminated with pesticides can cause acute toxicity. The most common toxic 
pesticide is dichloro-diphenyl-trichlor-ethane (DDT) used to control the malarial 
mosquito, which also causes a toxic reaction in humans. In addition, 
organophosphates and paraquat were reported to cause toxic effects in 
humans.22  
Industrial chemicals are also very threatening to humans. For example, chronic 
exposure to cadmium causes kidney damage while acute toxicity causes 
testicular damage.23 Vinyl chloride used to manufacture plastics causes liver 
trauma.24 Prolonged exposure to asbestos causes bronchial carcinoma (lung 
cancer).25  
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Some natural products are toxic to humans, too. For example, plant products 
such as pyrrolizidine alkaloid, pennyroyal oil, ricin, bracken, and fluoroacetate 
cause liver injury, abortion, cell damage, cancer, and heart failure, 
respectively.26-30 Snake venom causes a lowering of arterial blood pressure, 
haemolytic anaemia, and a rapid pulse.31  
Carbon monoxide from car exhaust and other sources combines with 
haemoglobin in red blood cells leading to respiratory failure, brain damage, and 
cardiac arrhythmia.32 Ingestion of ethylene glycol, an ingredient in antifreeze, 
can lead to acidosis, as well as kidney and brain damage.33 Cyanide causes 
cardiac and respiratory failure. In addition, chronic use of alcohol can lead to 
liver injury such as liver cirrhosis.34 Glue sniffing is very common among 
teenagers: toluene, the most common solvent available in glue, causes 
narcosis.35  
  
1.3 Pharmacology 
Pharmacology is the study of drug effects on the functions of the body systems. 
The mutual interactions of drugs with the body are divided into two classes: 
pharamcodynamics and pharmacokinetics. Drugs are administered orally or 
parenterally through a non-gastrointestinal route such as intravenous, 
intramuscular, subcutaneous injection, topically, inhalation and sublingual. 
Forensic toxicologists should have knowledge about drug interactions with living 
humans and their biotransformation in order to assess toxicity and to give a 
reliable interpretation.11  
1.3.1 Pharmacodynamics 
Pharmacodynamics is the study of the effects of drugs on the body, including 
their mechanisms of action, medical uses and side effects. Most drugs produce 
their effects by activation or inactivation of receptors which normally respond to 
endogenous chemicals such as neurotransmitters or hormones, while some drugs 
are inhibitors for certain transport process or enzymes.11  
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1.3.2 Pharmacokinetics 
Pharmacokinetics is the study of the effect of the body on the drug including 
absorption, distribution, metabolism, and excretion (ADME). Once a drug is 
administered, it must cross a membrane to be absorbed and enter the 
bloodstream. A membrane is composed of a strongly hydrophobic bilayered lipid, 
so drugs that are capable of dissolving in lipids are more easily absorbed. There 
are many factors that affect drug absorption such as the pKa of the drug, the pH 
of its environment and its stability in the stomach acid. Drug absorption depends 
on the ionization form of drug, either acidic or basic. The Henderson-Hasselbach 
equations are used to determine how much of a drug will be absorbed (Equation 
1-1 to 1-3).5,11  
pH= pKa - log unionized/ionized                                        Equation 1-1 
For acids: pH = pKa + log [ionized]/ [unionized]                 Equation 1-2 
For bases: pH = pKa + log [unionized]/ [ionized]                 Equation 1-3 
For example, aspirin is an acidic drug and in the stomach (pH 2) will be 
unionized and lipophilic therefore absorbed readily, whereas basic drugs become 
more ionized and hydrophilic in the stomach and are not absorbed. By contrast 
basic drugs in the small intestine (pH8) become unionized and are absorbed 
easily. 
When a drug enters the bloodstream, its distribution into the tissues of each 
organ is influenced by blood flow to the organs. Distribution to highly perfusion 
organs such as the brain, kidney and liver is faster than distribution to adipose 
tissue. Lipid-soluble substances have the ability to penetrate capillary and cell 
membranes such as the blood-brain barrier (BBB). Ionization effect affects not 
only the penetration of the drug through membranes but also the distribution 
between aqueous compartments, for instance urinary alkalinisation accelerates 
excretion of weak acids and retards weak bases whereas urinary acidification 
increases excretion of weak bases and reduces excretion of weak acids. 
Therefore, it is very important in cases of drug toxicity to accelerate the 
elimination of the drug from the body. One way to do this is through the 
alkalinisation of plasma by the administration of sodium bicarbonate, which 
 9 
leads to the extraction of a weak acid drug from CNS to plasma. On the other 
hand, acidification of plasma by administering an acetazolamide will inhibit its 
extraction. Consequently, the drug will concentrate in CNS, and its neurotoxicity 
will be increased. In addition, urine alkalinisation through administering 
bicarbonate accelerates the elimination of aspirin in cases of aspirin toxicity.5,11  
Metabolism or biotransformation is used to convert lipophilic compounds to 
hydrophilic compounds that can be excreted readily in urine. Therefore, the 
main function of metabolism is to detoxify drugs and xenobiotics (foreign 
compounds). This reaction mainly occurs in the liver and occurs in two phases 
described below.36  
Phase I or functionalization is the preparation of the drug for Phase II by the 
addition of one ore more new functional groups to the compound such as -OH, -
NH2, -COOH and –SH. The Phase I metabolic reaction can be oxidation involving 
cytochrome P450 enzymes, hydrolysis, hydration, oxidation by other enzymes, 
and reduction as shown in figure 1-3. 
 
 
 
 
 
 
 
 
 10 
ON
NCl
CH3 O
N
NClN-Demethylation
Diazepam  Nordiazepam  
 
OH
N
H
CH2OH
COCH2CL
O2N
OH
N
H
CH2OH
COCH2CL
NH2
Reduction
Chloramphenicol
 
      
O
N
N
H
NH2
O
N
OH
HYDROLYSIS
Isoniazide
 
Figure  1-3: Phase I reactions 
 
Phase II metabolism or conjugation is accomplished through the addition of an 
endogenous compound such as sugar, sulphate, or methyl to the functional 
group(s) added in Phase I as shown in figure 1-4. The most common reaction in 
Phase II is glucuronidation due to an abundance of UDP-glucuronic acid, which is 
a part of the glycogen synthesis in the body and is found in all tissues. The 
enzyme involved in this reaction is UDP-glucuronosyltransferase, which is located 
in the cytosol. 
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Figure  1-4: Phase II reactions 
 
In Phase I, cytochrome P450 enzymes catalyze the oxidation reactions of 
thousands of different drugs and chemicals with different structures. The 
catalysis also includes N-, O- and S-dealkylation. Most interactions between 
drugs and other substances such as another drug, food and chemicals occur by 
inducing or inhibiting the enzymes. For example, some drugs such as 
phenobarbitone, rifambicin, ethanol, and carbamazepine induce this enzyme 
and thereby decrease the concentration of a drug metabolized by this enzyme. 
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However, the most important of the interactions that play a major role in drug 
toxicity is a drug inhibitor because inhibition will lead to an increase in the 
concentration of drugs metabolized by the enzyme, causing toxicity. For 
instance, the antacid drug cimetidine is an enzyme inhibitor when taken with 
phenytoin, and warfarin will increase their toxicity. The concurrent use of the 
antibiotic drug erythromycin, which is an enzyme inhibitor, with narrow 
therapeutic index drugs such as theophylline and digoxin will lead to toxic 
effects of these drugs. Furthermore, grapefruit is an enzyme inhibitor and should 
be avoided when taking drugs.36-38  
Toxicologists also need to be aware of genetic factors that are related to 
variations in responses to drugs (polymorphism). The study of this phenomenon is 
called pharmacogenetics. For instance, there is an individual variation between 
people in CYP2D6 (subtype of CYP450) leading to extensive or poor metabolism 
of the antihypertensive drug deprisquine.16,36,39 
 
1.4. Samples used 
Generally, ingestion or intake of a drug or poison is followed by absorption, 
distribution, metabolism, and excretion, so the compound can be detected in 
different matrices. The choice of the specimen depends on the type of case and 
compound being investigated. Therefore, the forensic toxicologist should 
carefully select the proper matrix for each specific case. The most common 
matrices are blood, urine, and hair.4,11  
Blood is the complex fluid that transports the oxygen and nutrients to the cells 
and carries carbon dioxide and waste from the cells to be eliminated from the 
body. Blood plays a major role in the regulation of body temperature by 
transporting hormones within the body. It consists of plasma (55% by volume) 
and a cellular portion (45% by volume). Serum is a clear liquid exudate from 
clotted blood. In forensic toxicology, blood is considered to be the most useful 
biological fluid because of its advantages over other matrices. In other words, it 
can reflect the concentration of a poison at the time of death or time of the 
sample collection, and blood cannot be adulterated. However, many analytes 
cannot be detected in blood after a relatively short period of time, especially 
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drugs and other substances having short plasma half life. Furthermore, clotting 
of blood makes analysis difficult. Also, blood is an invasive matrix compared to 
the other matrices. The pH of blood is slightly alkaline and usually ranges 
between 7.2 and 7.4.3,4  
Urine is 95% water, and the other 5% is made up of sugar and acids, urea, and 
creatinine. Urine is produced continuously by the kidneys to eliminate waste and 
metabolites from the body. Urine pH can range from 4 to 8 depending on diet 
and drugs ingested. Unlike blood, urine is essentially free of protein and lipids, 
so it can be analyzed directly by immunoassay. Urine is the specimen of choice 
in workplace drug abuse testing, traffic safety and sports doping because it 
contains drugs in higher concentrations and for longer periods of time compared 
to blood. The disadvantage of using this matrix is that drug concentrations are 
not correlated with the pharmacological effects of the drugs, so there is no 
indication of the concentration of the drug at the time of death or sample 
collection. Moreover, it is easy to adulterate a urine sample, which is often 
contaminated by bacteria.4,40,41 
Hair is extensively used in drug screening, and it is considered to be the ideal 
matrix because it has many advantages over other specimens. For instance, it 
provides information about chronic use of a drug, it can be collected in a non-
invasive manner, it is very stable, it is not affected by storage conditions and it 
is difficult to adulterate. However, there are a few problems with using hair. 
The uptake of a drug into hair depends on the colour of the hair, for example, 
dark hair has more affinity than blond hair, and the concentrations of some 
drugs detected in hair may be affected by the use of hair products.42,43  
Oral fluid consists of saliva plus other components in the oral cavity. It is a non-
invasive matrix in which concentrations of drugs may be correlated with those 
found in blood. Oral fluid is often used to screen recent use of a drug in cases 
where a person is suspected of driving under the influence of drugs. However, 
drugs which are highly protein-bound in blood have low concentrations in oral 
fluid.44  
Other specimens such as bone, heart, bile, liver and gastric contents are 
collected at autopsy and are useful substances in case of extreme putrefaction.4  
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1.5 Forensic toxicology problems 
There are many problems facing forensic toxicologists, including finding reliable 
methods to detect unknown compounds in small volumes of sample and 
distinguishing structurally similar compounds. 
Decomposition of drugs during the post-mortem interval or during storage in the 
laboratory has been reported in previous studies, which may give errors in the 
interpretation of results.45-50,55 
Post-mortem drug concentrations change due to continuing drug metabolism 
after death, chemical decomposition, redistribution of the drug from organs, or 
as a result of putrefaction. Bacteria enter the oral cavity and then penetrate the 
gastrointestinal wall five hours after death, leading to putrefaction and drug 
decomposition. The products originating from putrefaction as a result of 
enzymatic and bacterial activity include indole, phenylacetic acid, butyric acid, 
pyridine, tryptamine, and tyramine, all of which will interfere with drug 
analysis. The most likely bacteria to affect post-mortem drug metabolism are 
clostridium perfringens, Bacteroides fragilis, and Escherichia coli, which contain 
oxygen-sensitive nitroreductase enzymes that are able to reduce nitroaromatic 
compounds. The other bacteria involved in post-mortem drug metabolism are 
bacillus spp, proteus miribalis, staphylococcus aureus, streptococcus, and 
faecalis.41,45-50 
In addition to contamination during the post-mortem period, contamination can 
be caused by poor sampling. An average person has between 100 to 100,000 
microbes per square centimetre of the skin depending on the time of day and on 
the hygiene of the individual who is the subject of analysis, especially if he or 
she has been exercising and there is sweat on the skin, which contains bacteria 
that may contaminate the sample. Furthermore, extensive clotting of blood 
after death or when no anticoagulant is added to the sample can make the 
analysis difficult because blood will clot in ten minutes after it is placed in a 
tube.45-51 
 In addition, chemical adulteration of samples, especially urine, can lead to 
wrong interpretation of results due to decomposition of the analyte.40 
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1.6 Aims 
The aims of the component studies described in this thesis were: 
To investigate the stability over one year of four drugs from the benzodiazepine 
group in whole blood at low and high concentrations under different storage and 
temperature conditions, with and without additives. The study also intended to 
investigate the stability of three opiate glucouronides in blood and urine stored 
for one year under different conditions. 
To develop a new method for the analysis of hydrolytically labile drugs such as 
benzodiazepines and cocaine in dried blood spots stored on filter paper and 
assess their degradation during a storage period of one year under different 
conditions. 
To develop a procedure for correction of drug losses after decomposition of 
hydrolytically labile benzodiazepines during storage under different conditions in 
blood and urine by quantification of the products of degradation. 
To study the stability of  organophosphates when stored in blood for three days 
at room temperature after the addition of sodium fluoride as preservative and 
also to assess the loss of analytes resulting from addition of sodium fluoride by 
detection of their degradation products. Furthermore, to assess the stabilization 
of these compounds by storing them as dried blood spots on filter paper as an 
alternative method to protect them from decomposition. 
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2   Stability of Drugs and Poisons: Literature 
Review 
2.1 Introduction 
Skopp et al.52 define stability as the “capability of a sample material to retain 
the initial value of a measured quantity for a defined period within specific 
limits when stored under defined conditions.” Shah et al.53 define stability as 
“the chemical stability of an analyte in a given matrix under specific conditions 
for a given time interval.” Waterman et al.54 refer to stability as the “ability to 
withstand loss of chemical due to decomposition” while for pharmaceuticals 
stability is related to the “storage time allowed before any degradation in the 
dosage form,” which is expressed in time as shelf life.54   
Drug concentration changes are observed in forensic cases. In the postmortem 
period a decrease in drug concentration can occur during the time between 
death and toxicological analysis of autopsy specimens as a result of drug 
redistribution,247,248ongoing drug metabolism by enzymes or bacteria and 
chemical degradation.3-6, Drug concentration in collection tubes was influenced 
by storage conditions during the storage time in the laboratory or during 
transportation. The temperature plays a major role in the drug stability and 
additives and preservatives usually have not been added. Very often, a period of 
several days occurs between sampling, screening, and quantification. In general 
all biological samples are stored in the laboratory until the final confirmatory 
analysis is carried out. The final confirmation may not actually be required until 
the case reaches court for legal process, and it may be carried out after a period 
of time. Within the United Kingdom, autopsy specimens frequently become court 
exhibits and are retained in the court premises prior to the commencement of 
the proceedings, often for periods of weeks or months, and often at room 
temperature. Any difference in the results between initial and subsequent 
analyses may well be the basis for arguments and disagreements over 
interpretation of the results by the medico-legal community, and more 
reanalysis may be requested. Therefore, knowledge of drug stability under 
different storage conditions is necessary for toxicologists to interpret case 
results reliably. 
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2.2 Drugs 
Drug loss during the post-mortem interval has been reported in previous studies. 
For example, Fumio and Yoshiaki investigated the tissue distribution of 
nitrazepam and its metabolite 7-aminonitrazepam in one case of nitrazepam 
toxicity.48 An elderly woman was found dead during winter in a shallow ditch. 
The ambient temperature was 2—8 °C and no putrefaction was noted. Different 
concentrations of nitrazepam and its metabolite 7-aminonitrazepam were found 
at different sites. High concentrations of both analytes were found in the brain, 
whereas low concentrations were observed in the liver. In addition, largely 
different concentrations in the veins and arteries were noted; these changes in 
the concentration were attributed to dilution by water that entered in the 
circulation through the lung, and by bacterial metabolism, which reduced 
nitrazepam to 7-aminonitrazepam.  
Robertson and Drummer investigated the stability of nitrobenzodiazepines, in 
particular nitrazepam, clonazepam and flunitrazepam, in blood and water.46 The 
result of this study showed that nitrazepam and clonazepam were stable in 
sterile fresh blood containing 1% sodium fluoride/potassium oxalate preservative 
when stored at 22 °C over 28 days while flunitrazepam lost approximately 25% of 
its original concentration under the same conditions. All three drugs lost 
approximately 29−51% after 9 h when stored at 37 °C. 7-Aminonitrazepam was 
stable at 4 °C but unstable at 22 °C and 37 °C; also, it declined by 25% after 28 
days whereas 7-aminoclonazepam was stable at all three temperatures. 7-
aminoflunitrazepam lost approximately 10% at all storage temperatures. No 
degradation was found for the drugs and corresponding metabolites in water 
under the same storage conditions. In the absence of preservatives, 25—50% of 
parent drugs were lost in blood stored at 22 °C after 10 days. All parent drugs 
were completely converted to their metabolites over 8 h at 22 °C in bacterially 
contaminated postmortem blood. 
 
In conclusion, all three parent drugs were found to be stable in blood stored at 
−20 °C over 24 months and 10 months at 4 °C, whereas their 7-amino 
metabolites were unstable at −20 °C after 2 months and 1 month at 4 °C. 
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Furthermore, postmortem nitrobenzodiazepines metabolism by bacteria has 
been investigated by Robertson and Drummer in blood at 4 °C, 22 °C, and 37 °C 
for 21 days.45 Flunitrazepam, nitrazepam, and clonazepam were found to be 
metabolized completely to their 7-aminometabolites in the presence of eight 
species of enteric bacteria. Activity of bacteria with respect to bioconversion 
was observed at 22 °C and 37 °C but not at 4 °C except for clostridium 
perfringens. The rate of bioconversion increased as the temperature increased. 
However, addition of fluoride oxalate at a concentration of 0.7 % (w/v) was 
found to reduce the bioconversion loss of these drugs from 100% to 13%, whereas 
1% (w/v) of fluoride oxalate reduced the loss to 4%. A higher concentration of 
fluoride oxalate, 2% w/v, did not further inhibit metabolism. The bioconversion 
activity is different from one species of bacteria to another. By contrast, no 
bioconversion was observed in sterile buffer after 21 days and less than 21 % of 
nitrobenzodiazepines were converted in sterile fresh whole blood. 
 
Stability of drugs in vitro has been reported in previous studies. For example El 
Mahjob et al.56 found clonazepam, flunitrazepam, midazolam, and oxazepam 
stable for 1 year when stored at −80 °C while the losses for all compounds when 
stored at −20 °C were 5% and 20% for high and low concentrations, respectively. 
In the refrigerator at 4 °C, the decreases in concentration were more than 50% 
for high concentration and more than 90% for low concentration. At room 
temperature the losses for all drugs were 100% and 70% for low and high 
concentrations, respectively. 
 
Alhadidi and Oliver studied stability of temazepam in blood and in aqueous 
solution.57 They found that temazepam was stable in blood when stored in the 
freezer at -20 °C for 1 year while in the refrigerator at 4 °C and at a room 
temperature of 20 °C significant decreases in concentration were noted after 3 
months. The amount of temazepam recovered after 1 year ranged from 47% to 
82% regardless of storage temperature. Temazepam in aqueous solution was 
found to be stable for 6 months regardless of the storage temperature and for 1 
year in the freezer; in the refrigerator and at room temperature the recovery 
after 1 year ranged between 42% and 58% regardless of storage temperature and 
the drug loss was less in blood than in water.  
Moreover, the same authors have reported on the stability of morphine and 
buprenorphine in whole blood.60 Both drugs were stored at −20 °C, 4 °C, and 25 
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°C, and were found to be very stable. For storage periods of up to 6 months, 85% 
of morphine and 77% of buprenorphine were recovered. After 1 year more than 
70% of the original concentrations were detected regardless of storage 
temperature, particularly when blood samples were stored in silanized glass 
vessels. In another study Alhadidi and Battah59 found that the anticholinergic 
agent trihexyphenidyl (THP) was stable for 6 months in blood and urine at 4 °C 
and -20 °C; however, at 25 °C THP was only stable for 3 months and 4 months in 
blood and urine, respectively. Chlorpromazine was found to be stable in blood 
for 10 months at −20 °C, 8 months at 4 °C and for 2 months at 25 °C, as 
reported by Alhadidi et al.60  
 
Levine et al.55 studied the postmortem stability of benzodiazepines in blood and 
tissue for several months — in particular diazepam, chlordiazepoxide, 
flurazepam and their desalkyl metabolites. Diazepam was found to be very 
stable at room temperature and under refrigeration over a 5-months period. 
Flurazepam and N-1-desalkylflurazepam were found to be stable under both 
storage conditions despite the slight decrease observed, which was less than 
20%. Chlorodiazepoxide and norchlordiazepoxide were unstable at the same 
storage temperatures. Neither chlorodiazepoxide nor norchlordiazepoxide could 
be detected after 18 days at room temperature from the spiking date. Addition 
of preservative and anticoagulant had little effect on the stability of 
norchlordiazepoxide at room temperature compared to chlordiazepoxide; the 
preservative partially protected chlorodiazepoxide from decomposition 
compared to the unpreserved sample. The results obtained were the same in 
blood and tissue. 
 
Lin et al.61 investigated the effect of storage temperature on the stability of 
morphine and codeine in urine samples stored at freezer, refrigerator, and room 
temperatures over 11 months. They showed that total morphine and total 
codeine concentrations decreased approximately up to 31% in the freezer and 
39% in the refrigerator, whereas free morphine and free codeine were only 
noted to have slight increases in all samples. In contrast, a large decrease of 
concentration of these drugs was observed when stored at room temperature. 
 
Baselt et al.62 reported a long-term stability study of blood containing cocaine, 
benzoylecgonine and ethanol, stored in glass collection tubes containing a 
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combination of preservative and anticoagulant at 4 °C for 1 year. The study was 
done to determine if minor improvements could prolong the long-term stability 
of drugs. The results of this study showed 100% loss of cocaine when the sample 
was stored in a collection tube containing sodium fluoride and potassium 
oxalate. However, substitution of oxalic acid instead of potassium oxalate 
reduced the loss to 76% from the day zero concentration while less improvement 
was noted in the concentration of benzoylecgonine and ethanol. Moreover, 
cocaine loss was after 1 year reduced to 60% after the addition to the sample of 
10 mg echothiophate, a known cholinesterase inhibitor, while no enhancements 
were noted for the stability of benzoylecognine and ethanol, which were found 
to be stable and not affected over the time in all preserved tubes, compared to 
cocaine.  
 
McCurdy et al.63 investigated the stability of cocaine, benzoylecognine (BZE), 
and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in whole 
blood stored in four different types of tube. Three of these contained different 
additives: sodium fluoride, EDTA and heparin, respectively. The fourth tube did 
not contain any additives. The samples were stored for 1 month at refrigerator 
and room temperatures. BZE and THC-COOH were found to be stable under all 
storage conditions whereas cocaine was unstable and losses were noted at both 
temperatures. Also, no improvement was noted in the sample containing 
additives. 
 
Holmgren et al.64 investigated the stability of 46 drugs in blood at −20 °C for 1 
year and the influence of preservative on drug stability when added to samples 
of vitreous humor. In this study, concentrations of ethanol, desmethylmianserin, 
7-amino-nitrazepam, THC, and zopiclone in blood were found to have decreased 
after 1 year, whereas ketobemidone and thioridazine were found to have 
increased in concentration. The study also showed a significant beneficial effect 
of potassium fluoride on the stability of ethanol and zopiclone in vitreous humor, 
which were found to decrease during storage in the absence of potassium 
fluoride. The rest of drugs were found to be stable under the same conditions. 
 
The stability of the ring-substituted amphetamines 3,4-methylenedioxy-
amphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-
methylenedioxyethylamphetamine (MDEA) have been examined by Clauwaert et 
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al.65  for 21 weeks at −20 °C, 4 °C, and 20 °C in blood, urine, water and serum. 
They found these compounds to be stable for the whole investigation period at 
high and low concentrations, in water and urine, and at all storage 
temperatures. A similar result was noted for storage in serum for 17 weeks and 
in whole blood for 5 weeks under all storage conditions. This study showed that 
the drugs are stable up to 21 weeks when stored at −20 °C in all matrices.  
 
Zaitsu et al.66 studied the long-term stability of various drugs and metabolites 
for 5 months at 25 °C, 4 °C, and -20 °C; the study also investigated the effect of 
addition of sodium azide (NaN3) as preservative and the use of an aseptic urine 
collection kit. In urine which was slightly contaminated by bacteria, 
amphetamine and methamphetamine were found to be stable for 5 months 
under all storage conditions whereas more than 32% of methamphetamine and 
44% of amphetamine were lost in severely contaminated urine. However, the 
losses of both analytes were completely prevented by either use of NaN3 or the 
aseptic collection kit. Estazolam was found to be stable under all conditions with 
or without preservative or aseptic collection kit whereas nitrazepam 
disappeared completely within 14 days in severely contaminated urine at room 
temperature. However this loss was completely inhibited by either NaN3 or the 
aseptic collection kit. Both nitrazepam and 7-aminoflunitrazepam (7AF) were 
found to be stable at −20 °C for 5 months. Further addition of NaN3 alone had a 
moderate effect on 7AF stability at the other two temperatures, while addition 
of NaN3 plus filtration sterilization was found to be most effective. Cocaine 
(COC) and 6-acetylmorphine (6AM) were found to be stable at 4 °C and −20 °C 
for 5 months in all storage conditions  while both of them were completely lost 
after 1 month in severely contaminated urine at 25 °C and after 75 days in 
slightly contaminated urine under the same conditions without any preservative 
treatment. Addition of NaN3 accelerated the decomposition of COC and 6AM 
whereas the decreases were completely inhibited after using the aseptic urine 
collection kit. 
 
Skopp et al.67 performed a study on approximately 13 benzodiazepines and their 
metabolites in blood and plasma for storage periods of up to 8 months at 4 °C. 
All compounds were found to decrease by at least 60% over the full period of 
study in both matrices; flunitrazepam and norflunitrazepam were less stable 
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than the other analytes followed by prazepam and lorazepam. The stability of 
the compounds was better in blood than in plasma. 
 
Skopp et al.68 also reported a study on the stability of morphine, morphine-3-
glucuronide (M3G), and morphine-6-glucuronide (M6G) in fresh blood, plasma, 
and postmortem blood in glass vials at −20 °C, 4 °C, and 20 °C for 6 months. 
Morphine and its glucuronide metabolites were found to be stable in both blood 
and plasma at −20 °C and 4 °C. At room temperature M3G was found to be 
stable in both matrices while morphine was stable in blood and decreased by 
23% in plasma by the end of study. M6G was lost from blood and plasma, 
approximately 23% and 14%, respectively at room temperature. In postmortem 
samples all compounds were found to be stable at −20 °C. Morphine was stable 
at 4 °C whereas M6G and M3G decreased by 10% and 40%, respectively. At 20 °C, 
the morphine concentration increased to 134% of the initial concentration 
whereas its metabolites decreased. 
 
Lutfi studied the stability of three benzodiazepines and four tricyclic 
antidepressant drugs in blood for up to 1 year.69 The stability results showed 
that diazepam was stable at −20 °C while at 4 °C and 25 °C losses occurred of 
20% and 46%, respectively. Desmethyldiazepam decreased by 43%, 53%, and 70% 
and temazepam by 30%, 38%, and 44% at −20 °C, 4 °C, and 25 °C, respectively. 
Amitriptyline was found to be stable at −20 °C and 4 °C while at 25 °C it was 
stable up to 5 months but had decreased by 42% after 12 months. Nortriptyline 
showed poor stability, with decreases in concentration of 44%, 54%, and 73% at 
−20 °C, 4 °C and 25 °C, respectively. Imipramine was stable for 1 year at −20 °C 
and for 7 months at 4 °C; however, at 25 °C it showed poor stability and 
decreased by more than 50% after 1 year. 
 
Cocaine, benzoylecgonine, nonconjugated morphine, codeine, 
methamphetamine and phencyclidine (PCP) stability in blood were studied by 
Giorgi and Meeker for 5 years at ambient temperature.70 The specimens were 
collected in gray–top container tubes containing sodium fluoride and potassium 
oxalate. These blood samples were collected from live individuals and stored at 
room temperature. Cocaine and its metabolites showed poor stability. Cocaine 
was not detected after reanalysis while BZE was not detected after 2 years. 
Morphine had decreased by 61.8% at the end of study whereas codeine was fairly 
 23 
stable during the study. Methamphetamine significantly decreased after 1 year 
of storage. PCP was measured at only 69.4% of the original concentration at the 
end of study. 
 
Isenschmid et al.71 noted that cocaine was stable in blood for 150 days if 
preservative (2% NaF) or organophosphate was added to the sample adjusted to 
pH 5 and stored at 4 °C or less. Unpreserved cocaine was hydrolysed to ecgonine 
methyl ester, while the addition of pseudocholinesterase (Pch E) inhibitor 
without reduction in pH caused cocaine to hydrolyse into benzoylecgonine. 
Furthermore, cocaine is hydrolysed to BE in a phosphate buffer. Cocaine was 
found to be more stable in unpreserved postmortem blood samples than blank 
blood because of the lower pH of the former. Also ecgonine methyl ester was 
found to be less stable than benzoylecgonine in unpreserved blood.  
 
The stability of the muscle relaxant pancuronium in blood has been studied by 
Kala and Lechowics.72 Pancuronium was stable for 7 months and 3 months when 
stored at −20 °C and room temperature, respectively. 
 
Dugan and Bogema studied the stability of amphetamine, methamphetamine, 
morphine, codeine, cocaine, phencyclidine, and 11-nor-delta-9-
tetrahydrocannabinol-9-carboxylic acid in urine at −20 °C for 12 months.73 The 
concentrations of these drugs did not change except for cocaine, which 
decreased by 37% of its original concentration after a 12-month period. 
 
The stability of the digitalis drugs digoxin and digitoxin in serum at 4 °C has 
been investigated by Datta.74 Both drugs were found to be stable for 3 days. In 
addition digoxin stability in saliva was studied by Lori et al.245, which was found 
to be stable for 2 weeks at room temperature. 
 
Forsdahl and Gmeiner measured the loss of salbutamol in urine at two different 
concentrations: this ranged between 2—4% at −18 °C and 8—12% at 4 °C after 2 
months.75 
 
Celma et al.76 studied short-term stability of paracetamol and chlorpheniramine 
in plasma. Both drugs were found to be stable for 1 day in the autosampler at 
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room temperature. Also, both drugs were resistant to three freezing and thawing 
cycles over a 3 month storage period at −20 °C. 
 
The stability of the antiretroviral non-nucleoside reverse transcriptase inhibitor, 
nevirapine (NVP, used for treatment and prevention of HIV) was investigated by 
Bennetto et al.77 in whole blood and serum in the refrigerator, at room 
temperature and in an incubator at 37 °C. Nevirapine was found to be stable for 
1 day at all storage conditions at both high and low concentrations. 
 
Barnada et al.78 studied calcium channel antagonist (CCA) photodegradation in 
serum samples during preparation for analysis by LC-MS/MS. The degradation of 
solutions containing nifedipine or nisoldipine in a clean glass vial was 96% after 2 
h when exposed to laboratory light, whereas the degradation in plasma was 25% 
after 2 h for both drugs. All compounds were found to be stable in plasma for 2 
months when stored at −20 °C and for 24 h at room temperature. 
 
The stabilities of the antipsychotic drug promazine and its metabolite 
desmethylpromazine were investigated by Oliver and Stephen in plasma and 
urine for 64 days at −20 °C.79 Both analytes were found to be stable during the 
whole observation period. 
 
Skopp et al.80 reported on the short-term stability of THCCOOH glucuronide 
(THC-COOHglu) in plasma for 10 days at −20 °C, 4 °C, 20 °C, and 40 °C. The 
results indicated that THC-COOHglu was stable only when stored at −20 °C and 
that the rate of decrease in THC-COOHglu concentration increased with 
temperature.  
 
Skopp et al.81 studied the stability of the hallucinogenic agent lysergic acid 
diethylamide (LSD) and its metabolites N-desmethyl–LSD and 2-oxo-3-hydroxy-
LSD in urine for 3 days. All analytes were found to be stable at −20 °C. At 4 °C 
and 22 °C, only LSD was stable and at 40 °C all analytes were unstable. 
 
The influence of cosmetic treatments such as bleaching and perming formulas on 
the stability of opiates in hair was examined by Putsch and Skopp.82 About 2−18% 
of starting opiate concentration could be detected after bleaching and about 
20−30% after perming. Morphine was found to be more sensitive to oxidative 
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destruction followed by codeine and dihydrocodeine. In another report Yegles et 
al.83 studied the effect of bleaching on the stability of benzodiazepines and 
opiates in hair. Concentrations of diazepam, nordiazepam, and 7-
aminoflunitrazepam decreased by 39.7%, 67.7%, and 61.8%, respectively in 
comparison to unbleached hair. Furthermore, significant decreases occurred in 
the concentrations of codeine, 6-acetylmorphine and morphine amounting to 
57.5%, 88.6%, and 67.4%, respectively. Cocaine and benzoylecgonine 
concentrations decreased by 24.6% and 36.4%, respectively.84 
 
Skopp et al.85 investigated the in vitro stability of cocaine (COC) in whole blood 
and plasma preserved with 0.25% potassium fluoride (KF) for 15 days at 4 °C and 
20 °C and for 3 days at 40 °C. The study also included the stability of 
benzoylecgonine (BZE), ecgonine methyl ester (EME) and ecgonine (ECG) stored 
in plasma at 4 °C and 20 °C. Cocaine continuously decreased whereas its 
metabolites appeared after storage for 1 day at 4 °C and 20 °C. At 40 °C, COC 
was detected for only 2 days. The sum of all hydrolysis products comprised 82% 
of the initial COC concentration at 40 °C. The degradation of cocaine in whole 
blood was less than in plasma. Both BZE and EME were found to be unstable and 
were hydrolysed to ECG, which was found to be the major hydrolysis product for 
COC, BZE, and EME. ECG was found to be stable at all storage temperatures and 
could be detected even if samples were stored under unfavorable conditions, so 
could be used to correct for loss of the parent drug.  
 
The stability data of different classes of drugs in biological samples has been 
reviewed recently by Peters and Maurer.86  
 
 
2.3 Pesticides 
2.3.1 Organophosphates 
Ageda et al.87 studied the stability of 14 organophosphorous insecticides in fresh 
blood at 37 °C, 25 °C, and 4 °C for 1 day. The study showed that concentrations 
decreased as the temperature increased. All compounds except malathion, 
trichlorfon, and fenitrothion were found to be stable at 4 °C. At room 
temperature all compounds were found to be unstable except thiometon, 
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isoxathion, diazinon, and sulprofos. Sulprofos is the only compound that was 
found stable at 37 °C. 
 
Moriya et al.88 investigated the effect of preservative (NaF) on the stability of 
organophosphates in blood for 3 days. Instead of preserving the compounds from 
degradation, sodium fluoride was found to accelerate the chemical degradation 
of the compounds. Dichlorvos completely disappeared within 15 min of addition 
of NaF (2% W/V) whereas chlorpyrifos decreased by 95% after 3 days. A similar 
observation was reported by Asri99 and this loss was attributed to alkaline 
hydrolysis after the addition of NaF. Therefore, Moriya et al.88 recommended 
that NaF preservatives should be avoided for samples containing 
organophosphorous compounds. 
 
 
 
2.4 Stabilisation of samples 
Degradation mechanisms may occur as a result of three main reactions: 
reduction, oxidation and hydrolysis. Therefore, stabilisation of samples can be 
achieved by inhibiting these reactions from occurring as well as inhibiting 
clotting and enzymatic and bacterial activity, in order to keep compounds stable 
in the sample for a long period of time. Since stability is an essential issue in 
forensic toxicology, the influence of the environmental and storage conditions 
on compound stability in different matrices should be understood in order to 
select a suitable method to preserve compounds against degradation as well as 
to optimize the best storage conditions.  
Some methods that have been used to stabilize analytes are listed below.  
2.4.1 Additives 
Blood clotting occurs very quickly, 4―8 min after placing blood in the collection 
tube. This makes sample analysis very difficult. Calcium plays a major role in 
this process. Chemical substances that prevent the clot formation process are 
called anticoagulants and include potassium oxalate, citrate, 
ethylenediaminetetraacetic acid (EDTA) and heparin. Usually oxalate is 
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combined with preservatives such as sodium fluoride (NaF), which is considered 
a weak anticoagulant. Fluoride/oxalate works by precipitating calcium while 
citrate and EDTA bind calcium to stop the clotting process from occurring. 
Heparin works by preventing conversion of prothrombin to thrombin, thereby 
preventing clot formation.51  
Sodium fluoride is an antienzymatic agent that inhibits the activity of enzymes, 
such as cholinesterase, and bacteria, thus inhibiting the reduction of 
nitroaromatic compounds by bacterial metabolism and enhancing the stability of 
drugs. Addition of a cholinesterase inhibitor such as echothiophate as well as 
fluoride/oxalate to samples containing cocaine reduced the loss of cocaine by 
60% compared to the loss after adding only fluoride/oxalate to the sample.45 
Brogan et al.89 studied the stability of cocaine in blood samples stored at room 
temperature for 2 days in 5 different tubes containing no additives, 0.25% NaF, 
0.5% NaF, 1% NaF and 0.25% NaF/K respectively. Cocaine was unstable in 
containers not containing any additives while equal enhancement of stability 
was observed in containers containing 0.25% and 0.5% NaF and increased when 
1% of NaF tube was used. The greatest inhibition of cocaine degradation was 
achieved when the gray-top vacutainer® containing 0.25% NaF/K was used and 
stored at room temperature or at 4 °C.  
Addition of sodium azide (NaN3) as preservative showed enhancement of drug 
stability in urine. An aseptic urine collection kit showed greater enhancement of 
drug stability than NaN3.
66 
In most studies additives showed enhancement of the drug stability when added 
to the sample whereas some studies showed little effect. However, additives 
should be carefully selected for such cases and analytes. For example, adding 
EDTA to samples containing morphine showed an increase in the morphine 
concentration by 4.8% compared to heparin anticoagulant.90 Furthermore, NaF 
accelerated the chemical hydrolysis of dichlorvos and chlorpyrifos when added 
to blood samples containing these compounds. Thus, it should be avoided in 
samples containing organophosphates.88 NaN3 has also been found to accelerate 
the degradation of cocaine and 6-acetylmorphine when added to urine 
samples.66 
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2.4.2 Filter paper 
Preserving compounds in dried blood spots on filter paper has been advocated in 
previous studies. For example, the antibacterial drugs enrofloxacin (EFX) and 
ciprofloxacin (CFX) were found to be stable for 4 weeks when stored in dried 
blood spots at −20 °C, 4 °C and room temperature.7 Tacrolimus, an 
immunosuppressant drug, was present in blood samples collected from patients 
and stored on filter paper for 1 month at 4 °C. It was found stable under these 
storage conditions.91 Furthermore, tacrolimus was found to be stable when 
stored at room temperature, 37 °C, 70 °C and −20 °C for 9, 7, 1, and 8 days, 
respectively.92 
Skopp93 has used filter paper to assess the degradation of some drugs. For 
example, ester type drugs, amphetamines, diazepam and its metabolites were 
found to be stable in dried blood spots for several days even when stored under 
a high temperature of 40 °C. Furthermore, cocaine is known to be very unstable 
and to degrade rapidly in blood samples.94 However, when stored in filter paper 
it was stable at −20 °C and at room temperature for 17 days. 
Metformin is used for type 2 diabetic patients: its stability was assessed for 2 
months in blood spots stored on filter paper at −70 °C and was found to be 
stable for the entire observation period. 95 
The stabilities of drugs in urine samples stored in filter paper have been 
investigated at −20 °C, 4 °C and room temperature for 12 weeks compared to 
aliquots of urine stored at −20 °C. Benzoylecgonine, morphine and PCP were 
found to be stable at all storage temperatures in both dried and frozen aliquot 
samples for the whole study period. Amphetamine was found to be stable in 
dried stains at all storage temperatures whereas 16% of its original concentration 
was lost from aliquots of urine stored at −20 °C after 12 weeks. Furthermore, 
THC-COOH was found to be stable in dried spots at −20 °C and 4 °C for 12 weeks 
while at room temperature it was stable for only 4 weeks. In frozen urine aliquot 
samples, THC-COOH was found to be stable for 12 weeks.96 
Stabilities of the antimalarial drugs chloroquine (CQ) and proguanil (PG) and 
their metabolites monodesethylchloroquine (MDCQ) and cycloguanil (CG) 
respectively were evaluated at −20 °C, 4 °C, 20 °C, and 50 °C for 1, 5, and 20 
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days. All compounds were found to be stable for 1 day at all storage conditions. 
CG was not affected by temperature and was found to be stable for 20 days at 
all storage conditions. CQ decrease by more than 50% at 20 °C and 50 °C after 5 
and 20 days of storage. Significant decreases of 30% and 80% in PG concentration 
were observed after 5 or 20 days at 50 °C respectively. However, MDCQ 
decreased at 20 °C after 5 and 20 days and completely disappeared after 5 or 20 
days of storage at 50 °C.97 
2.4.3 Freezing  
Usually samples after collection are kept at ambient temperature during 
transportation; in the laboratory reception or during registration then the 
samples will be stored at 4 °C for a few days until screening and confirmation 
are performed. After that samples will be stored at negative temperatures 
(freezer) for several months or years for reanalysis and legal purpose 
requirements. Most studies showed that as temperatures increase the stability of 
drugs decreased. Freezing enhances stability if drugs are stored at −20 °C or 
lower, such as −70 °C or −80 °C. Consequently the rate of degradation reactions 
will be minimized at low temperatures. Therefore, it is recommended by most 
studies that samples are kept in the freezer after collection, even during 
transportation from the place of collection.61-81 
2.4.4 Acidification 
Acidification of samples showed enhancement of the stability of some drugs, for 
example, substitution of the anticoagulant potassium oxalate by oxalic acid 
minimized the decrease in cocaine concentration from 100% to 76% loss after 1 
year of storage.62 
Hashimoto and Moriya98 investigated the postmortem stability of cocaine and 
cocaethylene in blood and tissues of humans and rabbits. They found that 
cocaine is less stable than cocaethylene in postmortem samples, and brain and 
muscle were considered the specimens of choice to detect cocaine and 
cocaethylene. In acidic conditions cocaine was stable and did not decompose. 
Moreover a study by Gupta showed that cocaine was stable in aqueous solution 
below pH 4 at 24 °C for 45 days.246 
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Asri99 found that acidification of solutions containing malathion in deionized 
water with preservatives such as EDTA/K and Heparin/Lithium lowered the pH to 
(5-6) and 7 respectively and reduced the degradation of the compound whereas 
addition of NaF was found to increase the pH value to basic (around 8) 
consequently accelerated the degradation of the compound.  
2.4.5 Antioxidants  
Addition of an antioxidant to serum samples enhanced the stability of drugs 
sensitive to oxidation reactions. The new-generation neuroleptic drug olanzapine 
was stabilised by adding 0.25% ascorbic acid as antioxidant during the extraction 
procedure and storage period. Samples not containing ascorbic acid lost 16% of 
the olanzapine compared to those with the antioxidant. Storage of samples not 
containing antioxidant for 1-2 weeks showed decreases in olanzapine 
concentration of 13-45%, respectively. At room temperature, about 40% was lost 
after 24 h compared to samples containing ascorbic acid. Different 
concentrations of ascorbic acid, 0.125%, 0.25% and 0.5% showed the same result: 
no differences were noted between them.100 
Ueyama et al.101 investigated the effects of three antioxidants in preventing 
oxidation of dialkylthiophosphates to their corresponding dialkylphosphates. 
About 10 mg/ml of ascorbic acid, sodium metabisulfite (SOD) or pyrogallol were 
added individually to human urine spiked with dimethylthiophosphate (DMTP) 
and diethylthiophosphate (DETP). Without antioxidant, dimethylphosphate (DMP) 
and diethylphosphate (DEP) were produced in 25% yield. In contrast, addition of 
any of the antioxidants to the sample prevented production of DMP and DEP 
effectively (although pyrogallol was less effective). Ascorbic acid showed an 
interference peak in the subsequent analysis and SOD was selected for use, 
which prevents the unwanted production of DMP and DEP to < 1%. 
The stability studies of drugs and pesticides are summarized in Table 2-1. 
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Table  2-1: Summary of drugs and pesticides stability 
Author Compound Matrix Conditions Results Comments 
Nitrazepam Blood 
-20 ºC, 24 months 
4 ºC, 10 months 
22 °C, 28 days 
Stable 
Clonazepam Blood 
 
-20 ºC, 24 months 
4 ºC, 10 months 
22 °C, 28 days 
Stable 
 
-20 ºC, 24 months 
4 ºC, 10 months 
Stable 
Flunitrazepam Blood 
 
22 °C, 28 days 
 
25% decrease 
 
-20 ºC, 2 months 
4 ºC, 1 months 
Stable 
7-aminonitrazepam Blood 
22 °C, 28 days 
 
25% decrease 
 
7-aminoclonazepam Blood 
-20 ºC, 2 months 
4 ºC, 1 months 
22 °C, 28 days 
Stable 
-20 ºC, 2 months 
4 ºC, 1 months 
 
Stable 
 
Robertson and 
Drummer46  
7-aminflunitrazepam Blood 
22 °C, 28 days 
 
10% decrease 
 
With 1% (w/v) NAF 
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-80 ºC, 1 year 
 
Stable 
-20 ºC, 1 year 
20% and 5% 
decrease for LC and 
HC, respectively  
4 ºC, 1 year 
90% and 50% 
decrease for LC and 
HC, respectively 
Clonazepam Blood 
22 °C, 1 year 
100% and 90% 
decrease for LC and 
HC, respectively 
-80 ºC, 1 year Stable 
-20 ºC, 1 year 
20% and 5% 
decrease for LC and 
HC, respectively  
4 ºC, 1 year 
90% and 50% 
decrease for LC and 
HC, respectively 
Flunitrazepam Blood 
22 °C, 1 year 
100% and 90% 
decrease for LC and 
HC, respectively 
-80 ºC, 1 year Stable 
-20 ºC, 1 year 
20% and 5% 
decrease for LC and 
HC, respectively  
4 ºC, 1 year 
90% and 50% 
decrease for LC and 
HC, respectively 
El Mahjoub et al.56 
Midazolam  Blood 
22 °C, 1 year 
100% and 90% 
decrease for LC and 
HC, respectively 
No additives 
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-80 ºC, 1 year Stable 
-20 ºC, 1 year 
20% and 5% 
decrease at LC and 
HC, respectively  
4 ºC, 1 year 
90% and 50% 
decrease at LC and 
HC, respectively 
Oxazepam  Blood 
22 °C, 1 year 
100% and 90% 
decrease at LC and 
HC, respectively 
-20 ºC, 1 year Stable 
4 ºC, 1 year 18% decrease  
Alhadidi and 
Oliver57 
Temazepam Blood 
25 °C, 1 year 53% decrease 
No additives 
-20 ºC, 1 year Stable 
4 ºC, 1 year 30% decrease Morphine Blood 
25 °C, 1 year 30% decrease 
No additives 
-20 ºC, 1 year Stable 
4 ºC, 1 year 30% decrease 
Alhadidi and 
Oliver58 
Buprenorphine Blood 
25 °C, 1 year 30% decrease 
No additives 
-20 ºC, 6 months 
4 ºC, 6 months Blood 
25 °C, 3 months 
-20 ºC, 6 months 
4 ºC, 6 months 
Alhadidi and 
Battah59 
Trihexyphenidyl 
Urine 
25 °C, 4 months 
Stable No additives 
-20 ºC, 10 months 
4 ºC, 8 months Alhadidi et al.60 Chlorpromazine Blood 
25 °C, 2 months 
Stable No additives 
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4 ºC, 5 months 
Diazepam Blood 
25 ºC, 5 months 
Stable 
4 ºC, 5 months < 20% decrease 
Nitrazepam Blood 
25 ºC, 5 months > 50% decrease 
4 ºC, 5 months 
Flurazepam Blood 
25 ºC, 5 months 
< 20% decrease 
4 ºC, 5 months N-1-
desalkylflurazepam 
Blood 
25 ºC, 5 months 
< 20% decrease 
4 ºC, 5 months > 50% decrease  
Chlordiazepoxide Blood 
25 ºC, 5 months 100% decrease 
4 ºC, 5 months < 20% decrease 
Levine et al.55 
Norchlordiazepoxide Blood 
25 ºC, 5 months 100% decrease 
With NAF 
-20 ºC, 11 months 5.3-31% decrease 
4 ºC, 11 months 5.4-39% decrease Morphine  Blood 
25 °C, 11 months 1-100% decrease 
-20 ºC, 11 months 14-25% decrease 
4 ºC, 11 months 12-22% decrease 
Lin et al.61 
Codeine Blood 
25 °C, 11 months 9.5-66% decrease 
No additives 
100% decrease 1 % (w/v) NAF/K Oxalate 
76% decrease  1 % (w/v) NAF/Oxalic Acid  Cocaine  Blood 4 °C, 1 year 
60% decrease 0.1% (w/v) echothiophate  
1 % (w/v) NAF/K Oxalate 
1 % (w/v) NAF/Oxalic Acid  
Baselt et al.62 
Benzoylecgonine 
Ethanol  
Blood 4 °C, 1 year Stable 
0.1% (w/v) echothiophate 
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4 ºC, 1 months 
Cocaine  Blood 
25 °C, 1 months 
> 50% decrease  
4 ºC, 1 months 
 
McCurdy et al.63 Benzoylecgonine 
THC-COOH 
Blood 
25 °C, 1 months 
Stable 
No improvement in any of the 
4 tubes (NAF, EDTA, Heparin 
and no additives) 
-20 °C, 21 weeks 
4 °C, 21 weeks 
Urine and 
water 
20 °C, 21 weeks 
-20 °C, 21 weeks 
4 °C, 21 weeks Blood 
20 °C, 21 weeks 
-20 °C, 21 weeks 
4 °C, 21 weeks 
Clauwaert et al.65 
Amphetamine 
MDA 
MDMA 
MDEA 
Serum 
20 °C, 21 weeks 
Stable No additives 
-20 º C, 5 months 
4 ºC, 5 months Estazolam Urine 
25 °C, 5 months 
Stable 
No improvement with NaN3 
and aseptic collection kit 
-20 ºC, 5 months 
4 ºC, 5 months Amphetamine Urine 
25 °C, 5 months 
-20 ºC, 5 months 
4 ºC, 5 months Methamphetamine Urine 
25 °C, 5 months 
Stable in sterile 
sample but unstable 
in severely 
contaminated 
sample 
-20 ºC, 5 months 
4 ºC, 5 months 
Stable 
Zaitsu et al.66 
Nitrazepam Urine 
25 °C, 5 months 100% decrease 
Stability enhanced with NaN3 
and aseptic collection kit 
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-20 °C, 5 months 
4 °C, 5 months 
Stable 
7-
aminoflunitrazepam 
Urine 
25 °C, 5 months 100% decrease 
-20 º C, 5 months 
4 ºC, 5 months 
Stable 
Cocaine Urine 
25 °C, 5 months 100% decrease 
-20 º C, 5 months 
4 ºC, 5 months 
Stable 
Zaitsu et al.66 
6-acetylmorphine Urine 
25 °C, 5 months 100% decrease 
Stability enhanced with 
aseptic collection kit but 
degradation increased when 
NaN3 used 
Skopp et al.67 
Diazepam  
Midazolam 
Prazepam 
Flurazepam 
Hydroxyethylflurazep
am 
Lorazepam 
Nordazepam 
Flunitrazepam 
Norflunitrzepam 
Desalkylflurazepam 
Clorazepate 
Clobazam 
Bromazepam 
 
Blood and 
plasma 
4 °C, 8 months > 60% decrease No additives 
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-20 º C, 6 months 
4 ºC, 6 months Blood 
25 °C, 6 months 
Stable 
-20 º C, 6 months 
4 ºC, 6 months 
Stable 
Morphine 
Plasma 
25 °C, 6 months 23% decrease 
-20 º C, 6 months 
4 ºC, 6 months Blood 
25 °C, 6 months 
-20 º C, 6 months 
4 ºC, 6 months 
M3G 
Plasma 
25 °C, 6 months 
Stable 
-20 º C, 6 months 
4 ºC, 6 months 
Stable 
Blood 
25 °C, 6 months 23% decrease 
-20 º C, 6 months 
4 ºC, 6 months 
Stable 
Skopp et al.68 
M6G 
Plasma 
25 °C, 6 months 14% decrease 
No additives 
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-20 ºC, 1 year Stable 
4 ºC, 1 year 20% decrease Diazepam Blood 
25 °C, 1 year 46% decrease 
-20 ºC, 1 year 43% decrease 
4 ºC, 1 year 53% decrease Desmethyldiazepam Blood 
25 °C, 1 year 70% decrease 
-20 ºC, 1 year 30% decrease 
4 ºC, 1 year 38% decrease Temazepam Blood 
25 °C, 1 year 44% decrease 
-20 ºC, 1 year Stable  
4 ºC, 1 year Stable  Amitriptyline  Blood 
25 °C, 1 year 42% decrease 
-20 ºC, 1 year 44% decrease 
4 ºC, 1 year 54% decrease Nortriptyline  Blood 
25 °C, 1 year 73% decrease 
-20 ºC, 1 year Stable  
4 ºC, 1 year Stable  
Lutfi69 
Imipramine  Blood 
25 °C, 1 year 50% decrease 
No additives 
Cocaine Blood 25 °C, 5 year 100% decrease 
Benzoylecgonine Blood 25 °C, 5 year 100% decrease 
Morphine Blood 25 °C, 5 year 62% decrease 
Codeine Blood 25 °C, 5 year Stable 
Methamphetamine Blood 25 °C, 5 year 100% decrease 
Giorgi and Meeker70 
Phencyclidine Blood 25 °C, 5 year 69.4% decrease 
No additives 
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-20 °C, 7 months Kala and 
Lechowics.72 
Pancuronium Blood 
25 °C, 3 months 
Stable No additives 
Amphetamine 
Methamphetamine 
Morphine 
Codeine 
Phencyclidine 
THC-COOH 
Urine -20 °C, 1 year Stable Dugan and 
Bogema73 
Cocaine Urine -20 °C, 1 year 37% decrease 
No additives 
Datta.245 Digoxin Saliva 25 °C, 2 weeks Stable No additives 
Lori et al.74 
Digoxin 
Digitoxin 
Serum 4 °C, 3 days Stable No additives 
-18 °C, 2 months 4% decrease Forsdahl and 
Gmeiner75 
Salbutamol Urine 
4 °C, 2 months 12% decrease 
No additives 
Paracetamol 
-20 °C, 3 freezing and 
thawing cycles for 3 
months Celma et al.76 
Chlorpheniramine 
Plasma 
25 °C, 1 day in 
autosampler 
Stable No additives 
4 °C, 1 day 
25 °C, 1 day 
Bennetto et al.77 Nevirapine 
Blood and 
serum  
37 °C (incubator), 1 
day 
Stable No additives 
Barnada et al.78 
Nifedipine 
Nisoldipine 
Plasma 
-20 °C, 2 months 
25 °C, 1 day 
Stable 
Protected from laboratory 
light 
Oliver and 
Stephen79 
Promazine 
Desmethylpromazine 
Plasma 
and  
urine 
-20 °C, 2 months Stable No additives 
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-20 °C, 10 days Stable 
4 °C, 10 days 
20 °C, 10 days 
Skopp et al.80 
THC-COOH-
glucuronide 
Plasma 
40 °C, 10 days 
Degradation 
increased when 
temperature 
increased 
No additives 
-20 °C, 3 days 
4 °C, 3 days 
22 °C, 3 days 
Stable 
LSD Urine  
40 °C, 3 days Unstable  
-20 °C, 3 days 
4 °C, 3 days 
Stable 
22 °C, 3 days 
Skopp et al.81 
N-desmethyl-LSD 
2-oxo-hydroxy-LSD 
Urine 
40 °C, 3 days 
Unstable 
No additives 
Diazepam 39.7% decrease 
Nordiazepam 67.7% decrease 
7-
Aminoflunitrazepam 
61.8% decrease 
Codeine 57.5% decrease 
6-acetylmorphine 88.6% decrease 
Morphine 67.4% decrease 
Cocaine 24.6% decrease 
Yegles et al.83 
Benzoylecgonine 
Hair Room temperature 
88.6% decrease 
Bleached 
Dichlorvos 
100% decrease 
within15 minutes 
Moriya et al.88 
Chlorpyrifos 
Blood 22 °C, 3 days 
95% decrease after 
3 days 
NAF (2% W/V) 
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-20 °C, 4 weeks 
Enrolfloxacin 
4 °C, 4 weeks Posyniak et al.91 
Ciprofloxacin 
Dried 
blood spot 
22 °C, 4 weeks 
Stable Stored in filter paper 
Hoogtanders et 
al.92 
Tacrolimus 
Dried 
blood spot  
4 °C, 1 month Stable Stored in filter paper 
Skopp94 
Amphetamine 
Diazepam  
Dried 
blood spot  
40 °C, 17 days Stable  Stored in filter paper 
Skopp93 Cocaine 
Dried 
blood spot  
-20 °C, 17 days Stable Stored in filter paper 
AbuRuz et al.95 Metformin 
Dried 
blood spot  
-70 °C, 2 month Stable Stored in filter paper 
-20 °C, 12 weeks 
4 °C, 12 weeks 
Dried 
urine spot 
25 °C, 12 weeks 
Benzoylecgonine  
Morphine  
Phencyclidine 
THC-COOH 
Aliquot of 
urine 
-20 °C, 12 weeks 
Stable 
-20 °C, 12 weeks 
4 °C, 12 weeks 
Dried 
urine spot 
25 °C, 12 weeks 
Stable 
Dubey et al.96 
Amphetamine 
Aliquot of 
urine 
-20 °C, 12 weeks 16% decrease 
Stored in filter paper 
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-20 °C, 20 days 
4 °C, 20 days 
Stable 
25 °C, 20 days 
Chloroquine 
Dried 
blood spot 
50 °C, 20 days 
>50% decrease 
-20 °C, 20 days 
4 °C, 20 days 
25 °C, 20 days 
Stable 
Proguanil 
Dried 
blood spot 
50 °C, 20 days 80% decrease 
-20 °C, 20 days 
4 °C, 20 days 
Stable 
25 °C, 20 days 
Monodesethylchloroq
uine 
Dried 
blood spot 
50 °C, 20 days 
100% decrease 
-20 °C, 20 days 
4 °C, 20 days 
25 °C, 20 days 
Lejeune et al.97 
Cycloguanil 
Dried 
blood spot 
50 °C, 20 days 
Stable 
Stored in filter paper 
Gupta247 
Cocaine  
Aqueous 
solution 
24 °C, 45 days Stable pH < 4 
Stable 0.25% ascorbic acid 
4 °C, 2 weeks 
45% decrease No antioxidant 
Stable 0.25% ascorbic acid 
Olesen et al.100 Olanzapine Serum 
25 °C, 1 day 
40% decrease No antioxidant 
Dimethylthiophospha
te (DMTP) 
Ueyama et al.101 
Diethylthiophosphate 
(DETP) 
Urine During the extraction 
Conversion to DMP 
and DEP reduced to 
< 1% 
1%(w/v) of SOD, ascorbic acid 
or pyrogallol 
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Skopp et al.85 Cocaine Blood 40 °C, 15 days 
100% decrease while 
degradation product 
increased 
0.25%(w/v) NAF 
Fumio and 
Yoshiaki48 
Nitrazepam 
Postmorte
m blood 
2-8 °C 
Different 
concentration of 
nitrazepam and 7-
amino-nitrazepam 
at different sites of 
nitrazepam case 
sample toxicity 
The change in the 
concentration is attributed to 
bacterial contamination or 
dilution by water that 
entered in the circulation 
through the lung 
100% converted to 
7-aminometabolites 
No additives 
13% converted to 7-
aminometabolites 
0.7%(w/v) NAF 
4% converted to 7-
aminometabolites 
1%(w/v) NAF 
Robertson and 
Drummer45 
Flunitrazepam 
Nitrazepam 
Clonazepam 
Postmorte
m blood 
22 ºC, 21 days 
4% converted to 7-
aminometabolites 
2%(w/v) NAF 
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4 °C, 1 day 
25 °C, 1 day Dichlorvos Blood  
37 °C, 1 day 
100% decrease 
4 °C, 1 day 44% decrease 
25 °C, 1 day Malathion Blood  
37 °C, 1 day 
100% decrease 
4 °C, 1 day 14% decrease 
25 °C, 1 day Trichlorfon Blood  
37 °C, 1 day 
100% decrease 
4 °C, 1 day 18% decrease 
25 °C, 1 day 61% decrease  Phenthoate Blood  
37 °C, 1 day 86% decrease 
4 °C, 1 day 15% decrease  
25 °C, 1 day 28% decrease Fenitrothion Blood  
37 °C, 1 day 82% decrease 
4 °C, 1 day Stable  
25 °C, 1 day 36% decrease Cyanophos Blood  
37 °C, 1 day 74% decrease 
4 °C, 1 day 5% decrease  
25 °C, 1 day 21% decrease Methidathion Blood  
37 °C, 1 day 63% decrease 
4 °C, 1 day 7% decrease  
25 °C, 1 day 17% decrease Dimethoate Blood  
37 °C, 1 day 43% decrease 
4 °C, 1 day Stable  
25 °C, 1 day 8% decrease Thiometon Blood  
37 °C, 1 day 38% decrease 
4 °C, 1 day 8% decrease 
25 °C, 1 day 9% decrease 
Ageda et al.87 
 
Isoxathion 
 
Blood  
37 °C, 1 day 35% decrease 
No additives 
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4 °C, 1 day Stable  
25 °C, 1 day 11% decrease EPN Blood  
37 °C, 1 day 28% decrease 
4 °C, 1 day Stable  
25 °C, 1 day 12% decrease Acephate Blood  
37 °C, 1 day 22% decrease 
4 °C, 1 day Stable  
25 °C, 1 day 6% decrease Diazinon Blood  
37 °C, 1 day 21% decrease 
4 °C, 1 day 
25 °C, 1 day 
Ageda et al.87 
Sulprofos Blood  
37 °C, 1 day 
Stable 
No additives 
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3 General Experimental Procedures Used in this 
Project 
3.1 Extraction 
The main role of extraction is to separate the analytes from their matrix and 
preferably also remove as many interferences from the sample as possible, such 
as protein and other biological components, before analysis. However, some 
difficulties normally occur in forensic toxicology in determining compounds in 
blood samples, such as haemolysis of the samples and putrefaction of a 
postmortem sample, as described earlier. Some samples may be contaminated 
by components of the container such as the rubber septa, which may make 
contact with the sample during collection and storage. The samples may also 
have solidified and coagulated, especially if no additives were used. 
Furthermore, the amount of the sample collected may be small or have very low 
drug concentrations. Therefore, using an efficient, first-rate technique for the 
extraction of samples is necessary in order to obtain a high recovery of the 
analytes of interest from biological samples.102 
 
The most common extraction techniques are liquid liquid extraction (LLE) and 
solid phase extraction (SPE). However, SPE posses advantages over LLE, as 
discussed in detail in the next section and solid phase extraction was used in the 
studies in this thesis. 
 
3.1.1 Solid phase extraction 
Solid phase extraction, first reported in 1974, is a relatively new technique and 
has become rapidly established in the clinical, biochemical, industrial, 
environmental, and pharmaceutical fields because of its powerful ability to 
provide clean extracts of dirty samples, such as those containing protein, salts, 
and resins in high amounts.102 
 
SPE has largely replaced LLE because of its advantages over LLE; for example, a 
lower sample quantity (100 µL or less) can be used in SPE. In addition, the small 
volume of solvents required in SPE is less than those used in LLE, making SPE 
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more economical. Moreover, the sorbents used in SPE are cheap and can be 
discarded after use. LLE is also more time consuming than SPE, which can 
provide higher recovery, selectivity, and reproducibility in comparison with LLE, 
and its procedure can be easily automated. 
 
The SPE extraction procedure is achieved through five steps, usually carried out 
with a vacuum work station. The first is conditioning of the column to solvate 
the functional groups of the sorbent in order to interact with and retain the 
analytes of interest. This also removes any fine particles and dust from the 
sorbent.  
 
The next step is the loading of the sample at a low flow rate without vacuum 
application to allow enough time for the target analyte to be retained in the 
column by interaction with the sorbent functional groups. However the sample 
should be pretreated with a suitable buffer before this step and addition of a 
suitable internal standard (IS), mixing then centrifuging. 
 
The third step is washing the column with appropriate solvents to remove 
unwanted matrix interferences retained in the sorbent without removing the 
analytes of interest. Then, drying of the column is achieved by applying full 
vacuum to remove as much residual aqueous solvent as possible, that may be 
immiscible with the elution solvent.  
 
Finally, it is necessary to elute the analytes of interest by using a small volume 
of solvent to disrupt all retention mechanisms operating between the sorbent 
functional groups and the analytes. 
 
Compounds may be retained on SPE sorbents by different mechanisms, 
depending on the functional groups bonded to the sorbent backbone (usually 
silica but also organic polymers). The most common SPE columns are described 
below.   
 
3.1.1.1 Hydrophobic SPE columns 
The sorbent backbone is bonded with hydrocarbon chains, such as C8 and C18. A 
non-polar analyte binds to the sorbent by hydrophobic interaction caused by Van 
Der Wall forces. Disruption is achieved by applying a suitable organic solvent to 
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displace the analytes from the column. The C18 column, for example the 
commercial product Bond Elut®, is the most common and widely used 
hydrophobic column because of its ability to retain a wide range of organic 
compounds by non-selective interactions. However, its disadvantage is that 
because it is non-selective, it also retains non-polar interferences from the 
matrix.  
3.1.1.2 Hydrophilic SPE columns 
This column is composed of a silica or polymer backbone bonded with carbon 
chains containing polar functional groups such as amines, hydroxyls and 
carbonyls. The analyte is retained in the sorbent as a result of polar 
interactions, including hydrogen bonding, π-π interactions, or dipole-dipole 
interactions. Polar analytes are often extracted from non-polar matrices such as 
oils with polar columns which need very strongly polar solvents to elute the 
analyte. The Oasis® column is an example of a hydrophilic column using a 
polymeric backbone. 
3.1.1.3 Ion exchange SPE columns 
This sorbent is composed of a silica or polymeric backbone bonded with carbon 
chains terminated with negatively or positively charged functional groups. 
Analytes are retained by ionic bonding between the charged sorbent and the 
oppositely charged analytes. There are two types of ion exchange: cationic and 
anionic.  
In a cationic ion exchange column, the sorbent is substituted with negatively 
charged groups, such as benzenesulfonic acid, propylsulfonic acid or a carboxylic 
acid, whic ion-pair with positively charged analytes (bases, usually amines) to 
form strong bonds. In elution, the analyte is carried out by using a basic solvent 
to neutralize and release the analyte from the cationic ion exchange sorbent. 
 In contrast, the sorbent in an anionic ion exchange column carries positively 
charged substituents, such as primary, secondary or quaternary amines, 
aminopropyl or diethylamino groups, which interact with negatively charged 
analytes (acids) through strong ionic bonds. These interactions are disrupted by 
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using an acidic solvent to neutralize analytes that are to be eluted from the 
column.  
3.1.1.4 Mixed mode SPE columns  
The sorbent contains both hydrophobic and ionic functional groups which provide 
two retention mechanisms. This type of column provides a clean extract because 
of its ability to retain a wide range of compounds with high selectivity without 
any interferences. Thus, it is widely used in forensic toxicology. For example, 
Bond Elut Certify® and CLEAN SCREEN® SZDAU020 contain hydrophobic C8 groups 
and a strong cationic exchanger  (benzosulfonic acid), while Bond Elut Certify II®  
contains hydrophobic C8 and a strong anionic exchange (quaternary amine).102 
 
3.2 Derivatization  
The presence of a polar functional group in an analyte such as a hydroxy or 
amino groups may cause a polar interaction between the analyte and the 
analytical column stationary phase or polar residues in the injector and column 
which have accumulated from previous analyses, especially in gas 
chromatography and gas chromatography/mass spectrometry, leading to peak 
tailing and poor detection of the compound. Therefore, the derivatization 
process is used to modify the chemical properties of a compound by chemically 
altering the polar active sites on the molecule, producing a thermally stable, low 
polarity and more volatile compound, thereby improving selectivity and 
detectability of the analyte prior to analysis. 
Derivatization is classified into three main groups: silylation, acylation and 
alkylation. Silylation is the most common and widely used derivatisation reaction 
in forensic toxicology and was used in this thesis for silylation of 
dialkylphosphate (DAP) compounds.
102,103 
3.2.1 Silylation 
Silylation is the introduction of a silyl group, usually the trimethylsilyl group, 
Si(CH3)3, into the analyte by substitution of the active hydrogen in the analyte 
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with the silyl group, thus reducing the polarity of the compound and decreasing 
hydrogen bonding. 
There are a large number of silylation reagents available commercially. In this 
thesis, N-tert-butyl-dimethylsilyl-N-methyl-trifluoracetamide (MTBSTFA) 
containing 1% t-butyldimethylchlorosilane (TBDMCS) was used as described in a 
previous study that used this derivatizing agent for DAP compounds. MTBSTFA 
reacts with carboxyls, hydroxyls thiols, and primary and secondary amines in a 
short time and at room temperature and the solution of analyte in the reagent 
can be injected directly into the gas chromatograph. Temperature and catalysts 
such as trimethylchlorosilane (TMCS) and TBDMCS are often used to increase the 
rate of reaction.103 
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3.3 Gas Chromatography/Mass Spectrometry (GC/MS) 
Gas chromatography (GC) is a separation technique used to separate volatile 
compounds from the sample by differential migration through a column 
containing the stationary phase.The samples should be injected into the flowing 
mobile phase rapidly. The injection port is connected to the top of the column 
which should be hot to vaporize the sample before enter to the column. There 
are different injection methods and the most common techniques are split and 
splitless injection mode. Split injection is less sensitive than splitless because a 
small fraction of the injected sample enters the column while the rest vents to 
the atmosphere via a control valve. Transportation of analytes through the 
column to the detector is performed by an inert gaseous mobile phase, usually 
helium or nitrogen. 104  
Analytical columns are coiled to allow them to be housed within a fan-assisted 
thermostatically controlled oven. Currently, GC uses mostly open tubular 
capillary columns made from fused silica, distinguished by their internal 
diameter, for example narrow bore columns have internal diameters of 
approximately 0.25 mm and megabore columns have a diameter of 0.5 mm.  
Columns also vary according to their length, from 10-100 m, stationary phase 
composition, from non-polar to polar, without or with microparticulate support 
(SCOT columns) and stationary phase layer thickness, from 0.1-several microns.  
Packed GC columns are still used for particular applications, such as analysis of 
gases, especially in an industrial environment. 104  
After the analytes are separated by the column, they are eluted into the 
detector to be registered and produce the gas chromatogram. The most 
important detector that is widely used in forensic toxicology is the mass 
spectrometer and the combined technique is termed gas chromatography/ mass 
spectrometry (GC/MS). 104  
GC/MS is used to identify and quantify analytes. The GC effluent from a capillary 
column is conducted directly into the ion source of the mass spectrometer, 
which is composed of an interface, an ion source, a mass analyzer and a 
detector. The interface is maintained at a high temperature to ensure that the 
sample components remain in the gas phase. The ion source is maintained under 
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vacuum and molecules eluting from the GC column are ionized before passing 
into the mass analyser. The most common ionization methods are electron 
impact ionization (EI, hard ionization) and chemical ionization (CI, soft 
ionization). In EI, molecules are bombarded with high energy electrons (70 
electron volts, eV), which is higher than the ionization potential of most 
molecules and enough to break internal bonds within the molecule to create a 
charged ion, the “molecular ion” and fragment ions. After that, the ions are 
separated according to their mass/charge ratios, which is achieved with a mass 
analyzer such as the time of flight, ion trap and quadrupole analyzers.  The 
quadrupole is the most common analyzer because it is small in size, inexpensive, 
has a lower operating voltage and offers ease of computer control. 104 
When ions enter the detector a significant amount of energy is tranferred to its 
surface. That energy is used to generate a more easily detected species, usually 
electrons or photons that can be detected by an electron or photo-multiplier. 
The multiplier can enormously amplify the signals produced by the ions. The 
amplified signal is converted into digital form with a high frequency analogue-to-
digital converter, then relayed to the computer data acquisition system.104 
The dynamic combination of GC and MS techniques results in a powerful 
separation and structural identification technique and has been used to analyse 
a wide range of compounds.105-109  
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3.4 Liquid chromatography - tandem mass spectrometry 
(LC/MS/MS) 
In this thesis, LC-MS/MS was used to analyze the compounds discussed in 
Chapters 4-7.  The instrument contains three main components: the HPLC 
system, the interface and the mass spectrometer.  
Liquid chromatography (LC) is a separation technique using a liquid mobile phase 
to separate analytes by differential migration through a column containing a 
microparticulate stationary phase. The LC system can be normal phase (NP) or 
reversed phase (RP). In NP, the stationary phase is more polar than the organic 
solvent and systems of this type are used for the analysis of non-polar 
compounds. However, NP is avoided in most laboratories because it generally 
involves mobile phases containing hazardous solvents such as hexane and 
dichloromethane. In RP, the stationary phase is less polar than the mobile phase 
and this type of system is suitable for analysis of polar compounds and is 
commonly used in forensic toxicology. The most common non-polar silica bonded 
stationary phase is C18, which has been used to separate many drugs.
112  
Transportation of the analyte in a RP system is achieved by the mobile phase, 
which usually contains an aqueous buffer and an organic solvent, such as 
acetonitrile or methanol. Selection of the mobile phase components is very 
important; for example, organic solvents such as acetonitrile and methanol are 
preferred because they are less hazardous than the solvents used in NP systems. 
The buffer used must be volatile, especially in LC/MS/MS, such as ammonium 
formate, ammonium acetate, acetic acid, and ammonia because a non volatile 
buffer such as phosphate buffer will precipitate in the ion source, leading to 
clogging and degradation of instrument performance. Further, high buffer 
concentrations should be avoided in order to prevent saturation of the surface of 
droplets formed in the LC-MS interface, consequently inhibiting the formation of 
the gaseous form of analytes and leading to a low instrument response. In 
addition, it is very important to adjust the pH of the mobile phase in order to 
ionize analytes of interest, either basic or acid, because the addition of a small 
amount of volatile acid to the mobile phase will ionize basic analytes while 
volatile bases will ionize acidic compounds.110,112 
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Before the analyte is introduced into the mass analyzer in the mass 
spectrometer component, it must be ionized and the solvent from the LC eluent 
must be eliminated in order to introduce the analyte in ionized gaseous form. 
This process is achieved in the interface. The most common interfaces are 
atmospheric pressure chemical ionization (APCI) and electrospray ionization 
(ESI), which is the most common ionization mode in analytical toxicology. In ESI, 
a high voltage (3-5 Kv) is applied to the ESI needle to evaporate the solvent into 
charged droplets, which exit the ESI probe. When the solvent evaporates, the 
droplet size decreases, ions come closer together and repell each other. When 
the repulsion overcomes the cohesive forces of surface tension, a series of 
columbic explosions results, which splits the droplet into microdroplets as a 
result of these explosions until the gas phase ions are produced. The ions move 
through the ion optic assembly to the mass analyzer.111,112  
The most common mass analyzer is an ion trap, which is known as the 
quadrupole ion trap mass analyzer. It consists of a ring “doughnut” electrode, to 
which an oscillating radiofrequency (RF) field is applied, and two hemispherical 
electrodes (endcaps) which are placed above and below the ring electrode. The 
end caps have small holes in the center allowing ions to pass in and out of the 
cavity. The ions that enter the cavity will be trapped in the ring electrode until 
RF is applied. As the frequency increases, trapped ions are selectively ejected 
out through the exit lens into the ion detection system. 111,112 
In the detection system, selected ions will strike the surface of a conversion 
dynode to produce one or more secondary particles. Then the secondary 
particles are focused by the curved surface of the conversion dynode and 
accelerated into the electron multiplier. If the secondary particles have 
sufficient energy, the electron multiplier cathode will eject electrons, which will 
strike the inner surface of the cathode to produce more electrons, thus the 
cascade of electrons produced results in a measurable current. The current will 
be converted to a voltage by an electrometer circuit and recorded by the MS 
data system. 111,112 
LC-MS/MS has been used to analyse a wide variety of compounds.113-125  
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3.5 Method validation 
Method validation is the application of experimental procedures in order to 
ensure that an analytical method is reliable and fit for its intended purpose. 
Validation of a method used in drug analysis is very important because an 
unreliable method may lead to false positive or negative results or to 
underestimating or overestimating the concentration of an analyte, resulting in a 
false interpretation. An incorrect interpretation may lead to the wrong 
treatment of the patient or unjustified legal consequences for a defendant in 
court. It is therefore very important to use validated methods in forensic 
toxicology in order to give accurate results which can form the basis of correct 
interpretations. 
Different guidelines have been published for method validation.126-133 The 
validation parameters used in this study were as follows: 
3.5.1 Linearity  
The linearity of a method, or calibration model, investigates the relationship 
between the concentration of the analyte in the sample and the detector 
response. This is achieved by analyzing the six sets of samples spiked with 
different concentrations of the analyte and plotting the resulting responses (y) 
versus the corresponding concentration (x). The degree of linearity is provided 
by the value of the correlation coefficient (r2). The method is considered 
acceptable if the linear correlation coefficient (r2) exceeds 0.99. 
3.5.2 Limit of Detection and Lower Limit of Quantitation  
3.5.2.1 Limit of detection (LOD) 
The LOD is defined as the lowest concentration of an analyte that can be 
detected and that can be differentiated from background noise. The LOD is 
measured by analysing samples spiked with decreasing concentrations of the 
analyte. LODs were calculated using Equations 3-1 and 3-2.  
                YLOD = YB+3SB                                 Equation 3-1       
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                LOD = (YLOD-YB)/m             Equation 3-2    Where YB is the intercept, SB 
is the standard error of the regression line, and m is the gradient.  
3.5.2.2  Lower limit of quantitation (LLOQ) 
LLOQ is defined as the lowest concentration of an analyte that can be 
quantitated with the required precision and accuracy. The LLOQ is measured by 
analyzing samples spiked with decreasing concentrations of the analyte. LLOQs 
were calculated using Equations 3-3 and 3-4. 
               YLLOQ = YB+10SB                                   Equation 3-3       
               LLOQ = (YLLOQ-YB)/m               Equation 3-4     
Where YB is the intercept, SB is the standard error of the regression line, and m 
is the gradient.  
3.5.3 Recovery 
Recovery is the percentage of analyte extracted from a sample and is used to 
measure the efficiency of the extraction method. Recovery of analytes was 
determined at three concentrations - low, medium and high - using Equation 3-5. 
Recovery (%) =  (peak area ratio of extracted standard/peak area ratio of 
unextracted standard) x 100                          Equation 3-5 
3.5.4 Precision  
Precision is the closeness of agreement between a series of tests results 
obtained under a set of prescribed conditions. In this thesis, precision was 
measured intraday and interday, and was calculated as the coefficient of the 
variation expressed as a percentage (CV %) or as the percent relative standard 
deviation (RSD %).  
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3.5.4.1 Intraday precision  
Standards were prepared at three concentrations - low, medium and high - and 
five replicates at each concentration were extracted. Each extract was analysed 
and the relative standard deviations at each concentration were calculated as 
the RSD %. An RSD % less than 20 % is considered to be acceptable.126 
3.5.4.2 Interday precision   
Five sets of standards at three different concentrations - low, medium and high - 
were extracted over five different days. The RSD% was calculated for each 
concentration. An RSD % less than 20 % is considered to be acceptable. 126 
 
3.6 Statistical evaluation of stability of substances during 
storage 
In this project, a statistical evaluation was made of the stability of drugs and 
other substances during storage based on the coefficient of variation of the 
method, obtained from measurement of the first day concentration (n=10 or 
n=5). A substance was considered to be significantly unstable (p < 0.05) if its 
concentration at the time selected was less than the value obtained from 
Equation 3-6.59,134  
Concentration threshold = C° - (1.96 × CV %)   Equation 3-6 
Where 
C⁰ =initial concentration 
CV %= coefficient variation of initial concentration 
Student’s t value for any sample in a series was calculated using Equation 3-7 
and the p value was calculated in Excel using the one tail t-test. 
t value = (C° - Cn)/ (CV %)                          Equation 3-7 
Where C° is the initial concentration and Cn is the concentration of the 
significant loss point. 
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4 Stability of Benzodiazepines in Whole Blood 
under Different Storage Conditions 
4.1 Introduction 
Benzodiazepines, one of the most common drug classes, act on the central 
nervous system as CNS depressants. Chlordiazepoxide, the first drug in this 
group, was discovered in 1955 and marketed in 1960 after a clinical application 
trial, which revealed different clinical effects such as its hypnotic, sedative, and 
anticonvulsant activities. Since that time, benzodiazepines have been widely 
prescribed and are used to treat insomnia and anxiety and as muscle relaxants. 
Benzodiazepines are classified according to structural features into 
N1-substituted-1,4-benzodiazepines, diazolobenzodiazepines, triazolobenzo-
diazepines and nitrobenzodiazepines subtypes. Alternatively they are classified 
according to pharmacokinetic half life into short- and long-acting 
benzodiazepine subtypes, which means that benzodiazepines with a half life less 
than 24 hours are considered to be short-acting and those with a half life greater 
than 24 hours are considered to be long-acting. Short-acting benzodiazepines are 
used to treat insomnia, whereas long-acting benzodiazepines are used to treat 
anxiety-related symptoms such as panic attack or social phobia. Many 
benzodiazepine drugs are controlled by the United Nations Convention on 
Psychotropic drugs (1971). These drugs are frequently abused by illicit users in 
combination with other compounds such as opiates, antidepressants, and 
alcohol. 135,136 
 
Benzodiazepines are often present in the blood of drivers involved in road 
accidents because they impair a driver’s attention and cognition.137,142 
Benzodiazepines are also capable of causing drug dependency and tolerance 
after regular use which may take weeks or months to develop.135,136 
Since benzodiazepines impair human performance and attention, some of them, 
such as flunitrazepam and alprazolam, are used by rapists to facilitate sexual 
assaults, Drug Facilitated Sexual Assault (DFSA).143,144 
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4.2 Benzodiazepines included in the present study 
Stability studies were carried out on four benzodiazepines which are described 
below and whose structures are given in Figure 4-1. 
 
Alprazolam is a triazolobenzodiazepine used therapeutically to treat panic 
disorder, panic attack, depression, agoraphobia, and generalized anxiety.  
Alprazolam has a therapeutic level in plasma ranging between 0.005 and 0.05 
mg/L, whereas a toxic concentration ranges between 0.1 mg and 0.4 mg/L, with 
2.1 mg/l being reported as the highest postmortem blood concentration. The 
side effects of alprazolam usually include sedation, drowsiness, confusion, 
aggression, nightmares, tachycardia, and palpitation. Alprazolam is metabolized 
by oxidation followed by conjugation to produce active metabolites α-
hydroxyalprazolam, 4-hydroxyalprazolam, and α, 4-dihydroxyalprazolam.145 
 
Lorazepam is a 3–hydroxy-benzodiazepine. It is administered orally as an 
anxiolytic, tranquilizer, muscle relaxant, anticonvulsant, and hypnotic drug. 
Lorazepam is rapidly absorbed from the digestive tract and its therapeutic 
plasma concentration reaches 0.018 mg/L after 2 hours while toxic 
concentrations in the blood range between 0.28-1.0 mg/L. Lorazepam is rapidly 
conjugated with glucuronic acid to produce an inactive metabolite that 
accumulates in plasma, achieving concentrations that exceed those of its 
parent145.  
Oxazepam is a 3-hydroxybenzodiazepine used clinically as an anxiolytic and 
hypnotic. The maximum therapeutic serum concentration has been reported as 
0.31 mg/L after 1.5 hours. Toxicity has been reported in 14 drivers arrested for 
impaired ability who had an average blood concentration of 2.4 mg/L. Moreover, 
two cases of oxazepam poisoning have been reported, with blood concentrations 
found at 4.4 and 6.1 mg/L. Oxazepam is rapidly conjugated with glucuronic acid 
to produce an inactive metabolite. 145 
The triazolobenzodiazepine estazolam is widely used as a sedative and hypnotic 
drug. Its molecular structure is similar to that of alprazolam and triazolam.  
Maximum plasma therapeutic concentrations of estazolam after an oral dose of 1 
mg ranged between 42-70 µg/L, while the blood concentration of estazolam in 
an overdose case was 1250 µg/L two days after a suicide attempt. Moreover, a 
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postmortem case has been reported involving overdose with estazolam and 
alcohol which had a blood concentration of estazolam of 480 µg/L. In addition, 
estazolam undergoes oxidative metabolism to produce 1-oxoestazolam and 4-
hydroxyestazolam. Both of these metabolites have some pharmacological 
activity. 145 
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Figure  4-1: Chemical structures of benzodiazepines included in this study. 
                
4.3 Aims 
The aim of this study was to determine the stability of selected benzodiazepines 
under a range of storage conditions which represent those likely to be 
encountered in routine forensic toxicology investigations in different parts of the 
world.  The drugs selected for this work have not previously been studied with 
respect to their long-term stability during storage. The effect of preservatives on 
drug stability was also studied using sodium fluoride and potassium oxalate as 
preservative and anticoagulant respectively, which are the most common 
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additives used in forensic toxicology and which have been found to affect the 
rate of hydrolysis of some types of analyte, such as organophosphate pesticicides 
(See Chapter 2 and Chapter 8). 
Alprazolam, lorazepam, oxazepam and estazolam stabilities at low and high 
concentrations in blood were investigated in preserved and unpreserved tubes in 
freezer, refrigerator and at room temperature for one year.  
 
4.4 Experimental Section 
4.4.1 Chemical and material: 
 
Alprazolam, lorazepam, oxazepam, and estazolam were purchased from LGC-
Promochem (Middlesex, UK) as 1 mg/ml solutions in methanol. Alprazolam-d5, 
lorazepam-d4, oxazepam-d5 and estazolam-d5 were purchased from LGC-
Promochem (Middlesex, UK) as 100 µg/ml solutions in methanol. Acetonitrile, 
methanol, cyclohexane, ethyl acetate, ammonium hydroxide, formic acid and 
potassium dihydrogen phosphate were obtained from BDH (Poole, UK). 
Ammonium formate, anhydrous disodium orthophosphate and sodium dihydrogen 
orthophosphate were purchased from Sigma-Aldrich (Dorset, UK). Clean screen® 
ZSDAU020 cartridges were purchased from United Chemical Technology UK. 
Tubes containing sodium oxalate were obtained from Tek Lab Ltd. 
 
4.4.2 Solutions: 
4.4.2.1 Preparation of 0.1M phosphate buffer pH 6.0: 
1 litre of solution was prepared by dissolving 1.7 g of anhydrous disodium 
orthophosphate and 12.14 g of sodium dihydrogen orthophosphate monohydrate 
in 800 ml of deionized water. The pH was adjusted to 6 with 1 M potassium 
hydroxide and the solution made up to volume with deionized water. 
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4.4.2.2 Preparation of 3mM ammonium formate and 0.001% formic acid 
This mobile phase was prepared by dissolving 0.189 g of ammonium formate in 
800 ml deionized water followed by addition of 10 µl of concentrated formic acid 
and making up to one litre with deionized water. 
 
 
4.4.2.3 Standard solutions of analytes 
Working standards of unlabelled and labelled drugs were prepared by diluting 
250 µl from each drug stock solution in 25 ml methanol to obtain a concentration 
of 1 µg/ml. Stock solutions of standards and internal standards were stored at 
-20 ⁰C. 
 
4.4.3 Preparation of blood samples: 
Packed human red blood cells, which had passed their usable date, were 
obtained from the Scottish National Blood Transfusion Service and were re-
suspended in an equal volume of isotonic saline to give a total volume of 800 ml. 
The original blood collection used ethylene diamine tetra acetic acid (EDTA) as 
anticoagulant. It was screened to check whether it contained benzodiazepines of 
interest in this study, and the result was negative.  
 
The blank blood was divided into two portions (400 ml each). One portion was 
spiked with a low concentration of four benzodiazepines drugs and mixed on the 
roller for one hour to give a final concentration of 50 ng/ml. The second portion 
of blank blood was spiked with a high concentration of drugs and mixed for one 
hour to produce a final concentration of 400 ng/ml. Ten aliquots of volume 1 mL 
from each portion were analyzed and found to be homogeneous (RSD% < 14 for 
all analytes as shown in Tables 4-6 to 4-13 as day zero concentrations), and the 
mean for each analyte was considered to be the day zero concentration. 
Subsequently, aliquots of blood (volume 2.5 mL) were pipetted into 300 x 2.5 ml 
tubes, half of which contained 2 mg sodium fluoride and 3 mg potassium oxalate 
per ml in 2.5 ml container while the others contained no additives. These 
prepared samples were stored as real case samples in the 300 containers.  
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4.4.4 Sample storage and time for analysis 
The prepared samples were divided into three groups and were then stored at 
three different temperatures (-20 ºC, 4 ºC, and room temperature) as shown in 
Figure 4-2. These storage temperatures were selected because they are 
frequently-used laboratory storage temperatures. The storage temperatures 
were monitored daily using permanently mounted digital thermometers with a 
resolution of 0.1 C°at the start of the study and subsequently at weekly intervals 
during the period of study. Temperatures were stable within a range of 
approximately 1 C ° (freezer and refrigerator) or 5 C° (room temperature, 
average temperature 20°C).  The times selected for analysis were at day 1 (day 
zero), 2, 4, 7, 14, 30, 60, 90, 180, and 365. 
 
 
 
Figure  4-2: Prepared samples were stored under different conditions 
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4.4.5 Analytical method 
The analytical method used in this study was based on a procedure published in 
the literature for analysis of benzodiazepines in oral fluid, in which a mixed 
mode sorbent was used for extraction followed by LC-MS/MS analysis.125 Since 
the method was to be applied to blood rather than oral fluid, it required to be 
fully validated for its intended purpose before it was used in the stability study 
as summarized in Table 4-1.  Details of the final method are given below. 
 
Table  4-1: Validation of analytical method 
Parameter Samples analysed 
Calculation of parameter and 
acceptance criteria 
Linearity 
Benzodiazepines standards 
were spiked into blood to 
produce two concentration 
ranges, 2-200 ng/ml and 25-800 
ng/ml.  The first set contained 
standards at concentrations of 
2, 5, 10, 25, 50, 100, 200ng/ml 
and the second set contained 
standards at 25, 50, 100, 200, 
400 and 800 ng/ml. 100 ng/ml 
of internal standards were 
added to each calibrator then 
these were extracted by SPE 
and analysed by LC-MS-MS. 
Ratio of peak areas of 
standards/internal standards 
100 ng/ml plotted versus the 
spiked analyte concentrations 
and linear correlation 
coefficient (r2) calculated. 
The linearity of analytes were 
acceptable if r2 > 0.99 
 
 
LOD 
 
 
 
 
 
LOD statistically calculated as 
the intercept of the 
calibration graph plus three 
times the standard error of 
the regression line as shown 
in the equation 3-1 and 3-2 in 
chapter 3. 
 
 
LLOQ 
 
 
 
 
 
 
Blank blood was spiked with 
0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1, 
2 and 5 ng/ml to produce 
regression lines used to 
calculate LOD and LLOQ. Then 
extracted by SPE and analysed 
by LC-MS-MS. 
LLOQ statistically calculated 
as the intercept of the 
calibration graph plus ten 
times the standard error of 
the regression line as shown 
in the equation 3-3 and 3-4 in 
chapter 3. 
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Recovery 
 
 
Blank blood was spiked with 
analyte at three concentrations 
(5, 50 and 100 ng/ml). Each 
concentration was extracted 
five times without addition of 
internal standard. Unextracted 
standards (n=2) at each 
concentration were also 
prepared without internal 
standard present and kept in 
fridge until the extraction 
achieved. Before drying the 
sample under nitrogen stream, 
100 ng/ml of internal standard 
was added to extracted and 
unextracted samples. 
 
 
The % of recovery at each 
concentration was calculated 
using the equation 3-5 in 
which mean peak area ratio 
of extracted samples  divided 
by mean peak area ratio of 
unextracted samples.( peak 
area ratio is peak area of 
product ion/ peak area of 
internal standard). 
 
 
 
 
 
 
Intraday precision 
 
 
 
Standards were prepared at 
three concentrations - 5, 50 
and 100 ng/ml - and five 
replicates at each 
concentration were extracted. 
 
 
Each extract was analysed 
and the relative standard 
deviations at each 
concentration were 
calculated as the RSD %. An 
RSD % less than 20 % is 
considered to be acceptable. 
 
Interday precision 
Five sets of standards at 5, 50 
and 100 ng/ml were extracted 
over five different days. 
 
The RSD% was calculated for 
each concentration. An RSD % 
less than 20 % is considered to 
be acceptable. 
 
Each day samples were analysed, two replicates were taken for analysis from the 
storage racks  for each of the different storage conditions, extracted within the 
day and left to run on the LC-MS/MS instrument overnight.  If the analysis could 
not be completed within 24 hours due to instrumental problems, extracts were 
kept in the deep freeze at -20°C until they could be analysed. A calibration 
curve was prepared for each set of samples over part of the linear range, 25-800 
ng/ml, which was considered sufficient for the analysis of the stored blood 
samples cotaining high and low drug concentrations. Benzodiazepine standards 
were spiked into blood to produce concentrations of 25, 50, 100, 200, 400, 800 
ng/ml and internal standards were added at concentrations of 100 ng/ml to each 
calibrator solution before extraction by SPE and analysis by LC-MS/MS. The 
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calibration models for all analytes were linear with R2 > 0.99 for all drugs (0.994, 
0.996, 0.996 and 0998 for alprazplam, lorazepam, oxazepam and estazolam 
respectively). 
 
4.4.5.1 Extraction of blood samples 
Prior to extraction, 1 ml from each blood sample was mixed with 3.5ml of 
phosphate buffer (pH6) and 100 µl of internal standard followed by 
centrifugation for 10 minutes at 2500 RPM. 
 
The solid phase columns were conditioned with 3ml of methanol, 3ml deionized 
water, and 2 ml of phosphate buffer (pH6), and then the supernatants of the 
samples were poured into the cartridges with no vacuum applied and allowed to 
pass through the absorbent under gravity flow. The columns were then washed 
with 2ml deionized water followed by 2ml phosphate buffer (pH6): acetonitrile 
(80:20 v/v) then dried for 1 minute under full vacuum. After that, 2 ml of 
cyclohexane was passed through the columns, and they were dried for 1 minute. 
The final step in the column washing was the addition of 2 ml of deionized water 
followed by drying for 5 minutes. 
 
Elution of analytes was achieved using 3 ml of ethyl acetate: ammonia (98:2 
v/v). The extracts were dried under a gentle stream of nitrogen at 40 °C, and 
then the residues were reconstituted in 80µl of initial HPLC mobile phase (3mM 
ammonium formate and 0.001% formic acid: acetonitrile, 75:25 v/v), of which 
20µl was injected into the LC-MS/MS instrument.  
 
4.4.5.2 LC-MS/MS analysis 
LC-MS/MS analysis was performed using a Thermo Finnigan LCQ Deca XP (Thermo 
Finnigan, San Jose, CA, USA) equipped with a surveyor HPLC system.  
Chromatographic separation was achieved using a Gemini C18 column (150 mm x 
2 mm ID, 5µm particle size) fitted with a guard column (4 mm x 2 mm, 5µm) 
with the same column packing. The mobile phase was a mixture of 3mM aqueous 
ammonium formate solution containing 0.001% formic acid and acetonitrile 
starting at 75:25 v:v and changing to 20:80 v:v between 15 and 17 minutes. It 
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was then held at 10:90 v:v between 17 and 18.5 minutes then reset to the 
staring composition between 18.5 and 25 minutes. 
 
The optimum mass spectrometric tuning parameters for analytes are shown in 
Table 4-2. Internal standard data were acquired in selected ion monitoring (SIM) 
mode and analytes were identified on the basis of their full MS-MS spectra. Two 
product ions were monitored. The underlined ions in Table 4-2 were used as the 
quantification ions because they were the most intense ions produced. 
Table  4-2: Optimum tuning parameters. 
Drug 
Precursor ion 
(m/z) 
Monitored ions* 
(m/z) 
Collision energy 
(ev) 
Alprazolam 309 281, 274 41 
Lorazepam 321 303, 275 28 
Oxazepam 287 269, 241 26 
Estazolam 295 267, 269 40 
 
Internal standards 
Alprazolam-d5 314 314 Not used 
Lorazepam-d4 325 325 Not used 
Oxazepam-d5 292 292 Not used 
Estazolam-d5 300 300 Not used 
• Underlined ion was used as the quantification ion. For internal standards, 
only the pseudomolecular ions were monitored and no collision energies 
were specified. 
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4.5 Results   
4.5.1 Validation results  
All validation parameters mentioned in Chapter 3 were investigated to validate 
the method before it was used in the stability study. The method was found to 
be satisfactory, as demonstrated in Tables 4-3, 4-4 and 4-5 and suitable for use 
in the stability study.  
4.5.1.1 Linearty  
The calibration models for all analytes were linear over the range 2-200 ng/ml 
with R2 >0.99 for all drugs as shown in Table 4-3. 
4.5.1.2 LOD and LLOQ 
As shown in Table 4-3 the LOD and LLOQ for all benzodiazepines ranged from 
0.29-1.13 ng/ml and 0.98-3.8 ng/ml respectively.      
Table  4-3 : Linearity, LOD, and LLOQ of drugs in 1 ml of blood 
LLOQ 
(ng/ml) 
LOD 
(ng/ml) 
Linearity 
            r2 
      (2-200 ng/ml) 
Drug 
3.80 1.13 0.999 Alprazolam 
2.50 0.76 0.994 Lorazepam 
1.78 0.53 0.995 Oxazepam 
0.98 0.29 0.998 Estazolam 
 
4.5.1.3 Recoveries  
The recoveries for all analytes at concentrations of 5, 50 and 100 ng/ml are 
given in Table 4-4 and ranged from 82-106 %. 
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Table  4-4: Mean recoveries of analytes. 
Mean Recovery% 
(RSD%, n=5) 
 Drug 
5ng/ml 50ng/ml 100ng/ml 
Alprazolam  
84 
(13) 
83 
(10) 
88 
(4) 
Lorazepam 
106 
(15) 
83 
(6) 
83 
(4) 
Oxazepam 
82 
(12) 
98 
(12) 
86 
(11) 
Estazolam 
92 
(12) 
89 
(10) 
96 
(6) 
 
4.5.1.4 Inter-day and intra-day precision 
The inter-day and intra-day precisions were all acceptable according to SOFT 
guidelines, being less than ± 20%.126 The values of % RSD were lower at higher 
concentrations and the intraday precision was lower than interday precision for 
most analytes. Results are shown in Table 4-5. 
 
Table  4-5: Interday and intraday precision results. 
Interday mean (RSD%, n=5) Intraday mean (RSD%, n=5) 
Drug  
5ng/ml 50ng/ml 100ng/ml 5ng/ml 50ng/ml 100ng/ml 
Alprazolam 
4 
(17) 
51 
(14) 
104 
(6) 
5 
(14) 
46 
(3) 
90 
(3) 
Lorazepam 
5 
(19) 
51 
(11) 
106 
(6) 
4 
(16) 
50 
(8) 
103 
(4) 
Oxazepam 
7 
(18) 
45 
(4) 
98 
(4) 
5 
(10) 
47 
(5) 
99 
(4) 
Estazolam 
4 
(12) 
51 
(8) 
107 
(2) 
5 
(10) 
46 
(4) 
96 
(2) 
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4.5.2 Stability results  
4.5.2.1 Alprazolam 
In the freezer (-20 °C), alprazolam is apparently stable for one year at both low  
and high concentrations, in preserved and unpreserved samples, and no 
significant loss was noted (P > 0.05).  
In the refrigerator (4 °C), alprazolam was also found to be stable regardless of 
the concentration and the addition of a preservative (P > 0.05). 
At room temperature, alprazolam was found to be stable for 6 months, but 
losses of 9% and 6% from the initial concentration for unpreserved and preserved 
samples, respectively were found after 1 year at low concentration. At high 
concentration, alprazolam was found to be stable for 6 months, but losses were 
observed after 1 year of 9% and 7% for unpreserved and preserved samples, 
respectively. Alprazolam concentrations versus time for the different storage 
conditions are shown in Table 4.6-4.7 and Figures 4.3-4.4.  The losses observed 
were not statistically significant for low concentration whereas at high 
concentration it was significant after one year. 
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Table  4-6: Stability of alprazolam 50 ng/ml under different storage conditions. 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero#  
49 
(6) 
49 
(6) 
49 
(6) 
49 
(6) 
49 
(6) 
49 
(6) 
2 
51 
(2.8) 
50 
(1.4) 
50 
(1.5) 
49 
(1.6) 
48 
(0.7) 
48 
(1.5) 
4 
50 
(1.4) 
50 
(2.7) 
49 
(4.5) 
48 
(6.0) 
49 
(0.7) 
49 
(0.8) 
7 
50 
(1.4) 
50 
(1.4) 
49 
(4.4) 
49 
(1.5) 
49 
(0.7) 
48 
(1.0) 
14 
50 
(0.7) 
50 
(1.4) 
50 
(1.4) 
50 
(1.2) 
50 
(1.8) 
50 
(2.1) 
30 
50 
(1.4) 
50 
(2.8) 
50 
(4.3) 
51 
(2.8) 
51 
(2.8) 
51 
(3.6) 
60 
50 
(1.4) 
50 
(1.4) 
50 
(4.5) 
49 
(1.6) 
49 
(0.7) 
50 
(2.2) 
90 
50 
(1.4) 
49 
(2.9) 
50 
(1.4) 
50 
(2.9) 
50 
(1.8) 
49 
(0.9) 
180 
49 
(1.4) 
49 
(1.5) 
49 
(4.6) 
48 
(3.0) 
48 
(0.8) 
48 
(1.3) 
365 
49 
(1.3) 
48 
(3.0) 
49 
(2.9) 
48 
(4.5) 
47 
(1.9) 
46 
(3.6) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=37) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Table  4-7: Stability of alprazolam 400 ng/ml under different storage conditions. 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
397 
 (14) 
397 
(14) 
397 
(14) 
397 
(14) 
397 
 (14) 
397 
 (14) 
2 
394 
(0.9) 
399 
(0.2) 
391 
(1.8) 
376 
(3.7) 
396 
(0.2) 
394 
(0.5) 
4 
399 
(0.4) 
398 
(0.2) 
390 
(0.2) 
390 
(2.6) 
398 
(0.2) 
396 
(0.2) 
7 
398 
(0.2) 
396 
(0.3) 
372 
(3.5) 
380 
(0.7) 
397 
(1.1) 
398 
(0.3) 
14 
400 
(0.2) 
399 
(0.2) 
399 
(1.4) 
408 
(5.8) 
390 
(1.3) 
392 
(0.9) 
30 
400 
(0.2) 
397 
(0.1) 
408 
(3.0) 
399 
(4.2) 
399 
(0.4) 
391 
(1.1) 
60 
399 
(0.9) 
399 
(0.2) 
408 
(3.1) 
398 
(4.0) 
399 
(0.2) 
392 
(0.9) 
90 
399 
(0.7) 
398 
(0.9) 
396 
(0.9) 
394 
(3.3) 
395 
(0.4) 
391 
(1.0) 
180 
397 
(0.3) 
396 
(0.4) 
394 
(0.5) 
393 
(3.1) 
392 
(0.8) 
392 
(0.9) 
365 
397 
(0.4) 
397 
(0.2) 
392 
(0.5) 
392 
(2.9) 
372 
(0.4) 
364 
(0.6) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=369) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Figure  4-3: Stability of unpreserved alprazolam at varying storage temperature. LC: Low 
concentration, HC: High concentration and RT: Room temperature 
 
 
 
Figure  4-4: Stability of preserved alprazolam at varying storage temperature. LC: Low 
concentration, HC: High concentration and RT: Room temperature 
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4.5.2.2 Lorazepam  
In the freezer (-20 °C), lorazepam was found to be stable for 6 months at low 
and high concentrations for both unpreserved and preserved samples, but after 
that, a loss of lorazepam was noted at low concentration. The loss from the 
original concentration was 19 % and 9 % for unpreserved and preserved samples, 
respectively. A decrease in lorazepam at high concentration was observed after 
one year of storage. The losses were 5% and 3% for unpreserved and preserved 
samples, respectively. 
 
In the refrigerator (4 °C), lorazepam at low concentration was found to be stable 
for 3 month. A loss in the concentrations of lorazepam was observed after six 
months of storage, and the losses were 30% and 26% for unpreserved and 
preserved samples, respectively. After one year, the losses in the concentrations 
were 50% and 42% for unpreserved and preserved samples, respectively. 
However, at high concentrations, lorazepam was found to be stable for 2 months 
in both samples, and a loss was observed after 3 months. The losses were 7% and 
5 % for unpreserved and preserved samples, respectively. After 1 year, the losses 
from the initial concentration were approximately 28% and 15% for unpreserved 
and preserved samples, respectively. 
 
At room temperature, lorazepam in unpreserved, low concentration samples 
were found to be stable for only 4 days, while a significant loss of 27 % from the 
original concentration was observed after 1 week (P < 0.05). After 3 months, 
only 10 % of lorazepam could be detected, and it was completely lost after 6 
months. The lorazepam at a low concentration with preservative was found to 
be stable for only 4 days and a significant decrease in concentration was 
observed after 1 week. The loss was approximately 25% with a p value < 0.05, 
and a continuous loss in the concentration was observed to proceed during the 
storage time. After three months, only 13% of the lorazepam could be detected, 
and it completely disappeared after 6 months. Lorazepam at high concentrations 
was stable for 2 days and 4 days in unpreserved and preserved samples 
repectively. The concentrations decreased by 5% after 4 days and 1 week in the 
unpreserved and preserved samples respectively (P < 0.05), and approximately 
4% could be detected for both samples after 6 months. After 1 year, lorazepam 
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could not be detected in either storage condition. Stability data are given in 
Table 4.8-4.9 and are shown in Figures 4.5-4.6. 
 
Table  4-8: Stability of lorazepam 50 ng/ml under different storage conditions 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
48 
(10.0) 
48 
(10.0) 
48 
(10.0) 
48 
(10.0) 
48 
(10.0) 
48 
(10.0) 
2 
50 
(1.4) 
51 
(2.1) 
50 
(2.9) 
50 
(4.3) 
49 
(1.1) 
49 
1.0) 
4 
51 
(2.7) 
50 
(1.4) 
50 
(1.4) 
49 
(0.3) 
43 
(9.2) 
43 
(10.0) 
7 
51 
(0.7) 
50 
(3.1) 
47 
(1.5) 
47 
(2.2) 
36 
(8.6) 
35 
(11.2) 
14 
51 
(1.4) 
49 
(4.3) 
48 
(3.6) 
46 
(6.7) 
36 
(9.5) 
32 
(3.3) 
30 
49 
(1.4) 
49 
(4.6) 
47 
(6.5) 
45 
(9.6) 
27 
(5.4) 
24 
(7.9) 
60 
50 
(2.8) 
49 
(0.4) 
44 
(7.6) 
42 
(4.9) 
17 
(7.9) 
10 
(8.5) 
90 
49 
(1.4) 
49 
(2.2) 
42 
(5.2) 
40 
(14.3) 
5 
(9.4) 
5 
(14.6) 
180 
47 
(3.9) 
47 
(3.5) 
35 
(3.9) 
37 
(5.9) 
0 
(0.0) 
0 
(0.0) 
365 
46 
(4.6) 
41 
(8.9) 
29 
(7.7) 
25 
(10.5) 
0 
(0.0) 
0 
(0.0) 
P*: preserved, N-P: unpreserved. (Concentration threshold=39) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Table  4-9: Stability of lorazepam 400 ng/ml under different storage conditions. 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
396  
(6.0) 
396  
(6.0) 
396  
(6.0) 
396  
(6.0) 
396 
(6.0) 
396  
(6.0)  
2 
396 
(0.4) 
396 
(0.5) 
392 
(0.2) 
388 
(2.2) 
398 
(0.2) 
399 
(0.3) 
4 
404 
(0.9) 
404 
(1.1) 
402 
(2.1) 
396 
(1.1) 
389 
(2.3) 
380 
(2.7) 
7 
404 
(1.1) 
400 
(0.7) 
394 
(4.1) 
396 
(2.9) 
384 
(4.9) 
372 
(4.7) 
14 
404 
(0.7) 
404 
(0.9) 
396 
(0.5) 
396 
(2.1) 
332 
(3.4) 
324 
(2.6) 
30 
404 
(0.7) 
398 
(0.2) 
396 
(2.2) 
396 
(0.5) 
296 
(4.2) 
296 
(3.7) 
60 
398 
(0.2) 
396 
(0.5) 
392 
(2.8) 
392 
(1.3) 
252 
(5.3) 
236 
(8.6) 
90 
399 
(0.2) 
396 
(0.3) 
382 
(1.2) 
374 
(0.1) 
144 
(7.4) 
132 
(6.1) 
180 
393 
(0.7) 
392 
(0.8) 
377 
(2.5) 
360 
(1.4) 
17 
(6.2) 
14 
(9.9) 
365 
388 
(2.4) 
380 
(0.5) 
340 
(3.8) 
288 
(1.5) 
0 
(0.0) 
0 
(0.0) 
P*: preserved, N-P: unpreserved. (Concentration threshold=384) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Figure  4-5: Stability of unpreserved lorazepam at varying storage temperature. LC: Low 
concentration, HC: High concentration and RT: Room temperature. 
 
 
 
 
 
 
Figure  4-6: Stability of preserved lorazepam at varying storage temperature. LC: Low 
concentration, HC: High concentration and RT: Room temperature. 
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4.5.2.3 Oxazepam  
Oxazepam at low concentrations in both unpreserved and preserved samples was 
found to be stable in the freezer (20 °C) for 12 months. Oxazepam 
concentrations decreased by approximately 5% in both conditions. On the other 
hand, oxazepam at high concentration was found to be stable for 6 months in 
both conditions while a significant loss was observed after one year. There was a 
19% and 12% loss in the concentrations in unpreserved and preserved samples, 
respectively (P < 0.05). 
In the refrigerator (4 °C) oxazepam at low concentration in both conditions was 
found to be stable for 6 month but it was not stable after 12 months. After 12 
months, oxazepam decreased by 31% and 28% for unpreserved and preserved 
samples, respectively (P < 0.05). Oxazepam at a high concentration was stable 
for 2 months, and a significant loss was observed under both conditions after 3 
months. The decrease in the concentration was 9% and 7% for unpreserved and 
preserved samples, respectively (P < 0.05). The decrease in the concentrations 
reached 26% and 23% for unpreserved and preserved samples, respectively, after 
12 months.  
At room temperature, oxazepam at a low concentration was found to be stable 
for 2 week under both conditions. The loss in the concentration was significant 
after 1 month. The loss was approximately 55% (P < 0.05) under both conditions. 
Further decreases in the concentrations proceeded dramatically. Approximately 
8% of the original concentration could be recovered after 3 months of storage 
under both conditions and it disappeared completely after 6 months. Oxazepam 
at a high concentration was stable for only 2 days under both conditions while a 
significant decrease was observed after 4 days. The loss was approximately 10% 
and 9% for unpreserved and preserved samples, respectively (P < 0.05) under 
both conditions. Approximately 5% of the initial concentration could be detected 
after 6 months in both unpreserved and preserved samples; however, no 
concentration could be detected after 1 year in either sample. Stability data are 
given in Table 4.10-4.11 and are shown in Figures 4.7-4.8. 
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Table  4-10: Stability of oxazepam 50 ng/ml under different conditions. 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
49 
 (8.0) 
49  
(8.0) 
49 
(8.0)  
49 
(8.0)  
49  
(8.0) 
49 
(8.0)  
2 
50 
(1.4) 
50 
(1.8) 
50 
(2.9) 
49 
(1.5) 
44 
(4.6) 
44 
(6.1) 
4 
50 
(1.9) 
50 
(2.8) 
50 
(1.4) 
49 
(4.5) 
44 
(7.6) 
43 
(9.2) 
7 
49 
(0.4) 
50 
(0.3) 
49 
(2.9) 
49 
(0.7) 
39 
(3.5) 
38 
(5.4) 
14 
50 
(0.3) 
50 
(2.8) 
49 
(1.4) 
49 
(2.9) 
35 
(8.6) 
34 
(4.3) 
30 
50 
(4.1) 
50 
(2.8) 
49 
(2.8) 
47 
(5.7) 
28 
(8.0) 
24 
(9.4) 
60 
50 
(4.2) 
49 
(0.3) 
46 
(4.5) 
46 
(5.9) 
23 
(13.5) 
18 
(12.9) 
90 
49 
(1.4) 
49 
(1.8) 
45 
(7.4) 
45 
(6.0) 
5 
(12.9) 
4 
(9.4) 
180 
48 
(1.4) 
48 
(1.5) 
43 
(3.2) 
41 
(4.9) 
0 
(0.0) 
0 
(0.0) 
365 
48 
(1.5) 
48 
(0.1) 
36 
(3.8) 
35 
(7.6) 
0 
(0.0) 
0 
(0.0 
P*: preserved, N-P: unpreserved. (Concentration threshold=33) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements. 
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Table  4-11: Stability of oxazepam 400 ng/ml under different storage conditions. 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 396 
(10.0) 
396 
(10.0)  
396  
(10.0) 
396  
(10.0) 
396 
(10.0) 
396 
(10.0) 
2 
396 
(0.4) 
400 
(0.2) 
396 
(0.9) 
396 
(3.7) 
392 
(0.8) 
392 
(0.9) 
4 
397 
(0.4) 
396 
(0.3) 
396 
(1.1) 
392 
(0.4) 
364 
(0.8) 
360 
(1.2) 
7 
396 
(0.4) 
396 
(0.1) 
388 
(2.9) 
388 
(1.5) 
344 
(0.6) 
344 
(0.8) 
14 
396 
(0.7) 
396 
(0.8) 
388 
(1.9) 
386 
(3.9) 
336 
(0.8) 
308 
(0.9) 
30 
396 
(0.7) 
392 
(0.9) 
384 
(4.3) 
384 
(2.7) 
272 
(1.8) 
252 
(2.5) 
60 
395 
(0.7) 
394 
(0.8) 
384 
(4.3) 
377 
(4.0) 
200 
(3.1) 
192 
(2.5) 
90 
393 
(1.0) 
392 
(1.1) 
372 
(0.8) 
364 
(1.9) 
97 
(5.3) 
78 
(10.9) 
180 
388 
(1.6) 
385 
(1.9) 
357 
(1.4) 
344 
(1.8) 
21 
(15.0) 
20 
(12.8) 
365 
352 
(0.9) 
324 
(0.7) 
308 
(3.1) 
296 
(3.4) 
0 
(0.0) 
0 
(0.0) 
P*: preserved, N-P: unpreserved. (Concentration threshold=376) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Figure  4-7: Stability of unpreserved oxazepam at varying storage temperature. LC: Low 
concentration, HC: High concentration and RT: Room temperature. 
 
 
 
Figure  4-8: Stability of preserved oxazepam at varying storage temperature. LC: Low 
concentration, HC: High concentration and RT: Room temperature. 
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4.5.2.4 Estazolam  
In the freezer (-20 °C), estazolam at low and high concentrations was found to 
be stable for one year in both unpreserved and preserved samples and no 
significant loss was observed (P > 0.05). 
In the refrigerator (4 °C), there was no significant decrease in the low and high 
concentrations in the preserved and unpreserved samples. The loss was less than 
2% of the original concentration (P > 0.05). 
At room temperature, no significant loss was observed for 12 months of storage 
at low and high concentrations under both conditions. However, after 1 year, 
estazolam concentration was decreased at low concentration by 9% and 8% in 
unpreserved and preserved samples, respectively. At high concentrations, it 
decreased by 4% and 3% for unpreserved and preserved samples, respectively (P 
> 0.05). Stability data are given in Table 4.12-4.13 and are shown in Figures 4.9-
4.10. 
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Table  4-12: Stability of estazolam 50 ng/ml  under different storage conditions. 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
49 
(10.0) 
49 
(10.0) 
49 
(10.0) 
49 
(10.0) 
49 
(10.0) 
49 
(10.0) 
2 
50 
(2.8) 
49 
(0.4) 
49 
(1.4) 
49 
(1.5) 
50 
(1.7) 
49 
(0.7) 
4 
50 
(1.8) 
50 
(0.7) 
50 
(1.0) 
49 
(2.9) 
49 
(0.7) 
49 
(0.3) 
7 
50 
(0.4) 
50 
(0.7) 
50 
(1.1) 
49 
(1.5) 
49 
(0.7) 
48 
(0.4) 
14 
50 
(0.2) 
49 
(2.1) 
49 
(0.7) 
49 
(2.9) 
48 
(1.8) 
48 
(2.3) 
30 
50 
(1.4) 
49 
(4.2) 
49 
(2.8) 
48 
(3.6) 
49 
(2.5) 
48 
(3.6) 
60 
49 
(0.1) 
49 
(0.3) 
48 
(0.7) 
48 
(2.9) 
48 
(0.7) 
49 
(2.2) 
90 
49 
(0.7) 
49 
(1.4) 
49 
(0.9) 
49 
(1.5) 
50 
(0.3) 
49 
(0.7) 
180 
50 
(0.4) 
49 
(0.1) 
49 
(1.4) 
49 
(1.5) 
49 
(0.6) 
49 
(0.7) 
365 
49 
(1.0) 
49 
(1.3) 
49 
(2.8) 
48 
(4.3) 
46 
(1.8) 
46 
(0.7) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=39) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Table  4-13: Stability of estazolam 400 ng/ml under different storage conditions. 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
391 
(7) 
391 
(7) 
391 
(7) 
391 
(7) 
391 
(7) 
391 
(7) 
2 
398 
(0.7) 
400 
(0.2) 
395 
(0.7) 
400 
(1.9) 
397 
(0.1) 
396 
(0.2) 
4 
400 
(0.2) 
400 
(0.4) 
400 
(1.7) 
396 
(1.1) 
399 
(0.2) 
396 
(0.2) 
7 
396 
(0.3) 
392 
(0.7) 
398 
(4.8) 
396 
(2.9) 
398 
(0.2) 
394 
(0.7) 
14 
396 
(0.7) 
392 
(1.3) 
394 
(0.8) 
395 
(2.3) 
398 
(1.4) 
394 
(0.3) 
30 
392 
(1.4) 
392 
(0.9) 
392 
(2.8) 
394 
(0.9) 
395 
(0.7) 
392 
(0.2) 
60 
395 
(0.8) 
392 
(1.3) 
392 
(2.8) 
393 
(1.0) 
394 
(0.8) 
392 
(0.3) 
90 
395 
(0.6) 
392 
(1.1) 
394 
(0.4) 
392 
(0.3) 
395 
(0.2) 
391 
(0.7) 
180 
392 
(0.9) 
391 
(0.8) 
392 
(0.4) 
390 
(0.5) 
394 
(0.3) 
390 
(0.4) 
365 
389 
(1.2) 
390 
(1.3) 
391 
(0.1) 
390 
(0.4) 
388 
(2.9) 
384 
(3.8) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=377) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Figure  4-9: Stability of unpreserved estazolam at varying storage temperature. LC: Low 
concentration, HC: High concentration and RT: Room temperature. 
 
 
 
Figure  4-10: Stability of preserved estazolam at varying storage temperature. LC: Low 
concentration, HC: High concentration and RT: Room temperature. 
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4.5.3 Summary of benzodiazepine stability in blood samples 
The stability of alprazolam, estazolam, lorazepam, and oxazepam in blood 
samples stored for one year under different storage conditions is summarized in 
Table 4-14. 
Table  4-14: Summary of benzodiazepine stability in blood under varied storage conditions 
Drug 
Storage 
conditions 
Results Comment 
-20 ºC, 1 year 
4 ºC, 1 year 
Stable  
Alprazolam  
25 ºC, 1 year 
Less than 9% 
decrease at HC  
-20 ºC, 1 year 
4 ºC, 1 year Estazolam  
25 ºC, 1 year 
Stable 
-20 ºC, 1 year 5% decrease at HC 
4 ºC, 1 year 
50% decrease at LC 
and 28% decrease 
at HC 
Lorazepam  
25 ºC, 1 year 
100% decrease at 
LC after 6 months 
and 100% decrease 
at HC after 1 year 
-20 ºC, 1 year 
19% decrease at 
HC 
4 ºC, 1 year 
31% decrease at LC 
and 26% decrease 
at HC Oxazepam  
25 ºC, 1 year 
100% decrease at 
LC after 6 months 
and 100% decrease 
at HC after 1 year 
• Less than 13% 
enhancement in 
stability when NAF 
(2% W/V) used  
• As temperature 
increased, stability 
decreased 
• Alprazolam and 
estazolam are more 
stable than lorazeam 
and oxazepam 
• Higher concentration 
of drugs can be 
detected for long 
time compared with 
low concentration 
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4.6 Discussion 
This study was undertaken to investigate the stability of four benzodiazepines 
that are widely prescribed in Saudi Arabia, and for which no information about 
their stability is available in the literature, although oxazepam has been 
investigated in whole blood without the addition of a preservative.56 In this 
study, the influence of temperature, concentration, and the addition of an 
anticoagulant and a preservative were examined to discover whether they had 
an effect on the stability of these compounds in blood over a period of one year. 
In forensic toxicology, a study of stability should comply with actual forensic 
cases and conditions. Therefore, the blood was prepared at low and high 
concentrations. The low concentration represented the therapeutic levels that 
would be found in drug monitoring in hospital or encountered in drug abusers 
accused of driving under the influence of drugs. The high concentration samples 
were similar to those encountered in a drug overdose case. Since authentic 
samples are routinely opened several times, in this study the spiked blood was 
distributed in small tubes, and each tube was used one time only to avoid any 
contamination that may occur after opening, consequently affecting the drug 
concentration by contamination with bacteria which may be in the air. The 
estimation of stability in this study is based on the results obtained in equation 6 
in Chapter 3 and the p value. If the loss in the concentration at the time 
selected during the study is more than 1.96 of the coefficient variation and the p 
value is < 0.05, then the decrease in the drug concentration is considered 
significant.59,134  
 
The study indicates that the concentrations of the 4 benzodiazepines are 
influenced by storage conditions. The storage temperature plays a major role in 
drug stability. As the temperature increased, drug concentrations were observed 
to decrease. All compounds showed good stability in the freezer. However, as 
clearly demonstrated in this study, a decrease in the high concentration can be 
expected after 12 months of storage for lorazepam and oxazepam in the freezer 
while alprazolam and estazolam were found to be stable for all periods of the 
study when stored in the freezer. In the refrigerator, which is the most common 
and feasible storage temperature used in laboratories and the place used to 
keep samples before analysis, a loss in lorazepam and oxazepam concentrations 
can be expected after 6 months for low concentrations and after 3 months for 
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high concentrations under both conditions whereas alprazolam and estazolam 
were found to be stable for one year, and no significant losses were observed.  
Contrary to what happened in the freezer, high losses in the concentrations were 
observed for all drugs including alprazolam and estazolam at room temperature. 
Lorazepam and oxazepam showed poor stability at room temperature. The 
concentration of oxazepam decreased significantly after 2 weeks and 4 days at 
low and high concentration, respectively, in both conditions, while the level of 
lorazepam decreased significantly from the original concentration after 1 week 
and 4 days at low and high concentrations, respectively. 
  
Degradation of benzodiazepines has been reported in previous studies, and this 
was attributed to hydrolysis reactions because most benzodiazepines contain an 
amide bond in their structure and are therefore prone to undergoing a hydrolysis 
reaction leading to cleavage of the amide. Two drugs in this study have amide 
bonds: lorazepam and oxazepam. For this reason, lorazepam and oxazepam 
exhibited poor stability compared to alprazolam and estazolam, which belong to 
the triazolobenzodiazpines and do not have an amide group in their structures. 
Instead, alprazolam and estazolam contain triazolo ring, which seems to make 
the drugs resistant to the hydrolysis reaction. It seems to enhance the stability 
of these compounds by protecting the compounds from decomposition when the 
biological samples are in storage. 
 
Hydrolysis of compounds may be chemical or enzymatic. The blood used in this 
study consisted of red blood cells suspended in isotonic saline and therefore did 
not contain plasma esterases. However, enzyme activity due to bacterial 
contamination would have been possible. In this situation, the reaction seemed 
to be chemical hydrolysis because enzymatic activity is reported to continue 
after sampling in unpreserved samples compared to those that are preserved, 
this enzyme activity being related to esterase, which affects ester-containing 
compounds but is not known to be involved in benzodiazepine breakdown. 
Moreover, the enzymatic effect of bacteria, which are reported to have 
degraded benzodiazepines such as nitrobenzodiazepines, is to convert 
nitrobenzodiazepines into corresponding aminobenzodiazepine metabolites. 
However, the nitro group was not present in the compounds investigated in this 
study; this effect can be excluded in this case, even if there was contamination 
involved, especially in unpreserved samples. Sodium fluoride (NaF) is an 
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antienzymatic preservative that showed little effect in this study because there 
was no clear role for this preservative to minimize or protect the compounds 
from degradation or maybe because the concentration of NaF in the tubes used 
to preserve the drugs in this study is small (0.2% w/v) while in the previous 
studies increase of NaF concentration showed reduction in the drugs degradation 
as mentioned in Chapter 2.62 NaF also seemed to have no effect in accelerating 
the hydrolysis reaction compared to unpreserved samples as has been reported 
in ester-containing compounds such as organophosphates which decompose 
quickly after the addition of sodium fluoride.88 Sodium fluoride is therefore safe 
if the analytes in the sample are benzodiazepines.  
 
Something similar was reported by Levine et al.55 (1983) regarding the effect of 
additives on the stability of benzodiazepines. Additives had a small effect on 
drug stability under all conditions, and the enhancement in the stability was 
estimated to be less than 10% compared to the unpreserved samples.3 This small 
effect may have been a result of anticoagulant activity, which was not 
noticeable in the unpreserved samples compared to preserved samples, 
especially those at room temperature. Elmahjob et al.56 found the same results 
as those obtained in this study, namely, that oxazepam is not detected at all at 
room temperature after 1 year at both low and high concentrations. Moreover, 
high concentrations can be detected for a long time in comparison to low 
concentrations, and this should be considered in the interpretation of either 
therapeutic or toxic concentration samples.  
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4.7 Conclusions 
The possibility of a decrease in benzodiazepine concentration should be 
considered, even if samples are stored at -20 ºC. Therefore, the analysis should 
be performed as soon as possible. In addition, samples should be stored at -20 ºC 
or lower to keep the drug stable for as long as possible. Furthermore, the 
addition of a preservative to the sample could enhance the stability without a 
possible loss of concentration by NaF, as reportedly happened with 
organophosphourous compounds. Anticoagulant should be added to the blood 
sample to prevent it from coagulating, an effect that could increase at a high 
temperature. 
 
The drugs containing an ester or an amide group are prone to degradation by 
hydrolysis and this should be carefully considered when they are being 
transported or stored and during the interpretation of results. Optimal storage 
conditions to stop or minimize the degradation of the drug are necessary to keep 
the drug stable for a long time. Further determination of degradation products 
as alternatives could also help the forensic toxicologist to confirm the presence 
of the parent drug in case the drug decomposes partially or completely as 
observed in the case of oxazepam and lorazepam after one year. 
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5 Stability of Opiate Glucuronides in Blood and 
Urine 
5.1 Introduction 
Opium, which means juice in Greek, is the name given to milky exudates 
obtained from the immature fruits of the plant papaver somniferum. The milky 
exudate contains several pharmacologically active compounds, including 
morphine and codeine. Members of the group of natural, semi synthetic or 
synthetic alkaloids are called opoids. Morphine and codeine are naturally 
occurring compounds known as opiates, while examples of semi-synthetic and 
synthetic compounds are oxycodone, fentanyl, buprenorphine, methadone, and 
tramadol. Opioids exert their effect by binding receptors at several sites in the 
CNS.135,136 
There are four major types of opioid receptors located throughout the body: µ 
(mu), κ (kappa), δ (delta), and σ (sigma). An analgesic effect is produced by 
opioids due to the interaction between the opoid and specific receptors at the 
terminal nerve ending, which blocks the release of neurotransmitters or pain 
stimuli. Interaction with the µ receptor results in analgesia, euphoria, miosis, 
and bradycardia, while binding to the κ receptor produces analgesia, miosis, 
diueresis, and sedation. The δ receptors are the site of binding of most 
endogenous opioid peptides (endorphins), which produce analgesia, dysphoria, 
delusions, and hallucinations. Binding to the σ receptor may produce central 
excitation, resulting in tachycardia, hallucinations, and hypertension. Opioids 
may be used therapeutically as postoperative analgesics after surgery, and for 
myocardial infarction (MI), trauma, and burns. Additionally, opioids are 
indicated for chronic pain, such as the pain associated with cancer. Opioids are 
also used as anti-tussives and anti-diarrhoeals, as well as antidotes - naloxone, is 
used for treatment of opioid intoxication and is an extremely potent opioid 
receptor antagonist. The main advantage of using opioids clinically is that they 
can produce an analgesic effect without loss of consciousness, unlike 
anaesthesia. However, the analgesia is accompanied by euphoria and sedation. 
Furthermore, respiratory depression may result from opioids, which is 
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considered a major disadvantage and side effect that can cause death in 
intoxication cases.135,136   
Morphine was the first compound discovered in opium, in 1803, when the 
German pharmacist Feredrik Serturner succeeded in isolating an analgesic 
compound, which he named morphine. Since that time, morphine has become an 
important treatment for severe pain and diarrhoea. Parenteral morphine is 
rapidly absorbed, while extensive first pass hepatic metabolism results in low 
bioavailability when morphine is taken orally. Therefore, the analgesic effect of 
morphine is greater when given parenterally rather than orally. 135,136 
The analgesic effect of morphine following oral administration in cancer patients 
is obtained at a mean serum concentration of 18 ng/ml. The major metabolic 
pathway for morphine is the conjugation with glucuronic acid on the free 
phenolic hydroxyl or alkanol groups to produce morphine-3-glucuronide (M3G) 
and morphine-6-glucuronide (M6G), respectively. M3G is a highly water-soluble 
metabolite and the predominant metabolite. M3G has a low affinity to opioid 
receptors; thus, no opioid reaction will be produced, but it seems to produce the 
side effects of morphine. On the other hand, M6G is a pharmacologically active 
metabolite, which is an analgesic twice as potent as morphine. Since morphine is 
the active metabolite of heroin and codeine, the presence of free morphine or 
its metabolites may also indicate heroin or codeine use. Following administration 
of a 15mg oral dose of morphine every 6 hours for 5 days, cancer patients have 
steady state plasma concentrations of morphine, M3G, and M6G of 0.014 mg/L, 
0.515 mg/L and 0.077 mg/L, respectively. 135,136,145 
Codeine is naturally occurring and can be obtained from opium or synthesised 
commercially by 3-O-methylation of morphine. Codeine is less potent than 
morphine and is used clinically in the treatment of mild to moderate pain and as 
an anti-tussive. Some over-the-counter (OTC) remedies include low doses of 
codeine in combination with non-opioid analgesics, such as paracetamol and 
aspirin. Oral and parenteral doses of codeine are well absorbed. Codeine is 
metabolised via O-demethylation to morphine and via N-demethylation to 
norcodeine, and conjugated to codeine-6-glucuronide (C6G), which has a similar 
pharmacological activity to codeine. Morphine has a 200 times greater affinity to 
the µ receptor than codeine and its pharmacological effect depends on the 
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formation of morphine. Cytochrome P450 (CYP) 2D6 catalyses the 
biotransformation of codeine to morphine. Around 7% of Caucasians and 50% of 
Chinese are deficient in this enzyme and do not experience the analgesic effect 
of codeine compared to those who have this enzyme. 135,136,146 
Peak concentrations following a 50 mg oral dose of codeine range between 0.05 
and 0.15 mg/L after 1 hour. The amounts of codeine and metabolites remaining 
in urine 24 hours after a 22 mg oral dose were as follows: free codeine (5-17%), 
codeine-6-glucuronide (C6G) and free codeine (32-46%), conjugated norcodeine 
and free morphine (10-21%), and conjugated morphine (5-13%). The composition 
of the metabolite in the urine from codeine ingestion after 3 days is similar to 
that following morphine and heroin use. However, the presence of C6G and 
norcodeine in the urine is indicative of codeine use, not morphine or heroin 
use.145  
The determination of a parent drug and its glucuronide metabolite is very 
important to interpretations in clinical and forensic toxicology. Estimation of 
metabolite/drug ratios can be used to assess the time interval after drug intake. 
Additionally, metabolite detection can be used to differentiate between chronic 
and recent drug use. Glucuronides are usually determined by cleavage of the 
glucuronide with an enzyme such as β-glucuronidase to release the parent 
compound, which is subsequently quantified. However, there are limitations 
with this method. The enzymatic hydrolysis may be inhibited competitively by 
matrix components such as phosphate, resulting in incomplete reaction. Also, 
conjugates may be cleaved more readily at some positions than other, for 
example, morphine-3-glucuronide is more easily cleaved than morphine-6-
glucuronide. In addition, different rates of hydrolysis of conjugates are obtained 
for many drugs depending on the enzyme preparation used. Furthermore, 
enzymatic reactions are time-consuming. Direct detection of the intact 
metabolites is very important to overcome the limitations involved in the 
enzymatic cleavage method. The opiate glucuronides have been detected 
directly by different methods listed in the literature.146-155  
Morphine, codeine, M3G, M6G and C6G chemical structures are shown in Figure 
5-1. 
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Figure  5-1: Chemical structures of morphine and codeine and their glucuronide metabolites. 
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5.2 Aims 
The aim of this study was to determine the stability of M3G, M6G and C6G in 
blood and urine samples with and without additives when stored in the freezer, 
in the refrigerator and at room temperature for 1 year. 
 
5.3 Experimental Section 
5.3.1 Chemical and material: 
Morphine-3-glucuronide (M3G), Morphine-6-glucuronide (M6G), Morphine-d6 
(MOR-d6), Codeine-6-glucuronide (C6G), and Codeine-6-glucuronide-d3 (C6G-d3) 
were purchased from Lipomed (Arleshide, Switzerland) as 1mg/ml solutions in 
methanol. Bond Elut LRC-C18 cartridges were purchased from Varian (Palo Alto, 
CA, USA). Ammonium carbonate, formic acid and ammonium hydroxide were 
purchased from BDH (Poole, UK). Methanol and acetonitrile were also obtained 
from BDH (Poole, UK). Ammonium formate was obtained from Acros Organic 
(Morris Plains, NJ, USA). 
 
5.3.2 Solutions: 
5.3.2.1 Preparation of 0.01M ammonium carbonate pH 9.3 
0.94 g of ammonium carbonate was weighed into a 1 litre volumetric flask. 
Approximately 800 ml of deionized water were added and the pH was adjusted 
to 9.3 with ammonium hydroxide. Then, the solution was made up to volume 
with deionized water. 
 96 
5.3.2.2 Preparation of 10mM ammonium formate and 0.001% formic acid 
The mobile phase was prepared by dissolving 0.631 g of ammonium formate in 
800 ml de-ionised water in a 1 L volumetric flask followed by the addition of 10 
µl of concentrated formic acid. The volume was then made up to the mark with 
deionized water. 
5.3.2.3 Standard solutions of analytes 
Working standards of unlabelled and labelled drugs were prepared by diluting 
250 µl from each drug stock solution in 25 ml methanol to obtain a concentration 
of 1 µg/ml. Stock solutions of standards and internal standards were stored in a 
freezer at -20ºC.  
 
 
5.3.3 Preparation of blood and urine samples: 
Time-expired packed red blood cells were obtained from a blood bank (Scottish 
Transfusion Service, Glasgow Western Infirmary) and were re-suspended in equal 
volume of isotonic saline (0.1M sodium chloride solution) before use to give a 
final volume of 400 ml. They were screened to check whether they contained 
the opiate glucuronide, of interest in this study, and the result was negative.  
 
The blank blood was spiked with M-3G, M-6G, and C-6G to give final 
concentration of 100 ng/ml of each analyte and was then mixed on a roller for 1 
hour to ensure that all compounds were distributed equally in the blood (RSD% < 
13.7 for all analytes as shown in Tables 5-2, 5-4 and 5-6 at day zero 
concentrations). This concentration was selected according to the average 
concentrations of these analytes found in the case samples reported by Bogus et 
al. (1997).148 Five samples from the prepared blood were analysed and found to 
be homogeneous, and the mean concentration of each analyte was considered to 
be the day zero concentration. 
 
Blank urine obtained from a healthy volunteer was spiked with the same 
compounds as added to the blood to produce a final concentration of 100 ng/ml 
of each analyte in a total volume of 400 ml. The urine was mixed on the roller to 
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ensure all compounds were distributed equally. Five samples from the prepared 
urine were analysed and found to be homogeneous (RSD% < 9.8 for all analytes as 
shown in Tables 5-3, 5-5 and 5-7 at day zero concentrations), while the mean 
concentration obtained for each compound was considered to be the initial 
concentration. 
 
The prepared blood sample was distributed into 150 tubes, half of them 
preserved (fluoride/oxalate) and the other half unpreserved containers. The 
prepared urine was distributed into tubes in a similar manner to the blood 
samples. Each day samples were analysed, two replicates were taken for analysis 
from the storage racks  for each of the different storage conditions, extracted 
within the day and left to run on the LC-MS/MS instrument overnight.  If the 
analysis could not be completed within 24 hours due to instrumental problems, 
extracts were kept in the deep freeze at -20°C until they could be analysed. A 
calibration curve was prepared for each set of samples over the range of 5-200 
ng/ml.  
 
Opiate glucuronide standards were spiked into blood or urine to produce 
concentrations of 5, 10, 25, 50, 100, 200 ng/ml and 100 ng/ml of internal 
standards were added into each concetrations then these were extracted by SPE 
and analysis by LC-MS-MS. 
 
 
 
5.3.4 Sample storage and times of analysis 
The prepared samples were divided into three groups and were then stored at 
three different temperatures (-20 ºC, 4 ºC, and room temperature). These 
storage temperatures were selected because they are frequently-used laboratory 
storage temperatures. The storage temperatures were monitored daily using 
permanently mounted digital thermometers with a resolution of 0.1 C°at the 
start of the study and subsequently at weekly intervals during the period of 
study. Temperatures were stable within a range of approximately 1 C ° (freezer 
and refrigerator) or 5 C° (room temperature, average temperature 20°C).  The 
times selected for analysis were at day 1 (day zero), 2, 4, 7, 14, 30, 60, 90, 180, 
and 365. 
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5.3.5 Analysis 
The method used for extraction and analysis was based on a published method 
for extraction of opiates and their glucuronides from blood.147 The same method 
was subsequently validated for the same compounds in urine.249 
Prior to extraction, 1ml from each sample was added to 3ml of 0.01M ammonium 
carbonate (pH 9.3). Next, 100 µl (100 ng/ml) of working internal standard 
solution (1 µg/ml), containing deuterated analogues of the target analytes, was 
added, then the mixture was vortex mixed and centrifuged for 10 minutes at 
2500 rpm. 
Bond Elut C18 SPE columns were conditioned with 3ml methanol, 3ml deionized 
water, and 3ml of 0.01M ammonium carbonate (pH 9.3), and then the 
supernatant of each sample was applied to the column, after which the SPE 
cartridges were washed twice with 3ml 0.01 ammonium carbonate (pH 9.3) and 
dried for 10 minutes. Elution of the retained analytes was achieved using 3ml 
methanol. The eluate was evaporated to dryness under a gentle stream of 
nitrogen at 50 °C. The residue was reconstituted in 150 µl of the initial mobile 
phase (97:3 v/v), of which 20 µl was injected into the LC-MS/MS instrument. 
 
5.3.6 Instrumentation 
The method used for analysis by liquid chromatography-tandem mass 
spectrometry was based on a published method.147 
LC-MS/MS analysis was performed using a Thermo Finnigan LCQ Deca XP (Thermo 
Finnigan, San Jose, CA, USA) equipped with a surveyor HPLC system.  
Chromatographic separation was achieved using a Synergy Polar RP column 
(150mm x 2mm ID, 4µm particle size) fitted with a guard column (4mm x 2mm, 
Phenomenex, Torrance) with the same column packing. The mobile phase was a 
mixture of (A) 10mM aqueous ammonium formate solution containing 0.001% 
formic acid and (B) acetonitrile. The gradient started at 97% of solution A for 3 
minutes, decreasing to 84.5% at 8 minutes, to 74% at 13 minutes, and to 20% at 
26 minutes; 5% of solution A was maintained for 3 minutes before resetting to 
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the starting composition between 29 and 36 minutes. The parameters selected 
for these compounds are shown in Table 5-1. Inernal standard data was aquired 
in selected ion monitoring (SIM) mode and analytes were identified on the basis 
of their full MS-MS spectra. One product ion was monitored and used as the 
quantification ion because it was the most intense ion produced. In the 
published method M3G-d3 and M6G-d3 coeluted with some analytes and were 
replaced with MOR-d6. As a result, MOR-d6 was used for M3G and M6G 
quantification while C6G-d3 was used for C6G quantification.147 
 
Table  5-1: Optimum tuning parameters 
Drug 
Precursor ion 
(m/z) 
Monitored ion* 
(m/z) 
Collision energy 
(eV) 
Morphine-3-G 462 286 29 
Morphine-6-G 462 286 29 
Codeine-6-G 476 300 30 
 
Internal standards 
Morphine-d6 292 292 Not used 
Codeine-6-G-d3 479 479 Not used 
• Underlined ion was used as the quantification ion. For internal standards, 
only the pseudomolecular ions were monitored and no collision energies 
were specified. 
 
M3G and M6G had the same precursor ion and product ion, which are produced 
by the same collision energy. However, they had different retention times. The 
M3G retention time was 3.42 min, while the M6G retention time was 6.25 min. 
The C6G retention time was 11.09 min. 
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5.4 Stability results  
5.4.1 Stability of M3G in blood and urine 
In the freezer (-20 °C), M3G was found to be stable in blood for 1 year. Small 
changes in the concentration were oberved after 1 year of storage in which 
approximately 3% and 5% of the compound was lost in preserved and unpreserved 
samples, respectively (0.1 > p > 0.05). In urine, M3G was also found to be stable 
for 1 year in preserved and unpreserved samples. A statistically insignificant loss 
in preserved samples was observed at month 12, in which M3G decreased by 
approximately 5% of the initial concentration, while in unpreserved samples, the 
compound had decreased by 7% at month 12 (0.1 > p > 0.05 for both points). 
After one year, more than 92% of the compound was recovered from the blood 
and urine in both preserved and unpreserved samples. 
In the refrigerator (4 °C), M3G was found to be stable for 6 months in both 
preserved and unpreserved blood samples. Significant losses of 14% and 18% 
were observed after 1 year for preserved and unpreserved samples, respectively 
(p < 0.05). M3G was found to be stable for 3 months in preserved and 
unpreserved urine, whereas after 6 months, M3G had decreased by 13% and 17% 
in preserved and unpreserved samples, respectively (p < 0.05). More than 82% 
and 72% of the compound was recovered after 1 year from blood and urine 
samples, respectively. 
At room temperature, M3G was found to be stable for 2 months in preserved and 
for 1 month in unpreserved blood samples. In the preserved blood sample the 
compound had significantly decreased by 14% from day zero concentration, while 
approximately 14% was lost in the unpreserved sample after 2 monts of storage 
(p < 0.05 for both samples). In urine M3G was found to be stable for 2 weeks for 
both conditions. Thereafter, the concentrations in preserved and unpreserved 
urine decreased by 14% and 16%, respectively by the end of the first month of 
storage (p < 0.05). After one year, more than 46% of M3G was recovered from 
blood samples, and more than 22% was recovered from urine samples in both 
conditions. Stability data are given in Tables 5-2 and 5-3. 
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Table  5-2: M3G stability in blood at 100 ng/ml 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
98 
(6.0) 
98 
(6.0) 
98 
(6.0) 
98 
(6.0) 
98 
(6.0) 
98 
(6.0) 
2 
99 
(0.7) 
102 
(2.8) 
96 
(1.5) 
95 
(2.2) 
102 
(2.8) 
90 
(6.0) 
4 
100 
(2.1) 
97 
(1.5) 
96 
(0.7) 
97 
(2.9) 
98 
(2.2) 
93 
(3.1) 
7 
101 
(3.4) 
99 
(5.2) 
95 
(5.0) 
98 
(1.5) 
95 
(1.4) 
94 
(0.7) 
14 
98 
(5.2) 
97 
(2.9) 
102 
(4.9) 
96 
(1.4) 
97 
(2.1) 
95 
(4.9) 
30 
97 
(4.5) 
97 
(2.2) 
98 
(2.1) 
95 
(5.7) 
94 
(3.0) 
92 
(1.5) 
60 
98 
(4.8) 
101 
(1.9) 
99 
(3.7) 
98 
(4.8) 
87 
(1.9) 
84 
(3.8) 
90 
98 
(1.9) 
95 
(4.1) 
96 
(1.0) 
92 
(3.7) 
84 
(3.2) 
81 
(2.5) 
180 
97 
(0.7) 
98 
(5.7) 
89 
(8.1) 
88 
(5.9) 
73 
(7.8) 
68 
(6.1) 
365 
95 
(3.2) 
93 
(1.8) 
84 
(6.4) 
80 
(7.3) 
55 
(5.1) 
46 
(3.9) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=86) 
# Day zero concentration is mean of 5 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Table  5-3: M3G stability in urine at 100 ng/ml 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
99 
(5.0) 
99 
(5.0) 
99 
(5.0) 
99 
(5.0) 
99 
(5.0) 
99 
(5.0) 
2 
102 
(2.1) 
99 
(2.2) 
99 
(1.4) 
98 
(0.7) 
102 
(2.1) 
100 
(0.7) 
4 
100 
(3.4) 
99 
(1.4) 
99 
(2.1) 
99 
(0.8) 
99 
(0.7) 
99 
(2.2) 
7 
102 
(0.7) 
101 
(2.1) 
102 
(1.3) 
98 
(1.4) 
98 
(2.9) 
99 
(5.2) 
14 
103 
(2.8) 
104 
(4.9) 
104 
(4.9) 
100 
(2.8) 
94 
(7.1) 
92 
(7.3) 
30 
99 
(5.9) 
97 
(3.7) 
97 
(2.2) 
96 
(2.4) 
85 
(2.8) 
83 
(4.9) 
60 
98 
(5.2) 
98 
(2.2) 
94 
(0.8) 
93 
(1.5) 
71 
(4.8) 
66 
(7.9) 
90 
99 
(2.9) 
97 
(2.3) 
93 
(5.5) 
91 
(7.4) 
62 
(2.2) 
57 
(6.5) 
180 
95 
(0.7) 
94 
(1.5) 
86 
(6.9) 
82 
(8.2) 
44 
(2.3) 
32 
(9.2) 
365 
94 
(1.4) 
92 
(1.5) 
78 
(6.6) 
71 
(9.5) 
30 
(9.4) 
22 
(12.8) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=89) 
# Day zero concentration is mean of 5 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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5.4.2 Stability of M6G in blood and urine 
In the freezer (-20 °C), M6G was found to be stable for 1 year in both blood and 
urine and no significant loss was observed during this period (0.1 > p > 0.05). 
More than 96% of analyte was recovered from the blood and urine after 1 year of 
storage.  
In the refrigerator (4 °C), M6G in the blood sample was found to be stable for 1 
year, with losses less than 15% of the original concentrations (0.1 > p > 0.05). 
After 1 year, more than 87% of the original concentration of M6G was recovered 
from the preserved and unpreserved blood samples. The preserved and 
unpreserved urine samples were stable up to 3 months and 2 months 
respectively. A significant loss was observed in the preserved sample after 6 
months, which decreased by approximately 10% (p < 0.05) from the initial 
concentration, while the unpreserved sample decreased by approximately 12% (p 
< 0.05) after 3 months of storage. More than 76% of the compound was recovered 
after 1 year from urine samples in both conditions. 
At room temperature, M6G was found to be less stable than in the freezer and 
refrigerator. M6G was found to be stable for 2 months in blood and two weeks in 
the urine. Three months after day zero, approximately 16% of M6G had been lost 
in the preserved and unpreserved blood samples (p < 0.05), while after 1 month 
approximately 14% and 16% had been lost from the urine preserved and 
unpreserved samples, respectively (p < 0.05). After 1 year of storage, 
approximately 64% and 57% was recovered from the preserved and unpreserved 
blood samples, respectively, while approximately 37% and 30% were recovered 
from the preserved and unpreserved urine samples, respectively. Stability data 
are given in Tables 5-4 and 5-5. 
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Table  5-4: M6G stability in blood at 100 ng/ml 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
98 
(7.0) 
98 
(7.0) 
98 
(7.0) 
98 
(7.0) 
98 
(7.0) 
98 
(7.0) 
2 
99 
(0.7) 
101 
(2.1) 
96 
(1.5) 
97 
(3.7) 
103 
(3.5) 
95 
(2.2) 
4 
100 
(0.7) 
99 
(4.4) 
98 
(0.7) 
97 
(5.3) 
98 
(0.7) 
95 
(2.1) 
7 
99 
(1.5) 
98 
(3.8) 
97 
(3.7) 
98 
(1.5) 
97 
(2.9) 
98 
(1.4) 
14 
99 
(2.9) 
98 
(2.2) 
98 
(1.4) 
96 
(2.2) 
101 
(1.4) 
100 
(3.6) 
30 
98 
(2.2) 
99 
(5.2) 
100 
(3.6) 
99 
(5.9) 
99 
(5.9) 
95 
(3.8) 
60 
101 
(1.7) 
99 
(5.1) 
97 
(5.3) 
97 
(3.6) 
88 
(3.8) 
89 
(1.7) 
90 
99 
(1.0) 
100 
(3.5) 
97 
(0.3) 
95 
(0.4) 
83 
(1.6) 
82 
(3.3) 
180 
100 
(3.5) 
98 
(2.2) 
94 
(4.6) 
93 
(4.1) 
76 
(1.4) 
75 
(6.7) 
365 
97 
(8.0) 
96 
(2.3) 
87 
(4.1) 
85 
(2.3) 
63 
(9.1) 
56 
(3.7) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=84) 
# Day zero concentration is mean of 5 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Table  5-5: M6G stability in urine at 100 ng/ml 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
 Day zero# 
97 
(5.0) 
97 
(5.0) 
97 
(5.0) 
97 
(5.0) 
97 
(5.0) 
97 
(5.0) 
2 
98 
(0.7) 
97 
(1.5) 
97 
(2.9) 
99 
(5.2) 
98 
(0.7) 
97 
(1.4) 
4 
100 
(1.4) 
99 
(1.4) 
99 
(2.9) 
99 
(1.5) 
99 
(0.7) 
98 
(0.9) 
7 
99 
(0.7) 
98 
(0.8) 
100 
(1.4) 
98 
(2.2) 
101 
(2.1) 
96 
(0.8) 
14 
101 
(0.9) 
100 
(1.5) 
103 
(2.1) 
99 
(0.7) 
97 
(0.6) 
94 
(2.2) 
30 
97 
(2.1) 
96 
(2.2) 
93 
(5.1) 
92 
(4.5) 
83 
(4.1) 
81 
(5.1) 
60 
98 
(1.2) 
97 
(1.4) 
91 
(1.5) 
89 
(2.3) 
77 
(5.7) 
68 
(3.4) 
90 
98 
(1.3) 
96 
(2.1) 
88 
(2.4) 
85 
(3.3) 
68 
(4.0) 
59 
(4.6) 
180 
96 
(0.6) 
97 
(2.3) 
87 
(0.8) 
81 
(3.4) 
57 
(7.6) 
48 
(9.4) 
365 
95 
(2.4) 
94 
(0.8) 
81 
(5.1) 
74 
(6.4) 
36 
(5.7) 
29 
(9.1) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=87) 
# Day zero concentration is mean of 5 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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5.4.3 Stability of C6G in blood and urine 
In the freezer (-20 °C), C6G was apparently stable in the blood and urine samples 
for 12 months. Losses were less than 7% (p > 0.05) in the concentrations in both 
matrix conditions after 1 year and more than 93% of the compound could be 
detected after 1 year in both matrices. 
In the refrigerator (4 °C), the compound was found to be stable for 12 months in 
blood and 2 months in urine samples, preserved and unpreserved, while a 
significant loss was observed after 3 months in urine sample. In the urine 
samples, C6G decreased by 8% and 10% in the preserved and unpreserved, 
respectively, after 3 months. At the 1-year interval following storage, more than 
91% and 89% of analyte was recovered from preserved and unpreserved blood 
samples, respectively, while more than 86% and 75% of analyte was recovered 
from the preserved and unpreserved urine samples, respectively. 
At room temperature, the compound was found to be stable for 3 and 2 months 
in the preserved and unpreserved blood samples respectively, while beyond this 
time a significant loss of 13% and 16% was estimated in the preserved and 
unpreserved samples, respectively, (p < 0.05). After 1 year, approximately 75% 
and 70% of the analyte was recovered from preserved unpreserved samples of 
blood, respectively. In the urine samples, the compound was found to be stable 
for 2 weeks in both preserved and unpreserved samples. In preserved urine, C6G 
decreased by 15.5% (p < 0.05) after 1 month of storage, while approximately 45% 
of the compound was detected after 1 year of storage. In unpreserved urine, 
C6G decreased by 18% after 1 month, while only 38% of the initial concentration 
was recovered after 1 year. Stability data are shown in Table 5-6 and 5-7. 
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Table  5-6: C6G stability in blood at 100 ng/ml 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 
Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
 Day zero# 
99 
(6.0) 
99 
(6.0) 
99 
(6.0) 
99 
(6.0) 
99 
(6.0) 
99 
(6.0) 
2 
100 
(3.5) 
98 
(2.2) 
99 
(3.7) 
98 
(2.5) 
98 
(4.4) 
98 
(3.7) 
4 
101 
(3.3) 
99 
(1.4) 
98 
(2.8) 
100 
(1.7) 
99 
(0.7) 
97 
(1.4) 
7 
99 
(0.7) 
97 
(3.0) 
102 
(0.6) 
99 
(0.8) 
98 
(0.5) 
99 
(0.9) 
14 
98 
(2.1) 
97 
(3.6) 
101 
(2.8) 
98 
(2.2) 
99 
(1.3) 
99 
(1.5) 
30 
101 
(2.7) 
102 
(1.4) 
100 
(3.6) 
99 
(4.4) 
101 
(1.4) 
97 
(5.3) 
60 
99 
(2.6) 
99 
(1.7) 
98 
(0.8) 
98 
(1.9) 
91 
(2.3) 
90 
(2.4) 
90 
98 
(5.6) 
98 
(2.8) 
98 
(3.8) 
97 
(6.4) 
89 
(4.9) 
83 
(4.7) 
180 
99 
(5.2) 
98 
(6.5) 
95 
(8.1) 
94 
(5.5) 
86 
(3.3) 
79 
(2.1) 
365 
96 
(5.0) 
93 
(1.3) 
91 
(3.1) 
89 
(2.8) 
75 
(5.5) 
70 
(3.6) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=88) 
# Day zero concentration is mean of 5 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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Table  5-7: C6G stability in urine at 100 ng/ml 
Storage condition  
Freezer 
(-20 °C) 
Refrigerator 
(4 °C) 
Room temperature 
 Time 
(day) 
P* 
(ng/ml) 
N-P* 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
P 
(ng/ml) 
N-P 
(ng/ml) 
Day zero# 
97 
(3.0) 
97 
(3.0) 
97 
(3.0) 
97 
(3.0) 
97 
(3.0) 
97 
(3.0) 
2 
99 
(1.4) 
100 
(2.1) 
102 
(3.6) 
97 
(1.5) 
100 
(2.1) 
99 
(1.5) 
4 
97 
(2.2) 
98 
(4.5) 
99 
(1.4) 
99 
(2.9) 
98 
(0.7) 
97 
(2.2) 
7 
99 
(1.4) 
96 
(1.5) 
97 
(0.7) 
98 
(1.3) 
99 
(1.2) 
96 
(0.7) 
14 
98 
(0.7) 
98 
(4.5) 
98 
(0.5) 
95 
(1.8) 
97 
(1.4) 
95 
(0.8) 
30 
97 
(2.9) 
96 
(1.5) 
96 
(0.9) 
94 
(2.2) 
82 
(1.7) 
80 
(3.4) 
60 
108 
(6.1) 
98 
(2.9) 
94 
(2.3) 
93 
(2.9) 
80 
(1.7) 
73 
(2.9) 
90 
95 
(1.5) 
97 
(0.7) 
89 
(3.8) 
87 
(4.7) 
69 
(4.2) 
60 
(3.4) 
180 
96 
(0.9) 
96 
(1.3) 
87 
(1.6) 
83 
(3.3) 
50 
(2.9) 
46 
(4.8) 
365 
94 
(2.2) 
93 
(3.7) 
86 
(2.5) 
75 
(4.6) 
44 
(4.9) 
37 
(8.1) 
P*: preserved, N-P*: unpreserved. (Concentration threshold=99) 
# Day zero concentration is mean of 5 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). 
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5.4.4 Summary of M3G, M6G, and C6G stability in blood and 
urine samples 
The stability of M3G, M6G, and C6G in blood and urine samples under different 
storage conditions is summarized in Table 5-8. 
Table  5-8: Summary of stability of M3G, M6G, and C6G in blood and urine samples for 1 year 
under different storage conditions 
Results 
Compound 
Storage 
conditions Blood Urine  
Comment 
-20 ºC, 1 year Stable  Stable 
4 ºC, 1 year 
18% 
decrease 
28% 
decrease M3G 
25 ºC, 1 year 
53% 
decrease 
78% 
decrease 
-20 ºC, 1 year Stable  Stable  
4 ºC, 1 year Stable  
24% 
decrease M6G 
25 ºC, 1 year 
43% 
decrease 
70% 
decrease 
-20 ºC, 1 year Stable  Stable  
4 ºC, 1 year Stable  
22% 
decrease C6G 
25 ºC, 1 year 
29% 
decrease 
62% 
decrease 
• Compounds 
more stable in 
blood than in 
urine 
• NaF (0.2% w/v) 
enhances the 
stability by less 
than 10% 
• C6G more 
stable than M3G 
and M6G  
• M6G more 
stable than M3G 
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5.5  Discussion 
This study demonstrated that decrease in the concentrations of these opiate 
metabolites must be expected during storage periods of up to 1 year. All 
compounds showed good stability when stored in the freezer during the whole 
observation period and no significant losses were noted. Higher temperatures 
significantly influenced the stability of M3G in blood samples, in which the 
compound steadily decreased after 2 months at room temperature and 1 year in 
the refrigerator, while in the urine sample it decreased after 1 month at room 
temperature and 6 months in the refrigerator. M6G in blood was very stable in 
refrigerator while in urine samples it was stable for 3 months and 2 months in 
preserved and unpreserved samples respectively. Similar findings were observed 
for M6G as for M3G at room temperature.  
No significant decrease was observed in the concentrations of C6G in blood or 
urine after 1 year in the freezer while in the refrigerator changes were observed 
in urine samples after 3 months whereas C6G was found to be stable in blood for 
1 year and no significant loss was observed. At room temperature, C6G was 
found to be stable in blood for 3 months and 2 months in preserved and 
unpreserved samples respectively, and was more stable than in urine, in which it 
was stable for only 2 weeks; beyond 2-4 weeks, significant losses were observed 
in both matrices in both conditions. 
Decomposition of these metabolites is clearly dependent on the storage 
conditions. Although the C6G decay was similar to M3G and M6G at the 
beginning, the C6G recovered at the end of the study was more than that of M3G 
and M6G. This implies that the chemical structure of these compounds has 
diffeent degrees of thermal instability. The phenol moiety in M3G and M6G might 
undergo an oxidation reaction through a process involving the phenolic group in 
their structure. This reaction was reported for morphine, in which the oxidation 
process yielded pseudomorphine as a result of oxidation. However, this reaction 
did not occur for codeine because the phenolic group is alkylated. Therefore, 
samples containing morphine and its metabolite should be protected from light 
and stored at negative temperatures after collection from individuals.   
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Degradation by hydrolysis of the opiate glucuronides is not a predominant 
reaction, which was reported in post-mortem cases to yield free morphine. 
Meanwhile, the oxidation is a minor process that may be affected by light.68 At 
the beginning, these compounds exhibited similar stability, but the samples may 
have been exposed to light during the opening and closing of the refrigerator, 
freezer, and cabinet doors at room temperature. Additionally, active oxygen 
may be scavenged by blood components such as haemoglobin.  
Summing up, morphine and M3G and M6G calculated as morphine equivalents, 
provided that the degradation of the morphine metabolite is not a result of a 
hydrolysis reaction or other minor degradation processes, is attributed to 
oxidation degradation as reported previously.68 In post-mortem samples bacteria 
may play a role in this reaction, which transmigrate through the gastrointestinal 
wall into the blood 5 hours after death occurred, as reported in the metabolism 
of nitrobenzodiazepines by intestinal bacteria. Furthermore, bacteria showed 
high β-glucuronidase activity in heart blood, which was reported by Skopp 
et al.68 The presence of bacteria, common in post-mortem blood and urine, as 
well as in the unprotected skin of less hygienic individuals, might affect the 
stability of these compounds, leading to accelerated degradation reactions.  
Bacteria might also utilise the glucose moiety of glucuronide metabolites to 
produce alcohol. In addition, urine from unhealthy persons, such as those 
complaining of urinary tract infection (UTI), may contain a high bacteria count 
which can strongly influence the stability of these compounds. Bacterial 
contamination of samples and its effect on drug stability should be considered 
and minimized by using preservatives. In the current study, the role of bacteria 
in the decomposition is excluded because these matrices were collected from 
healthy volunteers and the prepared samples were transferred into tubes, which 
were opened once and not reopened for subsequent analyses. Additives showed 
enhancement of the stability of these metabolites but only to a small extent, as 
observed in the work reported in Chapter 4, and that may be due to the small 
concentration of NaF (0.2% w/v) in the tube. However, if samples are collected 
from real post-mortem cases, the effect of the additives on the stability of these 
compounds may be greater.  
M3G was less stable than M6G, in agreement with the results reported by Skopp 
et al., while C6G was found to be the most stable among these compounds.68 
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In addition, the stability of these metabolites is not only influenced by 
temperature and additives but by the matrices, and the stability of these 
metabolites in blood was greater than in the urine, which might be the result of 
a lack of protective effects resulting from partitioning of the analytes into red 
blood cells. It has been reported that whole blood provides better protection 
against light exposure than plasma. Additionally, it was found that these 
metabolites are more stable in whole blood than in plasma, despite the fact that 
plasma contains protein, which may protect the compounds from degradation as 
a result of protein binding. The same finding was observed in this study although 
the blood matrix used did not contain plasma proteins. Blood contains 
haemoglobin which binds oxygen and this might have been expected to play a 
role in the degradation of compounds. However, the glucuronides were more 
stable in blood than in urine. The net effect may be the combined result of a 
protective effect due to partitioning of the metabolites into red blood cells as 
mentioned earlier and of the pH of the matrix. Blood pH is buffered by 
bicarbonate as well as by proteins, which in the present study could have been 
released by lysis of erythrocytes, whereas, as noted earlier, the urine pH may 
change significantly during storage. The pH of urine (pH 4-8) may accelerate the 
degradation process of compounds compared to that of blood (pH 7.2-7.4). 
Furthermore, at high temperatures and with time, urine pH may shift to alkaline 
as a result of the breakdown of urea to ammonia, and this could also accelerate 
the hydrolysis of these compounds.156 
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5.6 Conclusion  
This study investigated the stability of M3G, M6G and C6G in blood and urine at 
three different storage temperatures, with and without additives, and 
demonstrated that a low storage temperature is the optimum for preserving 
these compounds. Ideally, analysis of samples should be achieved as soon as they 
are received. Samples should be stored in a freezer at -20 °C or lower in order to 
protect analytes for a long period, while additives should be added even though 
their effect was small in this study, as they may show greater effects with post-
mortem samples which are known to contain bacteria that may accelerate the 
decomposition of compounds and limiting their detection. The addition of 
antioxidant substances, such as ascorbic acid or sodium metabisulfite, may 
enhance the stability of morphine metabolites against the oxidation process, and 
further study is suggested using antioxidants to preserve morphine metabolites. 
Storage conditions were not the only influence on the stability of compounds, 
but the nature of the biological matrix also had an effect such that compounds 
were more stable in blood than urine. Interpretation of results obtained from 
samples stored long-term should be carefully interpreted to avoid serious errors.   
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6 Stability of Cocaine and Benzodiazepines in 
Dried Blood Spots 
6.1 Introduction 
In the review given earlier (Section 2.4.2), the use of dried blood spots (DBS) is 
one of several approaches to stabilising drugs in blood specimens. The Guthrie 
card has been used for the collection of blood spots since 1960, when Dr Guthrie 
used blood collected on filter paper to measure phenylalanine in newborns.157 
Dried blood spots (DBS) have also been used in therapeutic drug monitoring and 
diagnostic screening as well as having been found suitable for drug analysis and 
for reducing the breakdown of drugs.91-97,158-172 However, only a few studies in 
this area have been published and the present work considerd DBS as a method 
for stabilising hydrolytically-labile drugs, including cocaine and selected 
benzodiazepines.91-97 
Cocaine is an active alkaloid obtained from the leaves of the plant Erythroxylon 
coca. Cocaine induces its effect via stimulation of release of the 
neurotransmitters dopamine, noradrenaline and serotonin in the peripheral 
organs and brain. Cocaine also stimulates the synthesis of these 
neurotransmitters by activation of the enzyme tyrosine hydroxylase. Further, 
cocaine prevents reuptake of released neurotransmitters into their respective 
neurones. Beside these effects cocaine inhibits release of the central nervous 
system (CNS) depressant Gamma-aminobutyric acid (GABA). Cocaine was used 
therapeutically as a local anaesthetic and is widely abused due to its stimulant 
properties and so it is frequently detected in forensic cases. Benzoylecgonine 
(BZE) is the main metabolite of cocaine in blood and urine which is produced by 
chemical and enzymatic hydrolysis of the methyl ester in cocaine. Other 
metabolites include norcocaine, ecgonine methyl ester (EME) and ecgonine. 
Smoking of cocaine produces anhydroecgonine methyl ester (AEME) by pyrolysis 
rather than metabolism while cocaethylene is a unique active metabolite of 
cocaine when cocaine is co-administered with alcohol. Peak plasma 
concentrations of cocaine were 104 to 424 ng/ml at 50 to 90 min after 
administration of cocaine hydrochloride in gelatine capsule to healthy male 
volunteers.135,136  
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Flunitrazepam (Rohypnol®) is a member of the 7-nitrobenzodiazepine class which 
has fluorine at position 2 of the phenol group and is used clinically as a hypnotic 
and anaesthetic induction agent.  It is also implicated as drug of abuse in drug 
facilitated sexual assault (DFSA). Flunitrazepam is administered orally or 
intravenously. The metabolism of flunitrazepam is via N-demethylation, N-
hydroxylation and glucuronidation, and reduction of the nitro group to the 
corresponding amine. The average peak plasma concentrations of flunitrazepam 
and 7-aminoflunitrazepam within 6-24 hours following a 2 mg oral dose were 0.5-
3 µg/l and 50-500 µg/l respectively. Blood concentrations in cases of 
flunitrazepam toxicity ranged from 0.01-0.05 mg/l. 135,136,144,145 
Diazepam (Valium®) is the second benzodiazepine used clinically to treat 
anxiety, muscle spasm and convulsion, orally or parenterally. Diazepam 
undergoes N-demethylation to nordiazepam while both of them are hydroxylated 
to give temazepam and oxazepam respectively. The peak blood concentration 
after a 10 mg oral dose of diazepam is 0.148 mg/L at 1 hour. Serum diazepam 
concentrations in intoxicated patients reach up to 20 mg/L.135,136,145  
Temazepam (Restoril®) is the 3-hydroxylated metabolite of diazepam and is used 
therapeutically as a hypnotic. An oral dose of temazepam (10 mg) leads to a 
peak plasma concentration in the range 0.205-0.43 mg/L within 15-90 minutes. 
Temazepam is metabolised and excreted in the urine as free and conjugated 
temazepam and free and conjugated oxazepam. Toxic doses of temazepam lead 
to blood temazepam concentrations in the range 0.9-14 mg/L. 135,136,145 
Nitrazepam (Mogadon®) is a 7-nitro–benzodiazepine which is used clinically as a 
hypnotic drug. The therapeutic plasma level following a 5 mg oral dose of 
nitrazepam is 0.035 mg/L after 2 hours while the blood concentration following 
toxic doses of nitrazepam (250 mg) are in the range 1.2-9 mg/L. Nitrazepam is 
reduced to an inactive metabolite, 7-aminonitrazepam. 135,136,145 
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The chemical structures of cocaine and benzodiazepines used in this study are 
shown in Figures 6-1 and 6-2. 
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Figure  6-2: Chemical structures of benzodiazepines used in this study. 
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The aim of this study was to investigate the stability of hydrolytically labile 
drugs in dried blood spots stored for 1 year in the freezer, the refrigerator and 
at room temperature. 
 
6.2 Experimental Section 
6.2.1 Chemical and material: 
Flunitrazepam, temazepam, lorazepam, oxazepam, nitrazepam and diazepam 
and the corresponding deuterated internal standards (flunitrazepam-d7, 
temazepam-d5, oxazepam-d5, lorazepam-d4 and diazepam-d5) were purchased 
from LGC Promochem (Middlesex, UK) as 100µg/ml solutions in methanol. 
Cocaine and cocaine-d3 were purchased from LGC Promochem as 100 µg/ml 
solutions in acetonitrile.  Stock solutions of standards and internal standards 
were stored at -20 ºC. Acetonitrile, methanol, cyclohexane, ethyl acetate, 
ammonium hydroxide, formic acid and potassium dihydrogen phosphate were 
obtained from BDH (Poole, UK).  Ammonium formate was purchased from Sigma-
Aldrich (Dorset, UK).  Clean Screen ZSDAU020 cartridges were purchased from 
United Chemical Technology UK. Sheets of Guthrie card 903® specimen 
collection paper (210 x 297 mm) were purchased from Whatman UK. 
 
6.2.2 Solutions: 
6.2.2.1 Preparation of 0.1M phosphate buffer pH 6.0 
1 litre of solution was prepared by dissolving 1.7 g of anhydrous disodium 
orthophosphate and 12.14 g of sodium dihydrogen orthophosphate monohydrate 
in 800 ml of deionized water. The pH was adjusted to pH 6 with 1 M potassium 
hydroxide and the solution made up to volume with deionized water. 
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6.2.2.2 Preparation of 3mM ammonium formate and 0.001% formic acid 
This mobile phase was prepared by dissolving 0.189 g of ammonium formate in 
800 ml deionized water followed by addition of 10 µl of concentrated formic acid 
and making up to one litre with deionized water. 
 
6.2.2.3 Standard solutions of analytes 
Working standards of unlabelled and labelled drugs were prepared by diluting 
250 µl from each 100 µg/ml drug stock solution in 25 ml methanol to obtain a 
concentration of 1 µg/ml. Stock solutions of standards and internal standards 
were stored in the freezer at -20 ºC.  
 
 
6.2.3 Preparation of DBS samples: 
Packed human red blood cells which had passed their usable date were obtained 
from the Scottish National Blood Transfusion Service and were re-suspended in 
an equal volume of isotonic saline. The original blood collection used ethylene 
diamine tetra acetic acid (EDTA) as anticoagulant.  The blood was spiked with 
drug compounds to produce a final concentration of 1000 ng/ml of each analyte 
(total volume was 10 ml) then mixed for one hour to ensure the homogeneity of 
all analytes in the blood. After that, 100 µl of the spiked blood was spotted on 
the filter paper to produce 100 spots. The spot diameter was equal to 13mm and 
each spot contained 100 ng of each analyte. 
 
The spotted samples were allowed to dry overnight at ambient temperature in 
the fume hood. Ten samples were analysed on the first day to check on their 
homogeneity and treated as the first day concentrations (RSD% < 9 for analyte as 
shown in Tables 6-6 to 6-12 at day zero concentration). Then the prepared 
samples were divided into three groups and placed in sealed plastic bags to 
protect them from contamination and humidity and were then stored at three 
different temperatures (-20ºC, 4ºC and room temperature). These storage 
temperatures were selected in relation to frequently-used laboratory storage 
temperatures.The storage temperatures were monitored daily using permanently 
mounted digital thermometers with a resolution of 0.1 C°at the start of the 
study and subsequently at weekly intervals during the period of study. 
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Temperatures were stable within a range of approximately 1 C ° (freezer and 
refrigerator) or 5 C° (room temperature, average temperature 20°C).  The times 
selected for analysis were at day 1 (day zero), 2, 4, 7, 14, 30, 60, 90, 180, and 
365. 
 
The bags remained sealed until they were opened for processing of the DBS.  DBS 
were analysed in duplicate for each time and storage temperature. 
 
 
 
Figure  6-3: 100µl aliquots of spiked blood were spotted on sheets of paper 903® to produce 
100 spots in total. 
 
 
 
6.2.4 Extraction procedure 
6.2.4.1  Optimisation of the extraction of analytes from DBS 
An evaluation was carried out of four different methods of extracting the 
analytes from DBS on filter paper, based on three different solvents (methanol, 
ethyl acetate and acetonitrile) and phosphate buffer (pH6), to establish which 
would give the best recoveries of the analytes.  
 
2ml blank blood was spiked with the analytes and was then spotted on the sheet 
of paper to give a final concentration of 50 ng of each analyte per spot.  The 
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spots were allowed to dry overnight. The spots were cut from the sheet with 
scissors, transferred to extraction tubes and 3.5 ml extraction solutions were 
added.  The tube was vortex-mixed and placed in an ultrasonic bath for one hour 
to extract the drugs from the paper. The paper was discarded then the extract 
was centrifuged at 2500 RPM for 10 minutes. Solid phase extraction columns 
were conditioned with 3ml of methanol, 3ml water and 2 ml phosphate buffer 
(pH6). After this, the sample extracts were passed through the cartridges with 
no vacuum applied. The columns were washed with 2ml water followed by 2ml 
phosphate buffer (pH6): acetonitrile (80:20 v:v). The final column washing step 
was the addition of 2 ml of water followed by drying for 5 minutes. Elution of 
analytes was achieved using 3 ml of ethyl acetate: ammonia (98:2 v:v). 
 
Unextracted standards (50 ng of each analyte) were prepared in duplicate. 
Before evaporation under a stream of nitrogen, 50ng of internal standard was 
added to all samples, and the samples were analysed by LC-MS/MS.  Extracts of 
DBS and the unextracted standards were analysed by LC-MS/MS and recoveries 
were calculated using the equation 3-5. The mean recoveries for all analytes are 
shown in Table 6-1. 
 
Table  6-1: Recovery of (50 ng/spot) drugs from DBS using three different solvents and 
buffer: 
Mean recovery % 
(RSD %, n=4)  
Drug 
Methanol Acetonitrile 
Ethyl 
acetate 
Buffer * 
Cocaine 
84 
(1) 
97 
(20) 
82 
(7) 
90 
(13) 
Flunitrazepam 
        86 
(11) 
71 
(12) 
57 
(17) 
93 
(3) 
Temazepam 
        94 
(9) 
68 
(8) 
76 
(14) 
86 
(2) 
Oxazepam 
63 
(2) 
31 
(10) 
37 
(17) 
95 
(12) 
Lorazepam 
64 
(4) 
49 
(3) 
59 
(6) 
83 
(12) 
Nitrazepam 
65 
(15) 
53 
(13) 
54 
(18) 
99 
(4) 
Diazepam 
98 
(7) 
68 
(10) 
78 
(11) 
100 
(5) 
 
* Phosphate Buffer pH 6 
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Phosphate buffer pH 6 showed the highest recovery compared to organic solvents 
(Table 6-1). Haemoglobin was also released from the spot when using buffer and 
consequently the buffer was used in the study to extract the drugs from DBS 
followed by SPE. 
 
 
6.2.4.2 Final extraction procedure for DBS 
DBS samples were removed from the paper with scissors and added to 3.5ml of 
phosphate buffer pH 6 containing 100µL of internal standard then vortex-mixed 
and placed in an ultrasonic bath for one hour to extract the drugs from the 
paper. The paper was discarded then the extract was centrifuged at 2500 RPM 
for 10 minutes. 
 
Solid phase extraction columns were conditioned with 3ml of methanol, 3ml 
water and 2 ml phosphate buffer (pH6). After this, the sample extracts were 
passed through the cartridges with no vacuum applied. The columns were 
washed with 2ml water followed by 2ml phosphate buffer (pH6): acetonitrile 
(80:20 v:v). The final column washing step was the addition of 2 ml of water 
followed by drying for 5 minutes. Elution of analytes was achieved using 3 ml of 
ethyl acetate: ammonia (98:2 v:v). The extracts were dried under a gentle 
stream of nitrogen, then the residues were reconstituted in 100µl of HPLC 
mobile phase, of which 20µl was injected into the LC-MS/MS instrument. The 
analysis was carried out in duplicate for each storage temperature. 
 
Each day samples were analysed, two replicates were taken for analysis from the 
storage racks  for each of the different storage conditions, extracted within the 
day and left to run on the LC-MS/MS instrument overnight.  If the analysis could 
not be completed within 24 hours due to instrumental problems, extracts were 
kept in the deep freeze at -20°C until they could be analysed. A calibration 
curve was prepared for each set of samples over the range of 5-200 ng/spot. 
Cocaine and benzodiazepines standards were spiked into blood to produce 
concentrations of 5, 10, 25, 50, 100, 200 ng/spot and 100 ng/spot of internal 
standards were added into each concentration, then these were extracted by 
SPE and analysed by LC-MS/MS. 
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6.2.5 Instrumentation 
LC-MS/MS analysis was performed using a Thermo Finnigan LCQ Deca XP (Thermo 
Finnigan, San Jose, CA, USA) equipped with a surveyor HPLC system.  
Chromatographic separation was achieved using a Gemini C18 column (150 mm x 
2 mm ID, 5µm particle size) fitted with guard column (4 mm x 2 mm, 5µm) with 
the same column packing. The mobile phase was a mixture of 3mM aqueous 
ammonium formate solution containing 0.001% formic acid and acetonitrile 
starting at 65:35 v:v and changing to 10:90 v:v between 13 and 13.5 minutes. It 
was then held at 10:90 v: v between 13.5 and 16.5 minutes then reset to the 
staring composition between 16.5 and 20 minutes. Optimum tuning parameters 
selected for all analyte are shown in the Table 6-2. The m/z of the nitrazepam-
d5 internal standard precursor ion is the same as the m/z of the oxazepam 
precursor ion (m/z=287) also both have the same tR of 5.8 min resulting to 
undesirable coelution. Therefore, oxazepam-d5 was used as internal standard in 
nitrazepam quantitation. Internal standard data was acquired in selected ion 
monitoring (SIM) mode and analytes were identified on the basis of their full MS-
MS spectra. Two product ions were monitored. The underlined ions in Table 6-2 
were used as the quantification ions because they were the most intense ions 
produced. 
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Table  6-2: Optimum tuning parameters 
Drug 
Precursor ion 
(m/z) 
Monitored ions* 
(m/z) 
Collision energy 
(ev) 
Cocaine 304 182, 150 32 
Flunitrazepam  314 286, 268 40 
Temazepam  301 283, 255 28 
Oxazepam  287 269, 241 26 
Lorazepam  321 303, 275 28 
Nitrazepam  282 254, 236 41 
Diazepam  285 257, 222 40 
 
       Internal standards 
Cocaine-d3 
 
307 
 
307 
Not used 
Flunitrazepam-d7  321 321 Not used 
Temazepam-d5 306 306 Not used 
Oxazepam-d5 292 292 Not used 
Lorazepam-d4 325 325 Not used 
Diazepam-d5 300 300 Not used 
• Underlined ion was used as the quantification ion. For internal standards, 
only the pseudomolecular ions were monitored and no collision energies 
were specified. 
 
 125 
6.3 Validation of analytical method 
The validation parametrs applied in this study were similar to the parameters in 
Table 4-1 except that the low concentration in this method was 10 ng/spot. 
6.4 Results  
6.4.1 Method validation results  
6.4.1.1 Linearity 
The relationships between analyte concentrations and peak area ratios were 
linear over the range 5-200 ng/spot and the linear correlation coefficients (r2) 
were better than 0.99 for all analytes as shown in Table 6-3. 
6.4.1.2 LODs and LLOQs 
LOD values for all analytes were 0.29-0.74 ng/spot, and LLOQ values were 0.99-
2.46 ng/spot. The results are shown in Table 6-3. 
Table  6-3: Linear correlation coefficients, LODs and LLOQs of drugs in DBS. 
LLOQ 
(ng/spot) 
LOD 
(ng/spot) 
Linear correlation 
coefficient 
(r2) 
Drug 
 
2.46 
 
 
0.74 
 
0.994 Cocaine 
1.58 
 
0.47 
 
0.999 Flunitrazepam 
 
1.08 
 
 
0.32 
 
0.996 Temazepam 
 
2.06 
 
 
0.62 
 
0.999 Oxazepam 
 
1.10 
 
 
0.32 
 
0.996 Lorazepam 
 
1.80 
 
 
0.54 
 
0.998 Nitrazepam 
 
0.99 
 
0.29 
0.996 Diazepam 
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6.4.1.3 Recoveries  
The recoveries for all analytes were in the range 81-106% as shown in Table 6-4. 
Table  6-4: Recoveries of analytes from DBSs 
Mean Recovery% 
(RSD%, n=5) 
Drug 
10ng/spot 50ng/spot 100ng/spot 
Cocaine  
90 
(12) 
91 
(16) 
              97 
             (11) 
Flunitrazepam 
89 
(16) 
93 
(9) 
103 
(13) 
Temazepam 
89 
(13) 
93 
(15) 
94 
(12) 
Oxazepam 
95 
(17) 
106 
(12) 
105 
(5) 
Lorazepam 
81 
(13) 
88 
(10) 
86 
(8) 
Nitrazepam 
90 
(12) 
99 
(16) 
100 
(2) 
Diazepam 
83 
(18) 
97 
(15) 
99 
(15) 
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6.4.1.4 Intraday and interday precision  
As shown in Table 6-5 the method showed good precision and the relative 
standard deviations (RSD%) for intra- and inter-day precision were in the ranges 
1.9-14.7 and 1.6-18.3 % respectively, which are considered to be acceptable. 
Table  6-5: Inter-day and intra-day precision results. 
Interday mean (RSD%, n=5) Intraday mean (RSD%, n=5) 
Drug  
10ng/spot 50ng/spot 100ng/spot 10ng/spot 50ng/spot 100ng/spot
Cocaine 
10 
( 6.7) 
53 
(6.7) 
98 
(9.7) 
13 
(12.8) 
48 
(8.0) 
96 
(5.4) 
Flunitrazepam 
12 
(11.7) 
47 
(11.7) 
98 
(6.9) 
10 
(8.1) 
48 
(5.6) 
95 
(4.2) 
Temazepam 
10 
(14.2) 
49 
(9.3) 
95 
(6.0) 
11 
(6.6) 
44 
(4.5) 
92 
(3.3) 
Oxazepam 
10 
(14.1) 
47 
(12.7) 
100 
(7.3) 
11 
(5.9) 
55 
(14.7) 
97 
(2.8) 
Lorazepam 
10 
(18.3) 
51 
(13.8) 
107 
(2.6) 
10 
(14.7) 
57 
(10.3) 
100 
(1.9) 
Nitrazepam 
13 
(16.9) 
48 
(16.8) 
99 
(2.9) 
14 
(10.9) 
46 
(8.0) 
93 
(3.2) 
Diazepam 
9 
(11.9) 
55 
(5.9) 
103 
(1.6) 
13 
(10.3) 
51 
(11.3) 
99 
(4.0) 
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6.4.2 Stability results  
6.4.2.1 Cocaine  
Cocaine in dried blood spots were found to be stable in the freezer and 
significant loss was not observed until after 2 months of storage, when there was 
a 17 % loss from the original concentration (p < 0.05). After 1 year approximately 
60% of the cocaine was recovered from DBS. 
 
In the refrigerator, cocaine was found to be stable for only 2 weeks. After 1 
month a significant loss of 15% from the day zero concentration was noted (p < 
0.05). Approximately 36% of the original cocaine could still be detected in DBS 
after 1 year. 
 
At room temperature cocaine was found to be stable for 4 days before a 
significant decrease was observed after 1 week which was an 18% decrease from 
the initial concentration at day zero (P < 0.05). The remaining cocaine that 
could be recovered from DBS after 1 year of storage at room temperature was 
approximately 14% of the starting concentration. The stability data are shown in 
Table 6-6. 
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Table  6-6: Stability of cocaine in dried blood spots stored in filter paper 
Storage condition 
Time 
(day) 
Freezer 
(-20 °C) 
(ng/spot) 
Refrigerator 
(4 °C) 
(ng/spot) 
Room temperature 
(ng/spot) 
Day zero# 
105 
(8.0) 
105 
(8.0) 
105 
(8.0) 
2 
106 
(8.2) 
104 
(11.5) 
100 
(2.8) 
4 
105 
(2.9) 
100 
(3.5) 
92 
(3.6) 
7 
103 
(2.0) 
98 
(5.6) 
86 
(4.6) 
14 
98 
(3.2) 
95 
(4.3) 
83 
(1.4) 
30 
96 
(10.4) 
89 
(9.4) 
81 
(7.4) 
60 
87 
(10.1) 
73 
(1.0) 
54 
(10.5) 
90 
72 
(10.9) 
59 
(8.7) 
33 
(2.4) 
180 
68 
(4.2) 
46 
(8.3) 
20 
(4.2) 
365 
63 
(1.5) 
38 
(12.8) 
15 
(11.0) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). (Concentration 
threshold=90). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 130 
6.4.2.2 Flunitrazepam 
Flunitrazepam was found to be stable in DBS when stored in the freezer and 
refrigerator for one year and no significant loss was noted during the complete 
observation period (0.1 > p > 0.05). The quantities of flunitrazepam recovered 
after one year in the freezer and refrigerator were 94% and 88% respectively. 
Significant loss of flunitrazepam at room temperature was observed after 1 
month of storage. Flunitrazepam decreased by 18% from the day zero 
concentration (p < 0.05) while approximately 76% of the compound was detected 
after 1 year. The stability results are shown in the table 6-7. 
 
Table  6-7: Stability of flunitrazepam in dried blood spots stored in filter paper. 
Storage condition 
Time 
(day) Freezer 
(-20 °C) 
(ng/spot) 
Refrigerator 
(4 °C) 
(ng/spot) 
Room temperature 
(ng/spot) 
Day zero# 
104 
(7.0) 
104 
(7.0) 
104 
(7.0) 
2 
99 
(3.3) 
98 
(1.3) 
102 
(0.7) 
4 
99 
(4.6) 
97 
(1.0) 
99 
(0.6) 
7 
98 
(1.2) 
96 
(1.4) 
99 
(3.4) 
14 
96 
(1.4) 
92 
(6.6) 
93 
(2.3) 
30 
95 
(2.2) 
91 
(3.9) 
86 
(3.0) 
60 
98 
(10.4) 
92 
(13.7) 
83 
(2.6) 
90 
99 
(8.9) 
97 
(1.1) 
84 
(4.6) 
180 
97 
(0.3) 
96 
(0.7) 
83 
(0.8) 
365 
98 
(14.3) 
92 
(6.8) 
79 
(7.9) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). (Concentration 
threshold=90). 
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6.4.2.3 Temazepam  
Temazepam was apparently stable in the freezer and refrigerator for 1 year of 
storage with no significant loss being observed (0.1 > p > 0.05). The quantities of 
temazepam recovered from DBS in the freezer and refrigerator after 1 year of 
storage were 96% and 89% respectively. At room temperature temazepam 
showed good stability for 6 months and a significant decrease of the drug 
concentration was observed after 1 year which was approximately 18% of 
starting concentration (p < 0.05). Approximately 82% of temazepam was 
recovered after 1 year of storage. Stability data are given in Table 6-8. 
 
Table  6-8: Stability of temazepam in dried blood spots stored in filter paper 
Storage condition 
Time 
(day) 
Freezer 
(-20 °C) 
(ng/spot) 
Refrigerator 
(4 °C) 
(ng/spot) 
Room temperature 
(ng/spot) 
Day zero# 
100 
(8.0) 
100 
(8.0) 
100 
(8.0) 
2 
97 
(2.6) 
98 
(3.8) 
99 
(9.5) 
4 
98 
(1.8) 
96 
(3.9) 
98 
(2.5) 
7 
97 
(4.5) 
94 
(3.3) 
96 
(2.2) 
14 
97 
(3.8) 
95 
(2.7) 
88 
(10.4) 
30 
98 
(4.5) 
94 
(4.8) 
86 
(7.1) 
60 
96 
(6.9) 
93 
(8.9) 
87 
(1.3) 
90 
95 
(3.4) 
89 
(2.1) 
86 
(5.4) 
180 
97 
(1.4) 
90 
(4.9) 
87 
(0.2) 
365 
96 
(6.8) 
89 
(4.8) 
82 
(7.1) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). (Concentration 
threshold=84). 
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6.4.2.4 Oxazepam 
Oxazepam was found to be stable in DBS for the whole observation period when 
stored in the freezer and refrigerator (p > 0.05) whereas a significant decrease 
occurred 3 months after storage at room temperature (p < 0.05), which was 20% 
from the day zero concentration. The amounts of drug recovered from DBS after 
1 year of storage in the freezer, refrigerator and at room temperature were 90%, 
85% and 75% respectively. Stability data are given in Table 6-9. 
 
Table  6-9: Stability of oxazepam in dried blood spots stored in filter paper 
Storage condition 
Time 
(day) 
Freezer 
(-20 °C) 
(ng/spot) 
Refrigerator 
(4 °C) 
(ng/spot) 
Room temperature 
 (ng/spot) 
Day zero# 
102 
(9.0) 
102 
(9.0) 
102 
(9.0) 
2 
101 
(7.6) 
98 
(3.2) 
98 
(8.9) 
4 
99 
(5.2) 
98 
(4.1) 
98 
(1.8) 
7 
99 
(5.3) 
97 
(3.9) 
97 
(2.1) 
14 
98 
(0.3) 
95 
(3.1) 
93 
(7.9) 
30 
97 
(4.1) 
94 
(5.0) 
89 
(13.5) 
60 
97 
(2.1) 
92 
(5.8) 
85 
(12.2) 
90 
95 
(2.5) 
88 
(5.4) 
82 
(8.3) 
180 
93 
(4.3) 
89 
(5.2) 
79 
(2.4) 
365 
92 
(3.7) 
87 
(8.8) 
77 
(1.9) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %).( Concentration 
threshold=84). 
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6.4.2.5 Lorazepam  
In the freezer and refrigerator lorazepam was found to be stable in DBS for 1 
year (p > 0.05) and no significant loss of the drug concentration was noted during 
the observation period. The drug remaining after 1 year was 97% and 88% of the 
starting amount in the freezer and refrigerator respectively. At room 
temperature a significant decrease of 16% was observed after 1 year of storage 
(p < 0.05) and the quantity recovered was 84% of its initial concentration. 
Stability data are given in Table 6-10.  
 
Table  6-10: Stability of lorazepam in dried blood spots stored in filter paper 
Storage condition  
Time 
(day) Freezer 
(-20 °C) 
(ng/spot) 
Refrigerator 
(4 °C) 
 (ng/spot) 
Room temperature 
 (ng/spot) 
Day zero# 
101 
(8.0) 
101 
(8.0) 
101 
(8.0) 
2 
101 
(2.4) 
99 
(5.1) 
97 
(1.8) 
4 
99 
(0.1) 
99 
(0.7) 
98 
(3.0) 
7 
100 
(1.4) 
99 
(1.5) 
98 
(1.7) 
14 
99 
(0.7) 
95 
(2.8) 
93 
(3.9) 
30 
98 
(5.8) 
94 
(3.2) 
90 
(2.0) 
60 
99 
(1.9) 
97 
(6.3) 
93 
(3.1) 
90 
103 
(10.1) 
101 
(2.1) 
98 
(1.2) 
180 
98 
(8.4) 
92 
(6.1) 
90 
(9.7) 
365 
97 
(4.5) 
88 
(4.9) 
84 
(1.6) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). (Concentration 
threshold=85). 
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6.4.2.6 Nitrazepam  
Nitrazepam was also found to be stable in the freezer and refrigerator, and no 
significant decrease was observed in the concentration over a 1 year period (p > 
0.05). The amounts of nitrazepam detected after 1 year were 93% and 84% from 
DBS stored in freezer and refrigerator respectively. However nitrazepam stored 
at room temperature showed a significant 18% decrease in concentration after 2 
months (p < 0.05) while 74% was recovered from DBS after 1 year of storage at 
room temperature. Stability data are shown in Table 6-11. 
 
Table  6-11: Stability of nitrazepam in dried blood spots stored in filter paper 
Storage condition  
Time 
(day) Freezer 
(-20 °C) 
(ng/spot) 
Refrigerator 
(4 °C) 
 (ng/spot) 
Room temperature 
 (ng/spot) 
Day zero# 
102 
(9.0) 
102 
(9.0) 
102 
(9.0) 
2 
102 
(0.4) 
101 
(2.7) 
101 
(10.2) 
4 
100 
(0.5) 
99 
(3.1) 
97 
(2.8) 
7 
100 
(1.7) 
97 
(5.3) 
96 
(4.5) 
14 
98 
(3.3) 
96 
(3.4) 
91 
(2.3) 
30 
98 
(1.6) 
96 
(6.1) 
85 
(3.4) 
60 
97 
(1.9) 
94 
(1.8) 
84 
(3.9) 
90 
96 
(2.8) 
92 
(3.2) 
81 
(1.7) 
180 
95 
(12.0) 
89 
(10.1) 
78 
(11.6) 
365 
95 
(4.6) 
86 
(3.8) 
74 
(8.2) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). (Concentration 
threshold=84). 
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6.4.2.7 Diazepam  
Diazepam was found to be very stable in both freezer and refrigerator, with no 
significant change in the concentration being observed (p > 0.05). Approximately 
95% and 87% of drug was recovered from DBS samples after 1 year period of 
storage in freezer and refrigerator respectively. At room temperature a 
significant decrease in concentration was observed at the end of study which 
was approximately 20 % of the initial concentration (p < 0.05). After 1 year of 
storage at room temperature 80% of diazepam could be detected in DBS samples. 
Stability data are given in Table 6-12. 
 
Table  6-12: Stability of diazepam in dried blood spots stored in filter paper 
Storage condition  
Time 
(day) Freezer 
(-20 °C) 
(ng/spot) 
Refrigerator 
(4 °C) 
 (ng/spot) 
Room temperature 
 (ng/spot) 
Day zero# 
100 
(7.0) 
100 
(7.0) 
100 
(7.0) 
2 
100 
(0.9) 
98 
(1.2) 
98 
(6.5) 
4 
99 
(2.4) 
98 
(0.9) 
96 
(5.1) 
7 
99 
(0.8) 
98 
(1.3) 
96 
(4.7) 
14 
98 
(3.7) 
98 
(3.9) 
96 
(2.8) 
30 
98 
(4.6) 
96 
(6.9) 
88 
(1.1) 
60 
99 
(8.2) 
97 
(3.8) 
90 
(3.7) 
90 
96 
(2.1) 
94 
(4.0) 
89 
(5.5) 
180 
98 
(1.3) 
93 
(9.5) 
86 
(7.2) 
365 
95 
(4.4) 
87 
(12.2) 
80 
(2.3) 
# Day zero concentration is mean of 10 measurements (RSD %). All other days 
concentration is average of two replicate measurements (RSD %). (Concentration 
threshold=85). 
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6.4.2.8 Summary of stability of cocaine and benzodiazepines in dried blood 
spot (DBS) for 1 year under different storage temperatures 
The stability of cocaine and benzodiazepines in DBS for 1 year under different 
storage conditions is summarized in Table 6-13. 
Table  6-13: Summary of the stability of cocaine and benzodiazepines in DBS stored under 
different storage conditions for 1 year 
Drug 
Storage 
conditions 
Results Comment 
-20 ºC, 1 year 40% decrease 
4 ºC, 1 year 64% decrease Cocaine 
25 ºC, 1 year 86% decrease 
-20 ºC, 1 year 
4 ºC, 1 year 
Stable  
Flunitrazepam 
25 ºC, 1 year 24% decrease 
-20 ºC, 1 year 
4 ºC, 1 year 
Stable  
Temazepam 
25 ºC, 1 year 18% decrease 
-20 ºC, 1 year 
4 ºC, 1 year 
Stable  
Oxazepam 
25 ºC, 1 year 25% decrease 
-20 ºC, 1 year 
4 ºC, 1 year 
Stable  
Lorazepam 
25 ºC, 1 year 16% decrease 
-20 ºC, 1 year 
4 ºC, 1 year 
Stable  
Nitrazepam 
25 ºC, 1 year 27% decrease 
-20 ºC, 1 year 
4 ºC, 1 year 
Stable  
Diazepam 
25 ºC, 1 year 20% decrease 
• All drugs can be 
detected after 1 
year regardless of 
storage 
temperature  
• As temperature 
increased, stability 
decreased 
• Benzodiazepines 
more stable than 
cocaine  
• More than 15% of 
cocaine and 74% 
benzodiazepines 
can be recovered 
after 1 year 
regardless of the 
storage 
temperature 
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6.5 Discussion  
As mentioned previously, dried blood spots stored on paper, such as the Guthrie 
card, have been used since 1960 for therapeutic drug monitoring, diagnostic 
screening and to reduce drug decomposition.157,91-97,158-172 The residual drug 
amounts in DBS for a 1-year period for the present study are shown in Figure 6-4, 
which compare favourably with stabilities in liquid aliquot samples. 
The stability of benzodiazepines under different storage conditions has been 
studied and published reports indicate that they are of low stability when stored 
at ambient temperature or higher. Most benzodiazepines other than 
triazolobenzodiazepines contain an amide group, which facilitates hydrolysis 
reactions to produce aminobenzophenone derivatives, whereas the presence of a 
triazolo ring in the structure makes the compounds more resistant to hydrolysis. 
Hydrolysis is a chemical reaction that uses water to split an amide or ester 
bond.173 In the benzodiazepine stability study described in Chapter 4, oxazepam 
in liquid aliquot samples was found to be stable in the freezer for 1 year and six 
months at low and high concentration respectively whereas in DBS it was very 
stable for one year. In the refrigerator it was stable for 1 year and 2 month at 
low and high concentration respectively while in DBS it was stable for 1 year 
without any significant loss and the drug remaining in DBS was more than in low 
and high concentration aliquot samples. After one year of storage at room 
temperature oxazepam completely disappeared from liquid samples while 
approximately 75% was recovered from DBS. 
 
 Lorazepam aliquot samples containing low and high concentrations of the drug 
were stable for 1 year and 6 months respectively when stored in freezer and for 
3 months and 2 months in the refrigerator while in DBS it was stable for 1 year 
without any significant loss observed. At room temperature lorazepam 
degradation is slower than in liquid samples. After 1 year lorazepam had 
completely disappeared from liquid samples. However, more than 84% of 
lorazepam was recovered from DBS samples stored at room temperature. These 
results prove the value and advantages of filter paper in preserving 
benzodiazepines, which was superior than the usual preservatives for liquid 
samples, which showed little effect on stability, as described in Chapter 4 and 
shown in table 6-14. Previous studies of diazepam and temazepam found that 
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these drugs are not stable when stored at 4 °C and 25 °C. However, DBS showed 
enhanced stability of these drugs at the same storage temperatures. 
Nitrobenzodiazepine compounds such as flunitrazepam and nitrazepam showed 
poor stability in liquid samples as a result of reduction and hydrolysis 
degradation reactions whereas in DBS reasonable amounts of the compounds 
were detected after 1 year even when stored at room temperature.46 
 
Cocaine is a widely abused CNS stimulant frequently detected in forensic cases. 
Cocaine is known to be unstable in blood samples and is rapidly degraded by 
enzymatic and chemical hydrolysis. The addition of a preservative with 
cholinesterase inhibitor activity can decrease enzymatic hydrolysis but does not 
stop chemical degradation from proceeding. Breakdown of cocaine in biological 
samples is attributed to the presence of the ester linkages in the structure. In 
the refrigerator, cocaine disappeared completely after 1 year of storage in tubes 
containing sodium fluoride and potassium oxalate. Acidification of the sample by 
substituting potassium oxalate with oxalic acid enhanced the stability by 24%. 
Further addition of cholinesterase inhibitor to the sample improved the stability 
by 40%. However, in the current study the loss of cocaine at the same storage 
temperature was reduced to approximately 60% of the initial concentration 
similar to effect of the addition of 10 mg echothiophate, a known cholinesterase 
inhibitor, to the sample. Addition of EDTA, heparin and sodium fluoride to 
samples containing cocaine showed no improvement.62 In this study more than 
77% of cocaine was recovered from DBS after one month of storage at three 
storage temperatures, which is in agreement with the results reported by Skopp 
et al.93 who found that more than 75% could be detected after 17 days of storage 
in filter paper. In DBS cocaine can be detected after 1 year of storage at all 
three storage temperatures. 
 
The low stability of cocaine compared to benzodiazepines is because it has two 
ester groups in its structure, making the compound more susceptible to 
degradation by hydrolysis. Also, compounds containing an ester are more readily 
decomposed by hydrolysis compared to those containing an amide group, 
because oxygen is more electronegative than nitrogen, which accelerates the 
hydrolysis of the compound.  
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Dehydration of the samples on the filter paper minimized the hydrolysis of drugs 
which are liable to this type of degradation and so the stability of the drugs in 
DBS was enhanced compared to liquid blood samples. DBS technique can be used 
to quantify the drugs from blood spot even if the volume of blood is unknown. 
The influence of storage temperature on the stability of drugs in DBS, as shown 
in Figure 6-4, was much less than when the drugs are stored in whole blood 
specimens. 
 
 
Figure  6-4: Stability of benzodiazepines and cocaine in DBS for one year. Initial 
concentrations were 100 ng/spot. 
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Table  6-14: Comparison of stability of lorazepam and oxazepam in liquid blood and DBS for 
1 year under different storage temperatures 
Results 
Drug 
Storage 
conditions 
Liquid blood 
sample  
DBS 
-20 ºC, 1 year 5% decrease at HC Stable  
4 ºC, 1 year 
50% and 28% 
decrease at LC and 
HC, respectively  
Stable  Lorazepam 
25 ºC, 1 year 
100% decrease after 
6 months and 100% 
decrease at HC 
after 1 year 
16% decrease 
-20 ºC, 1 year 19% decrease at HC Stable  
4 ºC, 1 year 
31% and 26% 
decrease at LC and 
HC, respectively  
Stable  
Oxazepam 
25 ºC, 1 year 
100% decrease at LC 
after 6 months and 
100% decrease at HC 
after 1 year 
25% decrease 
LC: Low concentration, HC: High concentration. 
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6.6 Conclusion  
A validated method has been developed which can be used for the quantitative 
analysis of drugs in small volumes of blood contained in dry blood spots. The DBS 
technique provides a suitable procedure for the storage and analysis of samples 
in forensic toxicology because they are easy to handle, transport and to store in 
the laboratory, even in the absence of refrigeration, which can be a problem in 
some countries.  It permits the analysis of a small volume of sample and as a 
result frequent collection of blood samples from donors is possible. In addition, 
the test analytes chosen for this study were drugs which are known to be rapidly 
degraded in biological samples and these were preserved when stored on paper, 
instead of adding the usual preservatives and anticoagulants. For some drugs the 
addition of preservatives is not recommended as they may accelerate the 
degradation of these drugs, for example organophosphorus pesticides, while 
anticoagulants are not recommended for other drugs as they can increase their 
concentrations, for example morphine. The DBS technique is therefore 
recommended as an additional procedure to be used in conjunction with 
conventional methods for preserving unstable drugs from decomposition and for 
avoiding potential errors in interpretation of analytical results resulting from the 
addition or absence of preservatives and anticoagulants.  
 
The water present in blood samples plays a very important role in hydrolysis 
reactions as an active reagent which cleaves drug molecules. The use of filter 
paper to store samples resulted in enhancement of drug stability due to the 
dehydration of the sample on the paper and consequent minimalisation of 
enzymatic and chemical hydrolysis of the drugs. 
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7 Correction for Loss of Benzodiazepines During 
Storage 
7.1 Introduction: degradation of drugs 
Degradation refers to the chemical breakdown of a parent compound or starting 
material to produce new molecules. Chemical degradation is different from 
metabolism, which takes place during life, but may take place at the same time 
as metabolism. Equally, post-mortem changes can also be caused if samples are 
contaminated by microbiological oragnisms. Chemical degradation of drugs in a 
sample may occur as a result of three main types of reaction: reduction, 
oxidation, and hydrolysis. Since benzodiazepines contain an amide group in their 
structures, it is susceptible to decomposition through a hydrolysis reaction, 
which is considered to be the most common degradation process in this group. 
Degradation of benzodiazepines in aqueous media yields benzophenone 
derivatives and glycine. Many authors have studied the degradation of selected 
compounds.  
For benzodiazepines, Nudelman and Waisbaun174,175 studied the acidic 
degradation of diazepam in an aqueous methanol solution, which produced new 
products through hydrolytic cleavage of the benzodiazepinone ring, such as 2-
methylamine-5-chlorobenzophenone and glycine. Furthermore, they also studied 
the kinetics of the reaction of 2-amino-5-chlorobenzophenone with hydrochloric 
acid in aqueous methanol and found that different products were obtained at 
different acid concentrations. 
Cabrera et al.176 investigated the mechanisms of alprazolam and diazepam 
hydrolysis. They found that diazepam is highly sensitive to hydrolysis and that 
the ring can be opened by cleavage of the amide C-N bond. In contrast, 
alprazolam showed high stability against acid and base hydrolysis. This stability 
of alprazolam was attributed to the triazole ring, which seems to inhibit the 
opening of the ring by hydrolysis. 
Identification of degradation products has been reported in previous studies. For 
example, diazepam and temazepam produce 2-methylamino-5-
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chlorobenzophenone (MACB), while chlordiazepoxide and oxazepam produce 2-
amino-5-chlorobenzophenone (ACB). The nitrazepam hydrolysis product is 2-
amino-5-nitobenzophenone (ANB), while hydrolysis of prazepam will produce N-
cyclopropylmethyl-2-amino-5-chlorobenzophenone (CMCB). Flunitrazepam 
degradation produces 2'-fluoro-2-methylamino-5-nitobenzophenone (MNFB), 
while bromazepam and lorazepam degradation produce (2-amino-5-
bromophenyl)(2-pyridyl) methanone (ABP) and 2-amino-2',5-
dichlorobenzophenone (ADB), respectively.177,188  
 
Breton et al.189 have reported instability of avizafone (pro-drug of diazepam), 
which degraded into unexpected new compounds―in particular diazepam, 
carbostyril, MACB, and ACB. These benzodiazepine degradation products were 
identified by chemical ionisation mass spectrometry.  
 
Cocaine is known to be rapidly degraded enzymatically and chemically by 
hydrolysis reactions. Detection of degradation product in biological samples has 
been reported previously by Skop et al.85, who reported a new method to 
quantify cocaine and its degradation products, BE, EME, and ecgoine. Ecgonine 
was found to be the final degradation product of cocaine and its metabolites. 
 
Sulphonamides are antimicrobial agents used in agriculture, animal husbandry, 
and human medicine to treat many kinds of infection by bacteria and other 
microorganisms. Sulfamethoxazole is one of the most common sulphonamides. 
Sulfamethoxazole and its degradation product N4-acetylsulfamethoxazole were 
detected in effluent samples collected from wastewater treatment plants 
(WWTPs) and in final effluent samples from five different WWTPs in the UK. 
Chloramine-T (N-sodium-N-chloro-p-toluenesulfonamide) used in drug treatment 
of different diseases of swine and poultry was found to degrade into p-
toluenesulfonamide and o-toluenesulfonamide in wastewater and these were 
detected in WWTPs and in groundwater below a former sewage farm.190  
 
The natural (17β-estradiol, E2) and synthetic (17α-ethinylestradiol, EE2) 
estrogens are among the most potent endocrine-disrupting chemicals found in 
the environment. The biological treatment of these compounds in WWTPs in 
order to reduce estrogenicity of the effluent prior to discharge into the 
environment is very important. Different methods were used in the treatment, 
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which produced different degradation products, and was observed in different 
WWTPs that used different treatments to remove estrogen. Identification of 
these products was reported; however, knowledge about their estrogenicity is 
very important in order to optimize the method that can remove estroginicity 
efficiently before discharging it to the environment.191  
 
Therefore, it is important both in therapeutics and in toxicology to detect the 
degradation products of drugs and other compounds. In forensic toxicology, it is 
important to detect the decomposition products as markers of drugs and poisons 
especially unstable substances, which can indicate the earlier presence of the 
drugs in cases in which samples were not properly stored or else were collected 
a long time after death.  
 
The aims of this study were to identify the degradation products of some 
benzodiazepine drugs and to develop a system for correcting for loss of 
benzodiazepines during storage by analysing their degradation products in blood 
and urine using SPE and LC-MS/MS. An additional aim was to assess the 
degradation of benzodiazepines when stored under unfavourable conditions for 1 
month. Initially, a method for the analysis of benzodiazepines and their 
degradation products in blood and urine needed to be developed and optimised 
prior to full validation of the method. 
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7.2 Experimental Section 
7.2.1 Chemicals and Materials 
Diazepam, temazepam, oxazepam, and chlordiazepoxide and their corresponding 
deuterated internal standards (diazepam-d5, temazepam-d5, and oxazepam-d5) 
were purchased from LGC-Promochem (Middlesex, UK) as 100 µg/ml solutions in 
methanol. Aminobenzophenone (AB), 2-amino-5-chloro aminobenzophenone 
(ACB), 2-methylamino-5-chloro aminobenzophenone (MACB) ammonium formate, 
ammonium acetate, and β-glucuronidase crude solution were obtained from 
Sigma-Aldrich (Dorset, UK). Stock solutions of standards and internal standards 
were stored at -20 ºC. Acetonitrile, methanol, cyclohexane, ethyl acetate, 
ammonium hydroxide, formic acid, isopropanol, dichloromethane, and potassium 
dihydrogen phosphate were obtained from BDH (Poole, UK). Clean Screen 
ZSDAU020 cartridges were purchased from United Chemical Technology UK.  
 
 
7.2.1  Solutions 
7.2.1.1 Preparation of 0.1 M Phosphate Buffer pH 6.0 
1 litre of solution was prepared by dissolving 1.7 g of anhydrous disodium 
orthophosphate and 12.14 g of sodium dihydrogen orthophosphate monohydrate 
in 800 ml of deionised water. The pH was adjusted to 6 with 1 M potassium 
hydroxide and the solution made up to volume with deionised water. 
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7.2.1.2 Preparation of 0.1 M Acetate Buffer pH 4.5 
2.93 g of sodium acetate trihydrate was weighed into 400 ml of deionised water 
in a 500 ml volumetric flask, and then 1.62 ml of glacial acetic acid was added 
to the mixture. The pH was adjusted to 4.5 with 0.1 M acetic acid. The solution 
was made up to volume with deionised water. 
7.2.1.3 Preparation of 3mM Ammonium Formate and 0.001%, 0.002%, 0.004% 
and 0.01% Formic Acid Solution 
These mobile phases were prepared by dissolving 0.189 g of ammonium formate 
in 5 x 1 L volumetric flasks filled with 800 ml deionized water followed by the 
addition of 10, 20, 40, or 100 µl of concentrated formic acid respectively and 
making up to one litre with deionized water. 
 
7.2.1.4 Preparation of 5mM Ammonium Acetate  
38.54 g of ammonium acetate was weighed out into a 500 ml volumetric flask 
and made up to volume with deionised water to prepare 1 M solution of 
ammonium acetate. 5 ml of this solution was added to a 1 litre volumetric flask 
and 800 ml of deionised water was added. Ammonia was used to adjust the pH to 
4.7 and made up to volume with deionised water, resulting in 5mM of solution. 
7.2.1.5 Standard Solutions of Analytes 
Working standards of unlabelled and labelled drugs were prepared by diluting 
250 µl from each drug stock solution in 25ml methanol to obtain a concentration 
of 1 µg/ml. Stock solutions of standards and internal standards were stored in a 
freezer at -20 ºC.  
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7.3 Optimisation of Analytical Method for Diazepam, 
Temazepam, and MACB  
7.3.1 Optimization of Mobile Phase 
7.3.1.1 Optimum tuning parameters for diazepam, temazepam and MACB 
In order to obtain good mass spectrometry conditions, solutions of standards 1 
µg/ml were introduced into the mass spectrometry interface using a syringe 
pump at 5 µl/minutes.  The capillary temperature, sheath and auxiliary gas flow 
rates and collision energy were optimized for each analyte. The compounds were 
analysed with MS parameters slected in table 7-1. Inernal standard data was 
aquired in selected ion monitoring (SIM) mode and analytes were identified on 
the basis of their full MS-MS spectra. Two product ions were monitored. The 
underlined ions in Table 7-1 were used as the quantification ions because they 
were the most intense ions produced. 
 Table  7-1: Optimum tuning parameters for diazepam, temazepam and MACB. 
Drug 
Precursor ion 
(m/z) 
Monitored ions* 
(m/z) 
Collision energy 
(ev) 
Diazepam  285 257, 222 40 
Temazepam  301 283, 255 28 
MACB 246 228, 168 28 
Internal standards 
Diazepam-d5 300 300 Not used 
Temazepam-d5 306 306 Not used 
• Underlined ion was used as the quantification ion. For internal standards, 
only the pseudomolecular ions were monitored and no collision energies 
were specified. 
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7.3.1.2 Comparison of 5mM Ammonium Acetate and 3mM Ammonium 
Formate Mobile Phases 
In a previous study, Breton et al. used 5mM ammonium acetate and 
trifluroacetic acid as the mobile phase to analyse avizafone and its degradation 
products including diazepam and MACB; diazepam was well detected while MACB 
showed poor detection .189 3mm ammonium formate was used as the mobile 
phase for analysing benzodiazepines in many published papers.120,125 Therefore, 
this experiment was devised to investigate the ionization of these compounds in 
LC-MS/MS by comparing 5 mM ammonium acetate and 3mm ammonium formtate 
as mobile phases. An unextracted standard was used, composed of 100 µl of 
working solution and 100 µl of internal standard mixture, which was evaporated 
under a stream of nitrogen and reconstituted in 200 µl of mobile phase: 20 µl 
was injected 5 times. An average peak area was calculated for each analyte 
under each condition. The results are shown in Table 7-2. 
Table  7-2: Comparison of effect of 5mM ammonium acetate and 3mM ammonium formate on 
analyte response. 
Average peak area 
Compound 5mM ammonium acetate 3mM ammonium formate  
Diazepam 81,436,949 504,035,879 
Diazepam-d5 147,335,965 2,616,514,447 
Temazepam 111,024,296 848,728,838 
Temazepam-d5 156,902,245 2,779,937,122 
MACB 3,352,629 24,533,361 
 
It is clear from the results demonstrated in Table 7-2 that 3mM ammonium 
formate gives a high response for diazepam, temazepam, MACB and internal 
standards compared to 5mM ammonium acetate; thus, it was used as the mobile 
phase in this study. Further investigation using different concentrations of 
formic acid in addition to 3mM ammonium formate may improve the response of 
the analytes.  
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7.3.1.3 Comparison between 0.001%, 0.002%, 0.004% and 0.01% of Formic 
Acid in 3mM Ammonium Formate Solution 
Formic acid was added routinely to the mobile phase at different 
concentrations, especially if the analyte was basic; therefore, this experiment 
was carried out to investigate whether increasing the formic acid concentration 
could increase the response for these analytes and to identify the best 
concentration to give maximum sensitivity for analysis of the analytes. Four 
mobile phases were prepared containing different concentrations of formic acid. 
0.001%, 0.002%, 0.004%, and 0.01% in 3mM ammonium formate solution. An 
unextracted standard was used, composed of 100 µl of working solution, and 100 
µl of internal standard mixture were blown down under nitrogen. Then it was 
reconstituted in 200 µl of mobile phase, and 20 µl was injected 5 times. An 
average peak area was calculated for each analyte under each condition as 
shown in Table 7-3. A previous study reported that an increase in the response of 
the analyte was obtained after the addition of formic acid to the mobile phase; 
however, adding high concentrations of formic acid resulted in a decrease in the 
response. Therefore, the concentrations investigated in this experiment ranged 
from 0.001% to 0.01% of formic acid.  
Table  7-3: Effect of formic acid on analyte response  
Average peak area 
3mM ammonium formate Compound 
0.001% F.A 0.002% F.A 0.004% F.A 0.01% F.A 
Diazepam 
590,778,121 698,968,355 819,240,270 767,030,169 
Diazepam-d5 2,761,448,341 2,804,888,014 2,887,214,387 2,788,373,228 
Temazepam 
1,164,515,006 1,390,582,615 1,408,164,021 1,429,463,318 
Temazepam-d5 3,018,607,830 3,152,031,037 3,339,199,932 3,304,103,181 
MACB 
66,000,325 94,113,152 147,862,546 120,441,274 
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As shown in Table 7-3, the addition of 0.004% formic acid to 3mM ammonium 
formate solution gave a higher response for MACB, diazepam, and dueterated 
standards while 0.01% of formic acid was better for temazepam only. However, 
its response with 0.004% of formic acid was still good and better than a low 
concentration of formic acid. Therefore, a mobile phase containing 3mM 
ammonium formate and 0.004% as buffer was used to analyse these compounds 
by LC-MS/MS. 
7.3.2 Optimisation of Extraction Method 
The extraction method used to extract benzodiazepines described in Chapter 4 
and as summarized in Table 7-4 was used here to extract diazepam and 
temazepam and their degradation product MACB from blood.125  
Table  7-4: SPE method for extraction of benzodiazepines from blood 
 
Step Solvent 
Conditioning 3ml methanol, 3ml DI water, 2ml phosphate buffer pH 6 
Washing 
2ml DI water, 2ml phosphate buffer pH6/acetonitrile 
(80:20  v/v), 2ml cyclohexane then dry for 5 minutes, 2ml 
DI water then dry for 5 minutes 
Elution 3ml ethyl acetate/NH4OH (98:2) 
 
An unextracted standard containing 50 ng of working solution was prepared in 
duplicate. An extract of 50 ng of these compounds from blood was also prepared 
in duplicate. After extraction and before evaopration, 50 ng of internal standard 
mixture was added to the extracted and unextracted standards to assess the 
recovery obtained using this method. The results are shown in Table 7-5. 
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Table  7-5: Average recoveries (%) of diazepam, temazepam, and MACB using SPE 
procedure  
Compound Average Recovery% (n=2) 
Diazepam 
90 
Temazepam 
88 
MACB 
16 
 
As shown in Table 7-5, this method showed good recovery for diazepam and 
temazepam, but MACB recovery was not acceptable. It may be that the 
compound was lost during the washing step, was not attracted to the sorbent, or 
did not elute efficiently from the sorbent; thus, a series of studies were 
undertaken to modify this method in order to enhance the recovery of this 
compound. 
7.3.2.1 Monitoring of Extraction Wash  
The effects of cyclohexane and acetonitrile on the recovery were investigated in 
this method. Cyclohexane was used in the washing step to remove the 
interferences from the cartridge; instead of discarding the cyclohexane solvent, 
50 ng of standard was extracted and the cyclohexane was collected and analysed 
to determine whether analyte was lost in this step. The chromatogram in Figure 
7-1 shows that MACB was eluted by cyclohexane, whereas there was no elution 
of diazepam and temazepam.  
Recoveries without cyclohexane and without cyclohexane and acetonitrile in the 
washing step were consequently investigated. Extracted and unextracted 50 ng 
standards of these compounds were prepared in duplicate. Before blow down, 50 
ng of internal standard mixture were added to the samples before analysis. 
 
 152 
Table  7-6: Average recoveries (%) of diazepam, temazepam, and MACB after modifying 
washing step  
Recovery % (n=2) 
Compound 
No cyclohexane  
No cyclohexane and 
acetonitrile 
Diazepam 96 91 
Temazepam 81 83 
MACB 36 47 
 
It is clear from Table 7-6 that after excluding cyclohexane and acetonitrile 
solvents from the washing step, the recovery of MACB increased with little effect 
on the diazepam and temazepam recoveries, so these solvents were excluded in 
the following experiments. 
 
 153 
RT: 8.00 - 20.00 SM: 5G
8 10 12 14 16 18 20
Time (min)
0
10
20
30
40
50
60
70
80
90
100
R
el
a
tiv
e
 
Ab
u
n
da
n
ce
0
10
20
30
40
50
60
70
80
90
100
Re
la
tiv
e 
Ab
u
n
da
n
ce
0
10
20
30
40
50
60
70
80
90
100
Re
la
tiv
e
 
Ab
u
n
da
n
ce
Diazepam 19.31
18.33
17.24
14.8913.7013.39 16.6411.94
10.75
9.588.41
Temazepam9.01
19.23
13.30
18.0516.9512.06 13.7211.30
14.91
15.80
MACB
RT: 16.01
AA: 47774751
NL: 9.81E5
m/z= 256.5-257.5 F: 
+ c ESI Full ms2 
285.00@40.00 [ 
150.00-300.00]  MS  
ICIS TEST31
NL: 5.39E5
m/z= 282.5-283.5 F: 
+ c ESI Full ms2 
301.00@28.00 [ 
200.00-350.00]  MS 
TEST31
NL: 3.18E6
m/z= 227.5-228.5 F: 
+ c ESI Full ms2 
246.00@35.00 [ 
200.00-300.00]  MS  
ICIS TEST31
 
Figure  7-1: Analysis of cyclohexane wash by LC-MS/MS 
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7.3.2.2 Comparison of pH 6 and 4.5 as a Buffer 
The use of a pH lower than pH 6 was also investigated to examine which buffer 
pH could provide high recovery. An standard mixture containing 50 ng of all 
analytes in blood was extracted in duplicate. Unextracted 50 ng standards of 
these compounds were also prepared in duplicate. Before evaporation under a 
stream of nitrogen, 50 ng of internal standard mixture was added to all prepared 
samples, extracted and unextracted. The results are shown in Table 7-7 below.  
Table  7-7 : Average recoveries (%) of diazepam, temazepam, and MACB using buffers of 
different pH.  
Average Recovery % (n=2) 
Compound 
pH 6 pH 4.5 
Diazepam 
92 94 
Temazepam 
87 90 
MACB 
45 59 
 
Using the lower pH showed an improvement in the recoveries of all compounds. 
This may be explained because, as the pH of the buffer decreased, the 
ionization of the analytes increased, leading to enhanced ionic interactions 
between the analytes and the SPE sorbent. It was decided to use an acetate 
buffer with pH 4.5 in the subsequent experiment. 
7.3.2.3 Comparison of Elution Solvents 
Selection of elution solvent may have an influence on the recovery of analyte. 
Sometimes a change from one elution solvent to another shows an enhancement; 
Ethyl acetate-Ammonium hydroxide ETAc-NH4OH (98:2 v/v) and Methylene 
chloride-Isopropanol-Ammonium hydroxide CH2Cl2-IPA-NH4OH (78:20:2 v/v/v) 
were compared in this experiment to investigate which solvent gave the best 
recoveries. Unextracted and extracted standards containing 50 ng of these 
compounds were prepared in duplicate. Before evaporation under a stream of 
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nitrogen, 50 ng of internal standard was added to all samples, and the samples 
were analysed by LC-MS/MS.  The results are shown below in Table 7-8. 
Table  7-8: Average recoveries (%) of diazepam, temazepam, and MACB using different 
elution solvents 
Mean Recovery % (n=2) 
Compound 
CH2Cl2-IPA-NH4OH 
(78:20:2 v/v/v) 
ETAc-NH4OH (98:2 v/v) 
Diazepam 
103 95 
Temazepam 
107 92 
MACB 
84 62 
 
Diazepam and temazepam recoveries remained relatively unaffected or slightly 
higher, while MACB showed improvement in the recovery when CH2Cl2-IPA-NH4OH 
(78:20:2 v/v/v) was used as elution solvent compared to ETAc-NH4OH (98:2 v/v). 
The energy of elution and the pH (12) of both elution solvents are the same; 
however, the difference in the recovery of MACB may be attributed to solubility 
differences of MACB in these elution solvents. Therefore, it was decided to use 
CH2Cl2-IPA-NH4OH (78:20:2 v/v/v) to elute the compounds in SPE. The final 
procedures for the SPE method are listed in Table 7-15.  
7.3.3 Validation of Analytical Method 
The validation parameters applied in this study were similar to the parameters in 
Table 4-1 except that the low concentration in this method was 10 ng/ml. The 
results are shown in tables 7.9-7.14.  
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7.4 Validation Results  
7.4.1 Validation Results in Blood 
7.4.1.1 Linearity  
The relationships between analyte concentrations and peak area ratios were 
linear over the range 5-200 ng/ml, and the linear correlation coefficients (r2) 
were better than 0.99 for all analytes as shown in Table 7-9. 
7.4.1.2 LOD and LLOQ 
LOD values for all analytes were 0.10-2.30 ng/ml, and LLOQ values were 0.40-
7.50 ng/ml. The results are shown in Table 7-9. 
Table  7-9: Linearcorrelation coefficients, LODs, and LLOQs of drugs in blood 
Analyte 
Linear correlation 
coefficients (r2) 
LOD 
(ng/ml) 
LLOQ 
(ng/ml) 
Diazepam 0.999 0.20 0.70 
Temazepam 0.994 0.10 0.40 
MACB 0.998 2.00 6.80 
Chlordiazepoxide 0.998 0.50 1.70 
Oxazepam 0.999 0.46 1.50 
ACB 0.992 2.30 7.50 
AB 0.993 2.10 6.95 
 
7.4.1.3 Recoveries  
The recoveries for all analytes were in the range 70-102% as shown in Table 7-
10. 
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Table  7-10: Recoveries of analytes from blood 
Mean Recovery, % 
(RSD%, n=5) Analyte 
10ng/ml 50ng/ml 100ng/ml 
Diazepam 102 (18) 101 (9) 94 (8) 
Temazepam 84 (19) 90 (5) 93 (1) 
MACB 86 (14) 90 (9) 96 (8) 
Chlordiazepoxide 93 (10) 91 (7) 95 (5) 
Oxazepam 92 (18) 97 (13) 94 (9) 
ACB 83 (8) 84 (16) 92 (11) 
AB 70 (13) 82 (11) 84 (6) 
 
7.4.1.4 Intraday and Interday Precision  
The method showed good precision, and the relative standard deviations (RSD %) 
for the intraday and interday precision were in the range of 1-18 and 2-18% 
respectively, which are considered to be acceptable. The results are shown in 
Table 7-11. 
 7-11: Interday and intraday precision results in blood 
Interday mean (RSD%, n=5) Intraday mean (RSD%, n=5) 
Analyte 
10ng/ml 50ng/ml 100ng/ml 10ng/ml 50ng/ml 100ng/ml 
Diazepam 
11 
(17) 
54 
(5) 
100 
(6) 
8 
(10) 
55 
(6) 
111 
(6) 
Temazepam 
11 
(15) 
53 
(5) 
104 
(4) 
11 
(4) 
51 
(6) 
93 
(5) 
MACB 
9.6 
(18) 
48 
(7) 
99 
(8) 
8 
(18) 
46 
(17) 
93 
(14) 
Chlordiazepoxide 
9 
(16) 
52 
(9) 
103 
(2) 
9.8 
(5) 
50 
(4) 
102 
(2) 
Oxazepam 
13 
(17) 
46 
(3) 
101 
(2) 
9 
(13) 
49 
(4) 
99 
(3) 
ACB 
12 
(18) 
49 
(6) 
100 
(5) 
12 
(5) 
50 
(4) 
101 
(1) 
AB 
12 
(18) 
53 
(8) 
97 
(10) 
13 
(5) 
51 
(6) 
97 
(3) 
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7.4.2 Validation Results in Urine 
7.4.2.1 Linearity  
The relationships between analyte concentrations and peak area ratios were 
linear over the range 5-200 ng/ml, and the linear correlation coefficients (r2) 
were better than 0.99 for all analytes as shown in Table 7-12. 
7.4.2.2 LOD and LLOQ 
LOD values for all analytes were 0.20-2.70 ng/ml, and LLOQ values were 0.78-
9.10 ng/ml. The results are shown in Table 7-12. 
Table  7-12: Linearity, LOD and LLOQ of drugs in urine 
Analyte Linearity r2 
LOD 
(ng/ml) 
LLOQ 
(ng/ml) 
Diazepam 0.996 0.20 0.78 
Temazepam 0.998 0.30 1.00 
MACB 0.99 1.35 4.50 
Chlordiazepoxide 0.991 0.49 1.66 
Oxazepam 0.99 0.29 0.99 
ACB 0.994 2.70 9.10 
AB 0.994 1.88 6.25 
 
7.4.2.3 Recoveries  
The recoveries for all analytes were in the range 74-103% as shown in Table 7-
13. 
Table  7-13: Recovery of analytes from urine 
Mean Recovery% 
(RSD%, n=5) Analyte  
10ng/ml 50ng/ml 100ng/ml 
Diazepam 91(15) 103 (6) 96 (8) 
Temazepam 88(7) 89 (12) 103 (10) 
MACB 84 (16) 86 (8) 97 (7) 
Chlordiazepoxide 86 (15) 87(9) 95 (6) 
Oxazepam 94(16) 95 (14) 95 (13) 
ACB 78 (17) 94 (4) 96 (6) 
AB 74(16) 90 (1) 91 (3) 
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7.4.2.4 Intraday and Interday Precision  
The method showed good precision, and the relative standard deviations (RSD %) 
for the intraday and interday precision were in the range of 1-15 and 2-17% 
respectively, which are considered to be acceptable. The results are shown in 
Table 7-14. 
 7-14: Interday and intraday precision results in urine 
Interday mean (RSD%, n=5) Intraday mean (RSD%, n=5) 
Analyte 
10ng/ml 50ng/ml 100ng/ml 10ng/ml 50ng/ml 100ng/ml 
Diazepam 
10 
(10) 
54 
(8) 
97 
(3) 
11 
(5) 
50 
(5) 
99 
(2) 
Temazepam 
9 
(13) 
54 
(7) 
100 
(5) 
10 
(5) 
49 
(6) 
101 
(4) 
MACB 
12 
(15) 
45 
(6) 
100 
(2) 
13 
(14) 
51 
(5) 
101 
(2) 
Chlordiazepoxide 
11 
(14) 
49 
(11) 
91 
(4) 
11 
(6) 
46 
(6) 
104 
(4) 
Oxazepam 
11 
(16) 
44 
(9) 
97 
(5) 
12 
(15) 
47 
(7) 
96 
(2) 
ACB 
10 
(17) 
45 
(16) 
94 
(2) 
13 
(9) 
48 
(10) 
95 
(5) 
AB 
10 
(13) 
53 
(11) 
101 
(10) 
11 
(10) 
52 
(8) 
100 
(1) 
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7.5 Degradation Study: Diazepam and Temazepam 
The aim of this study was to measure the rate of degradation of diazepam and 
temazepam in stored blood and urine samples and the rate of formation of their 
hydrolysis product MACB (2-methylamino-5-chlorobenzophenone). With these 
results an assessment would then be made of a method for correcting for losses 
based on the concentration of MACB.  With this objective in mind, conditions of 
storage were selected in order to result in degradation of the drugs in a short 
timescale. 
7.5.1 Introduction 
7.5.2 Stability Study in Blood and Urine 
Packed red blood cells were obtained from the Scottish National Blood 
Transfusion Service and were suspended in an equal volume of isotonic saline. 
This was used as blank blood. Blank blood (120 ml) was divided into two 60 ml 
portions, A and B, which were spiked with diazepam and temazepam 
respectively to give final concentrations of 1000 ng/ml. Each portion was 
divided into three aliquots of 20 ml and the drugs were subjected to accelerated 
decomposition for one month under three different storage conditions. The first 
condition was at high temperature in the oven at 80 °C, the second was in acidic 
conditions (pH 2) and the third was in alkaline conditions (pH 12). The times 
selected for analysis were at days 1 (day zero), 2, 4, 7, 14, and 30.  
A similar study was carried out using drug-free urine obtained from a healthy 
volunteer. 
7.5.3 Extraction Procedure 
Prior to extraction, 1ml of blood or urine was added to 3.5 ml of acetate buffer 
pH 4.5, and then 100 µl of internal standard mixture was added.  This was vortex 
mixed for 2 minutes then centrifuged for 5 minutes at 2500 rpm. The 
supernatant was loaded onto conditioned CleanScreen® ZSDAU020 cartridges. 
The SPE procedure used is listed in Table 7-15. 
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Table  7-15: SPE extraction procedure 
Step Solvent 
Conditioning 
3ml methanol, 3ml DI water, 2ml 
acetate buffer pH 4.5 
Washing 
2ml DI water, 2ml acetate buffer, 2ml 
DI water 
 
Dry for 5 minutes 
 
Elution 3ml CH2Cl2-IPA-NH4OH (78:20:2 v/v/v) 
 
For urine case samples in section 7.8.2, the same SPE method was used; 
however, before that, 1ml of urine sample was added to a tube containing 2ml 
of acetate buffer pH 4.5, 100 µl of internal standard mixture, and 10 µl of β-
glucuronidase solution, mixed vortex then incubated for 3 hours in an oven at 40 
°C in order to cleave the glucuronic acid moiety from drugs to detect the parent 
compounds.  
7.5.4 Instrumentation 
LC-MS/MS analysis was performed using a Thermo Finnigan LCQ Deca XP (Thermo 
Finnigan, San Jose, CA, USA) equipped with a Surveyor HPLC system. 
Chromatographic separation was achieved using a Gemini™ C18 column (150 mm 
x 2 mm ID, 5µm particle size) fitted with a guard column (4 mm x 2 mm) with 
the same packing material. The mobile phase was a mixture of 3mM ammonium 
formate solution containing 0.004% formic acid and acetonitrile starting at 65:35 
v:v and changing to 10:90 v:v between 13 and 13.5 minutes. It was then held at 
10:90 v:v between 13.5 and 16.5 minutes and then reset to the staring 
composition between 16.5 and 20 minutes. 
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7.5.5 Results of Diazepam and Temazepam Degradation 
7.5.5.1 Diazepam 
Diazepam started to decompose from the first day of incubation in the oven at 
80 °C, while MACB started to be detected after 4 days of degradation. After 1 
month, 30% of the original concentration of diazepam had been lost, whereas 
MACB increased from 17 to 98 ng/ml between day 4 and the end of the study, 
corresponding to 1.7% to 10% of the original amount of diazepam. In urine under 
the same conditions, diazepam degraded faster than in blood and completely 
disappeared after one month, whereas MACB gradually increased after 4 days of 
incubation and still was detected at 192 ng/ml (20% of the original amount of 
diazepam) after one month of observation. 
At pH 2, diazepam decreased gradually, while MACB appeared after one week of 
storage. After 1 month, 25% of the initial concentration of diazepam was lost, 
while MACB reached 91 ng/ml (9% of the original amount of diazepam). For urine 
under the same conditions, diazepam continuously decreased from the first day 
until it was not detected after one month, whereas MACB appeared in day 2 and 
increased to reach 254 ng/ml (27% of the original amount of diazepam) after one 
month. 
Under basic conditions at pH 12, diazepam decomposed in blood more quickly 
than in the other two conditions and lost approximately 50% of its initial 
concentration by day 30, whereas MACB increased from day 2 through day 30 to 
reach 167 ng/ml (17% of the original amount of diazepam). In urine, diazepam 
was not detected after 2 weeks, while MACB was detected on day 2 and 
gradually increased, then decreased after 1 week from 217 ng/ml to 95 ng/ml 
(23% and 10% of the original amount of diazepam, respectively). 
These results are shown graphically in Figures 7-2 to 7-7, which also shows 
graphs of the sum of diazepam and MACB during the 30-day period of the study. 
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Figure  7-2: Degradation of diazepam in blood at 80 °C 
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Figure  7-3: Degradation of diazepam in blood at pH 2 
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Figure  7-4: Degradation of diazepam in blood at pH 12 
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Figure  7-5: Degradation of diazepam in urine at 80 °C 
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Figure  7-6: Degradation of diazepam in urine at pH 2 
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Figure  7-7: Degradation of diazepam in urine at pH 12 
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7.5.5.2 Temazepam 
At 80 °C, the temazepam concentration decreased gradually from day zero until 
it was not detected after 1 month of incubation, while MACB was detected after 
1 day and its concentration increased to 317 ng/ml (32% of the original amount of 
temazepam) after 2 weeks, then dropped to 149 ng/ml (15% of the original 
amount of temazepam) after 1 month. In urine, temazepam decomposed very 
quickly and was not detected after one month of incubation, while MCB 
appeared after 1 day and increased gradually to the highest concentration after 
1 week at 193 ng/ml (21% of the original amount of temazepam), then dropped 
to 29 ng/ml (3.1% of the original amount of temazepam) after 2 weeks and was 
not detected after 1 month. 
In acid conditions at pH 2, temazepam lost more than 75% of its original 
concentration in the blood, while MACB increased gradually from day 2 to day 30 
to reach 272 ng/ml (27% of the original amount of temazepam). In the urine, it 
decomposed much more quickly than in blood and completely disappeared after 
one month, while MACB was detected on day 2 and continued to increase to 154 
ngl/ml (17% of the original amount of temazepam), then dropped to 65 ng/ml 
(7% of the original amount of temazepam) after 2 weeks and disappeared after 1 
month. 
In basic conditions at pH 12, temazepam concentration decreased gradually and 
was not detected after 2 weeks, whereas MACB was detected after 1 day and 
reached its highest concentration at day 4; then it decreased gradually from 191 
ngl/ml to 25 ng/ml after one month (from 19 to 3% of the original amount of 
temazepam). Temazepam in urine decreased more quickly and was not detected 
after 2 weeks, while MACB was detected after 1 day and increased to 274 ng/ml 
(29% of the original amount of temazepam) on day 4, then decreased gradually 
to 22 ngl/ml (2.4% of the original amount of temazepam) after 2 weeks and 
decomposed completely after 1 month. These results are shown graphically in 
Figures 7-8 to 7-13, which also shows graphs of the sum of temazepam and MACB 
during the 30-day period of the study. 
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Figure  7-8: Degradation of temazepam in blood at 80 °C 
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Figure  7-9: Degradation of temazepam in blood at pH 2 
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Figure  7-10: Degradation of temazepam in blood at pH 12 
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Figure  7-11: Degradation of temazepam in urine at 80 °C 
 
DEGRADATION OF TEMAZEPAM AT pH 2
0
200
400
600
800
1000
1200
0 10 20 30 40
TIME (DAY)
TEMAZEPAM
MACB
TEMAZEPAM+MACB
 
Figure  7-12: Degradation of temazepam in urine at pH 2 
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Figure  7-13: Degradation of temazepam in urine at pH 12 
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7.6 Degradation Study: Chlordiazepoxide and Oxazepam 
7.6.1 Introduction 
The aim of this study was to measure the rate of degradation of 
chlordiazepoxide and oxazepam in stored blood and urine samples and the rate 
of formation of their hydrolysis product ACB (2-amino-5-chlorobenzophenone). 
As for diazepam and temazepam, these results would allow an assessment to be 
made of a method for correcting for losses based on the concentration of ACB 
and conditions of storage were selected in order to result in degradation of the 
drugs in a short timescale. 
7.6.2 Stability Study in Blood and Urine 
Packed red blood cells were obtained from the Scottish National Blood 
Transfusion Service and were suspended in an equal volume of isotonic saline. 
This was used as blank blood. Blank blood (120 ml) was divided into two 60 ml 
portions, A and B, which were spiked with chlordiazepoxide and oxazepam 
respectively to give final concentrations of 1000 ng/ml. Each portion was 
divided into three aliquots of 20 ml and the drugs were subjected to accelerated 
decomposition for one month under three different storage conditions. The first 
condition was at high temperature in the oven at 80 °C, the second was in acidic 
conditions (pH 2) and the third was in alkaline conditions (pH 12). The times 
selected for analysis were at days 1 (day zero), 2, 4, 7, 14, and 30.  
A similar study was carried out using drug-free urine obtained from a healthy 
volunteer. 
 
7.6.3 Analytical method 
Extraction and analysis were performed using the method for diazepam and 
temazepam (Section 7.4).  Mass spectrometric conditions are given in Table 7-
16. Internal standard data was aquired in selected ion monitoring (SIM) mode 
and analytes were identified on the basis of their full MS-MS spectra. Two 
 169 
product ions were monitored. The underlined ions in Table 7-16 were used as the 
quantification ions because they were the most intense ions produced. It was not 
financially viable to use chlordiazepoxide-d5 therefore oxazepam-d5 was 
selected for chlordiazepoxide quantitation since its retention time was close to 
that of chlordiazepoxide (5.1 min and 5.95 min, respectively). 
Table  7-16: Optimum tuning parameter for chlordiazepoxide, oxazepam and ACB 
Drug 
Precursor ion 
(m/z) 
Monitored ions* 
(m/z) 
Collision energy 
(ev) 
Chlordiazepoxide  300 283,241 30 
Oxazepam  287 269,241 26 
ACB 232 154, 197 36 
Internal standard 
Oxazepam-d5 292 292 Not used 
• Underlined ion was used as the quantification ion. For internal standards, 
only the pseudomolecular ions were monitored and no collision energies 
were specified. 
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7.6.4 Results of Chlordiazepoxide and Oxazepam Degradation 
Study 
7.6.4.1 Chlordiazepoxide  
In the oven at 80 °C, the chlordiazepoxide concentration steadily decreased to 
reach 38% of its initial concentration at the end of the study. During this time, 
ACB appeared after 2 weeks and increased further by 1 month to 124 ng/ml (12% 
of the original amount of chlordiazepoxide). In urine, chlordiazepoxide 
decreased very quickly and was not detected after one month, while ACB was 
produced after 4 days, the concentration continued to increase until 2 weeks, 
then dropped to 140 ng/ml (13% of the original amount of chlordiazepoxide) by 
the end of the incubation period. 
In the acidified blood sample (pH 2), chlordiazepoxide decreased gradually to 
reach 49% of its original concentration, while the ACB concentration increased 
between day 4 and day 30 from 29 nmol/ml to 97 ng/ml (3% to 10% of the 
original amount of chlordiazepoxide, respectively). In urine, chlordiazepoxide 
was less stable than in blood and decomposed very quickly, with approximately 
7% of the starting concentration remaining after 1 month, while the ACB 
concentration increased from 57 ng/ml to 284 ng/ml (5% and 27% of the original 
amount of chlordiazepoxide, respectively) between day 4 and day 30. 
In the basified blood sample (pH 12), chlordiazepoxide decomposed very quickly, 
losing half of its original concentration after 24 hours, and was not detected 
after 4 days, while ACB was detected after 1 day and decreased gradually from 
118 ng/ml on day 2 to 81 ng/ml on day 7 and to zero ng/ml on day 14. In urine, 
more than 50% of the original chlordiazepoxide concentration decreased after 1 
day, while ACB started to appear after 1 day and dropped from 125 to 73 ng/ml 
between days 2 and 4 (12% and 7% of the original amount of chlordiazepoxide, 
respectively). After this time, neither the parent drug nor its degradation 
product was detected. These results are shown graphically in Figures 7-14 to 7-
19, which also shows graphs of the sum of chlordiazepoxide and ACB during the 
30-day period of the study. 
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Figure  7-14: Degradation of chlordiazepoxide in blood at 80 °C 
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Figure  7-15: Degradation of chlordiazepoxide in blood at pH 2 
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Figure  7-16: Degradation of chlordiazepoxide in blood at pH 12 
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Figure  7-17: Degradation of chlordiazepoxide in urine at 80 °C 
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Figure  7-18: Degradation of chlordiazepoxide in urine at pH 2 
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Figure  7-19: Degradation of chlordiazepoxide in urine at pH 12 
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7.6.4.2 Oxazepam  
At 80 °C, oxazepam decreased gradually from 100% at day zero to 2% at week 2 
and was not detected after one month, while ACB increased gradually from day 2 
to week 2, then dropped to 340 ng/ml (34% of the original amount of oxazepam) 
at day 30. The same degradation pattern was observed in urine but faster, in 
which oxazepam decreased from day 2 to day 7 to 17% of the original 
concentration, while ACB increased from 204 ng/ml on day 2 to 310 ng/ml at 
week 2 (19.8% and 30% of the original amount of oxazepam, respectively), then 
dropped to 241 ng/ml (23.5% of the original amount of oxazepam) on day 30. 
In acidified conditions at pH 2, oxazepam lost 88% of the original concentration 
after 2 weeks and was not detected after 1 month, while ACB was detected on 
day 2, which increased when oxazepam decreased. In urine, oxazepam lost 
approximately 95% of the initial concentration after 2 weeks and was not 
detected after this time, while ACB was observed to increase from day 2 to week 
2, then dropped to 311 ng/ml (30.3% of the original amount of oxazepam) when 
oxazepam was completely lost. 
In basified conditions at pH 12, approximately 50% of the original concentration 
of oxazepam was detected after 1 day and was not detected after 4 days, while 
ACB was detected after 1 day and dropped from 250 ng/ml to 143 ng/ml at day 4 
and 1 month, respectively (25% and 14% of the original amount of oxazepam, 
respectively). In urine, more than 50% of the initial concentration was lost after 
1 day and completely disappeared after 4 days, while ACB rose from 94 ng/ml on 
day 2 to 247 ng/ml on day 4, then dropped to 105 ng/ml after 1 month. These 
results are shown graphically in Figures 7-20 to 7-25, which also shows graphs of 
the sum of oxazepam and ACB during the 30-day period of the study. 
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Figure  7-20: Degradation of oxazepam in blood at 80 °C 
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Figure  7-21: Degradation of oxazepam in blood at pH 2 
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Figure  7-22: Degradation of oxazepam in blood at pH 12 
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Figure  7-23: Degradation of oxazepam in urine at 80 °C 
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Figure  7-24: Degradation of oxazepam in urine at pH 2 
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Figure  7-25: Degradation of oxazepam in urine at pH 12 
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7.7 Further Degradation of MACB to ACB and AB 
7.7.1  Stability Study in Blood  
The degradation of MACB and ACB in the previous studies suggested an additional 
experiment to investigate whether MACB can be degraded to ACB and ACB to 
aminobenzophenone (AB). 
MACB was subjected to a process of rapid decomposition at high temperature to 
investigate and detect further degradation products, in particular ACB and the 
possible end product, AB. 
Blank blood (20 ml) was spiked with MACB to give a final concentration of 1000 
ng/ml.The prepared samples were submitted to accelerated decomposition for 
one month under high temperature in the oven at 80 °C. The times selected for 
analysis were at days 1 (day zero), 2, 4, 7, 14, and 30. The prepared sample was 
analysed in duplicate after spiking and designated as the day zero concentration. 
Aminobenzophenone was analysed with the MS parameters listed in table 7-17.  
Table  7-17: Optimum tuning parameter for 2-aminobenzophenone (AB). 
Drug 
Precursor ion 
(m/z) 
Monitored ions* 
(m/z) 
Collision energy 
(ev) 
AB 198 120,105 28 
Underlined ion was used as the quantification ion. 
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7.7.2 Results of MACB Degradation 
In blood at 80 °C, MACB degraded gradually and approximately 65% was lost from 
the day zero concentration by the end of study, whereas ACB increased gradually 
after 4 days of incubation to reach 91 ng/ml (9% of the original amount of MACB) 
and continued to increase to reach 203 ng/ml (21% of the original amount of 
MACB) at the end of study. AB was not detected during the observation period. 
This result is shown graphically in Figure 7-26. 
 
 
DEGRADATION OF MACB AT 80 ⁰C
0
200
400
600
800
1000
1200
0 10 20 30 40
TIME (DAY)
CO
NC
EN
TR
AT
IO
N 
NG
/M
L
MACB
ACB
AB
MACB+ACB+AB
 
Figure  7-26: Degradation of MACB in blood at 80 °C 
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7.8 Effect of Cosmetics on Benzodiazepine Degradation 
7.8.1 Introduction  
Human natural hair colour is produced by a unique chemical pigment in the 
cortex of the hair called melanin. The production of this pigment is inherited 
and controlled by gene expression. The most common human hair colour is black 
or dark brown produced by a special pigment known as eumelanin; fair hair and 
red hair are produced by a specific melanin called phaeomelanin.192 
Alteration of the natural hair colour using artificial or natural products is 
influenced by many personal, psychological, and practical aspects. The most 
common reason to change the colour is to cover grey hair. Artificial hair colour 
has been used since Egyptian times when kohl and henna were used as artificial 
pigments in cosmetics. Roman women used a mixture of natural products such as 
wood ash, unsliced lime and sodium bicarbonate, wild fruit, and alcohol to 
mimic their light-haired slaves. In Restoration times, alkali, salt, and sun were 
popular while potassium hydroxide was also fashionable for lightening hair.192 
Para-phenylenediamine (PPD) was discovered in 1863 by the chemist 
Dr Hofmann, who reported the dyestuff properties of this substance. This 
discovery still is dominant; over 70% of permanent dyes in all products are 
derived from PPD.192 
In 1931 Clairol produced their first home colour. Millions of women used this 
colouring product, which was considered a real breakthrough. Since that time 
the development continued for the next 20 years when Wella launched the first 
crème permanent dyes in 1953. Recently modern international manufacturers of 
hair dye products have established research and development organizations to 
produce safe, reliable, and qualified hair colour products. The modern hair dyes 
are classified into four basic categories: temporary, semi-permanent, 
permanent, and other dyes. 192 
Temporary colourants can easily be removed from the hair at the first 
shampooing. Semi-permanent dyes are not exposed to oxidation and not bound 
to hair protein. Therefore they can be washed out after four to six wash cycles. 
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Permanent products cannot be washed out; they are the most popular because 
of their extreme versatility. 192 
The essential ingredients in permanent hair dye are precursors such as PPD (for 
dark brown or black shades) and p-aminophenol (for light auburn), which is 
oxidized in the hair shaft by hydrogen peroxide to active intermediates. Within 
the hair shaft these intermediates react with the additional ingredients in the 
product called “colour couplers” such as resorcinol, 1-naphthol, and pyrogallol. 
Then the product of this coupled reaction is oxidized to the final coloured dye 
molecules. These reaction products have low water solubility, which makes the 
product wash-resistant. 192 
Other active ingredients are used in the colourant base such as ammonia, which 
is needed to activate the system when hair is treated with hydrogen peroxide. 
Without ammonia no bleaching is observed. The level of ammonia and peroxide 
will determine how much bleaching will be produced. More is added for blonde 
shades than for dark shades; however, a high level of ammonia irritates the scalp 
and makes the product smell bad. It also raises the pH of the product to about 
10, which makes the hair swell. 192 
Hydrogen peroxide is also used to provide oxygen to fuel the reactions; no 
permanent colour occurs without this ingredient. Peroxide acts by oxidizing the 
dye species. The typical level is 3% to 4.5% on the head. 192 
Solvents such as dipropylene glycol, hexylene glycol, ethanol, and glycerin are 
used to solubilize the dye materials and improve viscosity. Surfactants/fatty 
alcohols are also added in the colourant base formula such as ceteareth-25 and 
steareth-2, which helps to remove oil and sebum from the hair surface. 192 
The presence of these compounds in hair may impact the instability of drugs in 
hair samples; it is reported that cosmetics influence the stability of some drugs.  
Hair cosmetic treatment has been shown to influence the stability of opiates and 
benzodiazepines, as mentioned in Chapter 2 and reported in literature.82-84,192-195 
The current study was undertaken to investigate whether hair bleaching 
materials have an effect on the degradation of these drugs or if the observed 
instability is a result of the washing procedure, or hair washing with water.  
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7.8.2 Chemicals and Materials 
Three commercial bleaching cosmetics with different brand names, Gerreni®, 
Loreal®, and Clairol® were purchased from a local pharmacy. 
7.8.3 Experimental section  
Each drug, diazepam, temazepam, oxazepam, and chlordiazepoxide was spiked 
with the bleaching materials in measuring cylinders to give a final concentration 
of 1000 ng/10µl to allow use of a small volume of bleaching material in order to 
avoid any blockage of SPE cartridges that might limit the extraction of the 
analytes of interest. Each drug was treated with three different bleaching 
agents. The prepared samples were mixed by vortexing for 5 minutes to dilute 
the drugs in the solution. Prepared samples (10 µl) were diluted with 3.5ml of an 
acetate buffer (pH 4.5) followed by the addition of 100 µl of internal standard, 
and centrifuging for 5 minutes at 2500 rpm. The SPE and analysis method were 
the same as those described earlier in this chapter. The prepared samples were 
analysed on the same day as spiking and one week after spiking to investigate 
the effect of the bleach on the drug and determine whether the degradation 
products could be detected, in the event that the drugs decomposed as a result 
of the action of bleaching material components. 
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7.8.4 Results  
The drug concentration decreased for all compounds during the time of the 
investigation and with all cosmetic materials being used in this study. However, 
the degradation products that were previously detected in blood and urine were 
not detected in this study, except for a small amount of MACB that was detected 
after degradation of temazepam in with the presence of Gerreni® components, 
which had the most pronounced effect on degradation of all drugs. 
7.8.4.1 Diazepam  
More than 50% of the initial concentration of diazepam was lost when treated 
with Gerreni® and approximately 35% with Loreal®, while negligible amounts 
were lost when Clairol® was used. In all situations, MACB was not detected after 
one week of study. The results are shown in Table 7-18. 
 
Table  7-18: Decomposition of diazepam by cosmetic materials  
Time 
Day zero 1 week 
Bleaching 
material 
Diazepam 
ng/10µl  
MACB 
ng/10µl 
Diazepam 
ng/10µl  
MACB 
ng/10µl 
Gerreni® 868 0 421 0 
Loreal® 976 0 627 0 
Clairol® 945 0 943 0 
 
 
 
7.8.4.2 Temazepam  
A very large proportion of temazepam was lost when added to Gerreni® after one 
week, while MACB was detected in small amounts, approximately 22ng /10µl. In 
the tube containing Loreal®, more than 40% of temazepam was lost, while in the 
Clairol® tube, less than 3% of temazepam was lost. In Loreal® and Clairol®, no 
MACB was detected. The results are shown in Table 7-19. 
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Table  7-19: Decomposition of temazepam by cosmetic materials 
Time 
Day zero 1 week 
Bleaching 
material 
Temazepam 
ng/10µl  
MACB 
ng/10µl 
Temazepam 
ng/10µl  
MACB 
ng/10µl 
Gerreni® 897 0 53 22 
Loreal® 963 0 557 0 
Clairol® 987 0 965 0 
 
7.8.4.3 Chlordiazepoxide  
As shown in Table 7-20, more than 62% of chlordiazpoxide was lost in the tube 
containing Gerreni® material, while ACB was not detected after one week. In 
Loreal® and Clairol® 19% and 5% of chlordiazepoxide were lost respectively, while 
ACB was not detected.  
Table  7-20: Decomposition of chlordiazepoxide by cosmetic materials 
Time 
Day zero 1 week 
Bleaching 
material Chlordiazepoxide 
ng/10µl 
ACB 
ng/10µl 
Chlordiazepoxide 
ng/10µl 
ACB 
ng/10µl 
Gerreni® 902 0 338 0 
Loreal® 
913 0 743 0 
Clairol® 
934 0 890 0 
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7.8.4.4 Oxazepam  
Oxazepam decreased by 89%, 32%, and 4% in Gerreni®, Loreal®, and Clairol® 
tubes respectively, while ACB was not detected in any of the tubes. The results 
are shown in Table 7-21. 
Table  7-21: Decomposition of oxazepam by cosmetic materials 
Time 
Day zero 1 week 
Bleaching 
material 
Oxazepam 
ng/10µl   
ACB 
ng/10µl 
Oxazepam 
ng/10µl   
ACB 
ng/10µl 
Gerreni® 820 0 94 0 
Loreal® 938 0 634 0 
Clairol® 963 0 925 0 
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7.9 Case Samples 
The established analytical method was applied to 12 blood and 7 urine samples 
from forensic cases, obtained from the Department of Forensic Medicine and 
Science, University of Glasgow. These samples had been kept in the deep freeze 
for up to 6 months after they were originally received and analysed. This study 
was intended to assess whether significant degradation of benzodiazepines had 
occurred during storage. The results are shown in Tables 7-22 and 7-23.  
 
7.9.1 In Blood  
   Table  7-22: Benzodiazepines and their degradation products in blood case samples 
Diazepam 
mg/L 
Temazepam 
mg/L 
Oxazepam 
mg/L 
SAMPLE 
NO 
1st* 2nd* 1st* 2nd* 1st* 2nd* 
 
Time 
Interval 
(month) 
AB 
mg/
L 
ACB 
mg/
L 
MACB 
mg/L 
1 0.15 0.12 0.10 0.09 0.12 0.10 <1 ND ND ND 
2 0.25 0.22 0.08 0.07 0.03 0.10 <1 ND ND ND 
3 0.02 0.02 0.01 0.02 ND* ND 1 ND ND ND 
4 0.04 0.03 0.32 0.30 0.03 ND 1 ND ND ND 
5 0.26 0.27 0.03 0.04 0.04 0.02 2 ND ND ND 
6 0.12 0.12 0.01 0.02 0.03 0.02 2 ND ND ND 
7 0.89 0.90 0.05 0.06 ND ND 3 ND ND ND 
8 1.30 1.27 0.22 0.21 0.26 0.23 3 ND ND ND 
9 1.40 1.37 1.70 1.68 >1 1.53 4 ND ND ND 
10 1.20 1.18 0.21 0.20 ND ND 4 ND ND ND 
11 0.20 0.19 0.06 0.05 ND ND 4 ND ND ND 
12 0.10 0.09 0.02 0.01 ND ND 4 ND ND ND 
 * 1st: The concenration of drug in the case sample at received time, 2nd: The 
concentration of drug in case sample after period of time. 
*ND: Not detected.
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7.9.2 In Urine  
Table  7-23: Benzodiazepines and their degradation products in urine case samples (not matched to the blood samples in Table 7-22) 
SAMPLE NO 
DIAZEPAM 
mg/L 
TEMAZEPAM 
mg/L 
OXAZEPAM 
mg/L 
CHLORODIAZEPOXIDE 
mg/L 
AB 
mg/L 
ACB 
mg/L 
MACB 
mg/L 
1 0.030 >1 0.397 ND* ND 0.111 0.072 
2 0.148 >1 >1 ND ND 0.424 0.097 
3 0.484 >1 >1 ND ND 0.903 >1 
4 0.069 >1 0.288 ND ND 0 0.321 
5 >1 >1 >1 ND ND >1 >1 
6 0.053 >1 >1 ND ND 0.319 0.323 
7 0 >1 0.337 ND ND 0.121 ND 
*ND: Not detected. 
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7.10 Summary of benzodiazepines degradation in 
blood and urine under different storage conditions  
The degradation of diazepam, temazepam, chlordiazepoxide, and oxazepam in 
blood and urine samples for one month under different storage conditions is 
summarized in Table 7-24. 
Table  7-24: Summary of degradation of diazepam, temazepam, chlodiazepoxide, and 
oxazepam in blood and urine samples under different storage conditions  
Results  
Drug Conditions  
Blood  Urine  
Comment  
80 ºC, 1 month 
30% 
decrease 
100% 
decrease 
Acidified pH 2, 
1 month 
25% 
decrease 
100% 
decrease 
Diazepam 
Basified pH 12, 
1 month 
50% 
decrease 
100% 
decrease 
80 ºC, 1 month 
100% 
decrease 
100% 
decrease 
Acidified pH 2, 
1 month 
77% 
decrease 
100% 
decrease 
Temazepam 
Basified pH 12, 
1 month 
100% 
decrease 
100% 
decrease 
80 ºC, 1 month 
62% 
decrease 
100% 
decrease 
Acidified pH 2, 
1 month 
51% 
decrease 
93% 
decrease 
Chlordiazepoxide 
Basified pH 12, 
1 month 
100% 
decrease 
100% 
decrease  
80 ºC, 1 month 
100% 
decrease 
100% 
decrease 
Acidified pH 2, 
1 month 
100% 
decrease 
100% 
decrease 
Oxazepam 
Basified pH 12, 
1 month 
100% 
decrease 
100% 
decrease 
• MACB 
concentration 
increased when 
concentration 
of diazepam 
and temazepam 
decreased 
• ACB 
concentration 
increased when 
chlordiazepoxid
e and oxazepam 
concentration 
decreased 
• MACB and ACB 
can be detected 
even if the 
parent 
compounds are 
undetectable 
• Degrades in 
urine faster 
than in blood  
• Degradation is 
dependent upon 
basic condition 
more than on 
the level of 
acidity and 
temperature 
conditions 
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7.11 Discussion and Conclusions 
Hydrolysis generally splits compounds into two molecules. Since benzodiazepines 
contain an amide group in their structure, they are susceptible to decomposition 
by hydrolysis reactions involving this functional group to produce carboxylic 
acids and amines. Benzodiazepine hydrolysis was extensively studied: 
degradation of benzodiazepines in aqueous media yielded benzophenone 
derivatives and glycine as degradation products; thus, in this study 
benzophenone derivatives were the major degradation products to be detected 
because the other product, glycine, may be produced in the sample from other 
sources: for example, glycine is used in medical and industrial applications as a 
sweetening agent, antacid agent, stabilizer, buffer and regulator, as a material 
in cosmetics, and as a supportive therapy for treatment of schizophrenia. 
Further, most proteins contain small quantities of glycine which in principle may 
be released by protein catabolism. Glycine was therefore excluded from this 
study, unlike the benzophenone derivatives, which are specific degradation 
products for benzodiazepine drugs. 199  
Temperature and pH significantly affected the rates of the hydrolysis reactions. 
Sometimes samples are kept for a period of time under unfavourable conditions, 
such as in high temperatures, according to the climate or during transportation 
at ambient temperature which may accelerate the hydrolysis reaction. This is a 
recognised problem in hot countries, especially in developing countries, which 
may not have the necessary resources to provide refrigeration during transport. 
The internal temperature of closed vehicles on a hot day can exceed 65 °C, and 
temperatures on exposed surfaces such as dashboards can reach 93 °C. The 
normal blood pH ranges from 7.2-7.4. Plasma pH shift was reported to increase 
to above pH 8 only a few hours after incubation at 37 °C. The effect of diet 
basicity or acidity on the blood pH is regulated in vivo by metabolic and renal 
mechanisms, whereas in vitro, this regulation system is not present, and it 
becomes more alkaline than the normal physiological pH a few hours after 
collection, as a result of CO2 losses during storage.
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On the other hand, urine pH ranges between 4 and 8 depending on diet, 
medication intake and state of health of the sample donor. Urine also contains 
other components such as ammonia, phosphates, salts, and bicarbonate, which 
188 
may change the pH of the sample after collection, leading to difficulty in the 
quantification of pH-labile compounds after storage. Also, it was reported that 
an increase in temperature is directly correlated with an increase in the urine 
pH. This explains the observed difference in the degradation of all drugs 
involved in this study, which was faster in urine than in blood. Urine becomes 
alkaline immediately after a meal and then gradually becomes acidic between 
meals. A high-protein diet is associated with acidic urine, while a vegetarian diet 
produces more alkaline urine as a result of the formation of bicarbonate from 
fruits and vegetables. Male and female urethras are colonized with 
microorganisms, even if samples are collected with prior external cleansing of 
the genitalia, with further contamination from intestinal flora in females. Urine 
samples are as a result often bacterially contaminated. Individual health status 
and drug intake also affect the urine pH. Respiratory and metabolic alkalosis, 
prolonged vomiting and urinary tract infection are the most common causes of 
alkaline urine, while respiratory and metabolic acidosis, diabetes mellitus, 
starvation and severe diarrhoea are the most common causes of acidic urine. 
Some medications also change the urine pH. Clinically, in drug overdose, it is 
observed that the urine pH changes to accelerate the clearance of some drugs.8 
Urine contains urea, uric acid and non-protein nitrogenous compounds, and 
during the time of storage, the stability of these compounds is affected by 
bacterial contamination. For example, urea is split by bacterial urease into 
ammonia and carbon dioxide, which may yield a urinary pH>8. In vitro 
adulteration with some manufactured products containing very basic or very 
acidic components can destroy the drugs in the sample. SAMHSA guidelines have 
established that urine pH cut-offs <3 or >11 are indicate adulterated urine 
samples. At high temperatures, urine pH changes to reach >9, and some authors 
have attributed that to the loss of CO2, while other authors argue that it is due 
to the production of ammonia. Therefore, all of these factors can accelerate the 
rate of hydrolysis reactions and lead to loss of the analyte of interest and, 
consequently, a false interpretation of case results. Under these expected 
conditions, the hydrolabile drugs were submitted to a range of non-ideal 
conditions in order to detect the degradation product specific for each analyte. 
The measured concentrations of degradation products can be used to correct for 
loss of the parent drugs and as indicators of drug intake in case in which the 
parent drug has completely decomposed under unfavourable conditions.156  
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The drug degradation reactions investigated in this study accelerated under all 
conditions. During decomposition of drugs under alkaline conditions, the 
hydrolysis of the compounds is initiated by nucleophilc attack of the hydroxide 
ion on the positively charged carbonyl carbon atom of the amide bond, leading 
to the production of a negatively charged intermediate compound that exhibited 
basic character; thus, it may induce the dissociation of the water molecule 
followed by protonation of the nitrogen atom. Finally, the C-N bond is broken, 
yielding a benzophenone product (Figure 7-27). Under acidic conditions, the 
hydrolysis reaction starts by protonation of the oxygen atom of the carbonyl 
group followed by nucleophilic attack by the hydroxide ion, protonation of the 
nitrogen atom and finally opening of the C-N bond. In both acidic and basic 
conditions, water assists this reaction, while in absence of acidic or basic 
catalysts, high temperature accelerates this reaction in the presence of water as 
observed in an oven at 80 °C.198,199 
The degree of hydrolysis was different under different conditions. An excess 
amount of OH- in basic conditions acts as a nucleophile, attacking the 
electrophilic carbonyl carbon, which explains the observed sensitivity of the 
drugs to degradation in basic conditions. Another reason explaining why drugs 
degraded faster in basic than in acidic conditions is that hydrolysis of drugs 
under acidic conditions may favour cleavage of the 4,5-imine bond, while in 
basic conditions hydrolysis favours cleavage of the 1,2 amide bond. However, in 
acidic conditions, the degradation product produced is benzophenone imine, 
ultimately hydrated to produce the benzophenone derivatives that were 
detected in this study under both conditions.199  
Diazepam, temazepam, and oxazepam contain an amide group that is prone to 
decompose following the previous mechanism by either amide or imine bond 
cleavage under all conditions, and the main degradation products were MACB 
and ACB as found in this study (Figures 7-27 and 7-28). 
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Figure  7-27: Hydrolysis of diazepam and temazepam 
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Figure  7-28: Hydrolysis of oxazepam 
 
In contrast, chlordiazepoxide does not contain an amide group in its structure. 
However, some studies have reported that ACB was detected as a degradation 
product in cases of chlordiazepoxide degradation similar to what was observed in 
this study. The proposed degradation mechanism of chlordiazepoxide is 
hydrolysis first to an intermediate lactam (demoxepam), which is formed by 
hydrolytic cleavage of methylamino substituent at the 2-position of the parent 
compound, which decomposes further to nordiazepam, which is then hydrolyzed 
to produce ACB as a final degradation product. That is why the ACB produced 
from chlordiazepoxide degradation is less than that produced from oxazepam; 
therefore, demoxepen and nordiazepam can be quantified in addition to ACB in 
case of chlordiazepoxide decomposition (Figure 7-29). 
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Figure  7-29: Hydrolysis of chlordiazepoxide 
 
Temazepam and oxazepam were found to be less stable than diazepam, perhaps 
because of the presence of (OH) on position 3 of the diazepine ring that may 
exhibit electron withdrawing properties, thereby accelerating the degradation of 
these compounds.  
MACB and ACB itself were found to be further degraded under some conditions 
created in this study. MACB was found to degrade further to ACB, and this result 
is similar to those of some previous studies, while AB was not detected as a final 
degradation product for these compounds as expected, perhaps because the 
bond energy between chlorine and carbon is higher than those between nitrogen 
and carbon thus another compound rather than AB may produced. 
MACB and ACB were not detected in the case blood samples, perhaps because 
the samples were stored properly in the refrigerator and freezer, which 
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stabilized the drugs from degradation. However, MACB and ACB were detected in 
the urine samples, which may be attributed to urine pH, bacterial 
contamination, or the enzyme used to cleave the drug glucuronide. 
Decomposition of benzodiazepines resulting from the presence of cosmetics was 
noted; however, hydrolysis is not the predominant degradation reaction under 
this condition, which is explained by the absence of MACB and ACB after 
degradation except for a small amount of MACB that was detected after 
hydrolysis of temazepam by Granini® bleaching. Also, this study indicates that 
the components of cosmetic materials are different in different brands, resulting 
in different effects on the stability of these compounds. In previous studies it 
was reported that oxidation of diazepam produced MACB.200,201 However, they 
used HCL in the experiment, which may explain why MACB was produced, 
meaning that it was produced by a hydrolysis reaction rather than an oxidation 
process; it seems likely that a compound other than a benzophenone is produced 
by an oxidation process. Further study is suggested to investigate the 
degradation products that may be produced by oxidation. 
In this study and under all conditions, the MACB and ACB concentration increased 
as degradation of the drugs proceeded and these products could be detected 
when the parent drugs had completely disappeared. Degradation of diazepam 
and temazepam in blood and urine under different conditions will produce MACB 
as the main hydrolysis product, while degradation of oxazepam and 
chlordiazepoxide will produce ACB as the main degradation hydrolysis product.  
MACB and ACB can be reliably detected in whole blood and urine and can be 
used, at least in part, to correct for losses of parent drugs.  They also serve as to 
indicate the original presence of these compounds in samples kept under poor or 
prolonged storage conditions if the case samples are suspected to contain 
benzodiazepines and the parent compound is not detected.  
This study showed that temperature and pH have important implications for the 
decomposition of benzodiazepines. Extended transportation time and increased 
environmental temperature may affect the pH of the urine samples, which may 
exceed 9 within 2 days, destroying the drugs and giving false negative results. 
Therefore, degradation products are promising compounds as markers that can 
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indicate the former presence of specific drugs in cases in which the drug is lost 
during transport and storage. 
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8 Stability of Organophosphorus Pesticides 
During Storage in Preserved Blood and Dried 
Blood Spots 
8.1 Introduction 
Organophosphorus compounds (OPs) are highly toxic pesticides that contain 
esters of phosphoric acid attached through oxygen, sulphur and nitrogen atoms. 
OPs are used in agriculture as insecticides, acricides, and fungicides. OPs exert 
their effect by inhibiting acetylcholinesterase enzyme (AChE) activity by 
irreversible phosphorylation of the enzyme; thus, human exposure to these 
compounds causes nerve synapse toxicity as a result of the accumulation of 
acetylcholine in the synaptic cleft, leading to paralysis and possibly death by 
asphyxia.9  It can be seen from Figure 8.1 that OPs usually have three organic 
substituents, including two methyl or ethyl substituents plus one other which is 
different between each OP.  The unique substituent is termed the “leaving 
group” as it is this substituent which is displaced when AChE is phosphorylated. 
OPs are rapidly metabolised in blood to yield dialkylphosphates (DAPs), which 
are excreted in urine within 6 to 24 hours. For example, the dichlorvous half-life 
in blood is 30 minutes, so detection of the parent compound after a period of 
time is difficult, whereas its metabolites can be found for a long time in urine. 
Phosphothionate undergoes oxidative desulfuration to produce its active 
phosphate analogue, which is a more powerful AChE inhibitor than the parent 
compound. For example, parathion is oxidised to paraoxon, which is more potent 
than parathion.202 
Acute and chronic exposure to OPs has been reported in forensic cases.203,204 In 
many parts of the developing world, pesticides account for most substance-
related deaths because they are readily accessible in these agricultural 
communities. Assessment of exposure to OPs was achieved by measurement of 
the activity of AChE in erythrocytes. If the activity of this enzyme is less than 
85% of the population mean value, then toxicity by OPs is suspected. However, 
inter-individual variation makes this assessment unsuitable for monitoring 
exposure to OPs and determination of exposure markers, such as OPs and their 
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metabolites, is a more powerful approach and suitable parameter to evaluate OP 
toxicity.203-205 In some medicolegal jurisdictions, the courts require unambiguous 
identification of the parent compound, which poses a problem for the 
toxicologist, and much effort has been expended on developing suitable 
analytical approaches. 
Numerous methods have been reported for determination of intact OPs in 
biological fluids,206-219 while other studies determined their DAPs as markers of 
occupational OP exposure.220-236 Few methods have been reported for 
determination of both OPs and their DAP metabolites.237-239 By looking at their 
molecular structure, we find that each OP compound will produce one of several 
different DAPs (see Figures 8.1 and 8.2). Dichlorvos degradation produces 
dimethylphosphate (DMP), while diazinon, chlorpyrifos, and parathion 
decomposes into diethylthiophosphate (DETP), and paraoxon decomposes to 
produce diethylphosphate (DEP).  Since DAPs have high polarity and water 
solubility characteristics, they required suitable derivatisation before analysis. In 
previous studies, the derivatising agents used were diazoalkanes and 
pentafluorobenzyl bromide (PFBBr) to form volatile derivatives prior to analysis 
by GCMS. However, diazolkanes is highly toxic (carcinogenic) and readily 
explosive, while PFBBr is a potent lachrymator and its decomposition product 
may cause damage to the GC column.226,233,235 Some studies used MTBSTFA + 1 % 
TDM to derivatize DAPs and this derivatising agent was used in this study for 
reasons of safety and efficacy.229,239  
Little can be done with respect to preventing OPs from degrading in the post 
mortem interval but some consideration can be given to stabilisation of samples 
after collection at autopsy.  However, Fumio et al. reported that the addition of 
the anti-enzymatic preservative sodium fluoride (NaF) to a blood sample 
containing OPs accelerated the degradation of dihlorvos and chlorpyrifos in the 
blood.88  
The aim of this study was to analyse the DAPs for selected OP produced as a 
result of oxidation and hydrolysis as markers for the parent compounds. The OPs 
selected for this study were those of significance in forensic cases in Saudi 
Arabia. Additionally, an alternative approach was evaluated, to investigate 
whether filter paper could avoid or reduce the degradation rate of these 
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compounds in blood samples stored as DBS rather than by adding a preservative. 
These aims required the development of a new, practical, routine method to 
extract OPs and their DAP metabolites from blood samples by SPE, followed by 
analysis by GCMS after suitable derivatisation. 
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Figure  8-1: Chemical structures of organophosphates (OPs). 
 
 
 
 
197 
OH P
O
O
O
CH3
CH3               
O
OH
P
OC2H5
OC2H5               OH
P
OC2H5
OC2H5
S
 
              DMP                                 DEP                              DETP 
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8.2 Experimental section 
8.2.1 Chemicals and materials 
Diazinon, chlorpyrifos, parathion, paraoxon, and dichlorvos were purchased from 
Sigma Aldrich (Dorset, UK) as 100µg/ml solutions in acetonitrile. 
Dimethylphosphate (DMP), diethylphosphate (DEP) and deithylthiophosphate 
(DETP) were also purchased from Sigma Aldrich and used to prepare standard 
solutions containing 100µg/ml in acetonitrile. Internal standard diazinon-d10 was 
purchased from Sigma Aldrich and prepared as a 100µg/ml solution in 
acetonitrile. Acetonitrile, methanol, cyclohexane, ethyl acetate, ammonium 
hydroxide, formic acid, isopropanol, dichloromethane and potassium dihydrogen 
phosphate were obtained from BDH (Poole, UK). Clean Screen ZSDAU020 
cartridges were purchased from United Chemical Technology UK. Bond Elut LRC-
C18 cartridges and Bond Elut Certify II cartridges were purchased from Varian 
(Palo Alto, CA). tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) 
containing 1 % tert-butyldimethylchlorosilane (TBDMCS) was purchased from 
Sigma Aldrich. Sheets of Guthrie card 903® specimen collection paper (210 x 
297mm) were purchased from Whatman UK. 
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8.2.2 Solutions   
8.2.2.1 Preparation of 0.04M phosphate buffer pH 2 
Sodium dihydrogen orthophosphate (4.8 g) was dissolved in 800 ml DI water in a 
1 L volumetric flask. The pH was adjusted to pH 2 with 1M hydrochloric acid. The 
volume was made up to the mark with DI water. 
8.2.2.2 Preparation of 0.1M phosphate buffer pH 6.0 
1 litre of solution was prepared by dissolving 1.7 g of anhydrous disodium 
orthophosphate and 12.14 g of sodium dihydrogen orthophosphate monohydrate 
in 800ml of DI water. The pH was adjusted to pH 6 with 1M potassium hydroxide 
and the solution made up to volume with DI water. 
 
8.2.2.3 Preparation of 0.1M sodium acetate buffer pH 7 with 5% methanol 
Sodium acetate trihydrate (6.8 g) was dissolved in 400 ml of DI water in a 500 ml 
volumetric flask. The pH was adjusted to pH 7 with 1M hydrochloric acid. The 
solution was made up to the volume with DI water then 25ml of the prepared 
solution was replaced with 25 ml of methanol. 
8.2.2.4 Standard solutions of analytes 
Working standards of unlabelled and labelled OPs and DAPs were prepared by 
diluting 100 µl from each OP stock solution in 10 ml acetonitrile to obtain a 
concentration of 1µg/ml. Stock solutions of standards and internal standard were 
stored at -20ºC.  
 
 
 
8.2.3 Instrumentation (GC-MS)  
A ThermoQuest GCMS instrument was used, fitted with an HP-5 capillary column 
(30m × 0.32mm × 0.25µm film thickness) and helium carrier gas. The column 
temperature was programmed from 100 °C to 300 °C at a rate of 12 °C /minute 
and held at 300 °C for 5 minutes. The temperature of the injector was 280 °C. 
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The split/splitless injection mode was used with a purge time of 40 s. The 
ionisation energy was 70eV in the EI+ mode. 
 
8.2.4  Identification of retention times and fragmentation 
Retention times and mass fragments for all compounds and their de-uterated 
standards were identified using unextracted standards after derivatision. 100 µl 
of standard working solutions of OPs, DAPs and internal standards (1 µg/ml) were 
evaporated to dryness under a stream of nitrogen at room temperature. For OPs, 
the residue was reconstituted in 50 µL of ethyl acetate; then 1 µl was injected 
directly into the GCMS, while DAP residues were derivatised in a mixture using 
50 µl of ethyl acetate/MBSTFA+1% TDM (50:50 v/v) and placed in the heating 
block for 30 minutes. 1 µl was injected for analysis by GCMS (Table 8-1). 
Table  8-1: Retention times and fragment ions of OPs, DAPs and internal standards. 
Compound  Retention time (min.) Fragment ions (m/z) 
DMP 4.9 153, 183 
DEP 6.06 155, 211 
DETP 6.59 171, 227 
Dichlorvos 3.94 109, 185 
Chlorpyrifos 12.88 97, 197 
Diazinon 10.94 137, 179 
Parathion 12.91 97,139 
Paraoxon 12.15 109, 149 
Diazinon-D10 10.85 138, 153 
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The underlined ions were used for quantitation because they were the most 
intense ions obtained. Fragmentation of some compounds produced the same 
ions but this was acceptable if they had different retention times, for example, 
the ion at m/z 109 was produced from the fragmentation of dichlorvos and 
paraoxon but these OPs had different retention times. Diazinon-D10 was used as 
an internal standard.  
 
8.2.5 Optimisation of derivatisation  
Some authors reported that high temperature is required to derivatise DAPs 
which do not contain sulphur, while DAPs containing sulphur atoms must be 
derivatised at room temperature to avoid loss of sulphur by oxidation during this 
step.229 Other authors proposed an intermediated temperature 40-50 °C to 
derivatise DAPs simultaneouslyand 40 °C was used for derivatisation in the next 
step.239 OPs should not react with the derivatising reagent but an evaluation was 
made of their stability in the presence of the reagent. 
Reconstitution of all compounds in the derivatising agent only gave poor 
detection for some OPs. Thus, OPs and DAPs were reconstituted in different 
solvent: derivatising agent ratios to optimise the response for all compounds. 
100 µL of standard solutions of all compounds and internal standard, all at 1 
µl/ml, were added to sealed vials in duplicate. Following evaporation, 
derivatisation was carried out at 40°C for 30 min using three different ratios of 
MTBSTFA +1%TBDMCS:ethyl acetate (EtOAc), which were 1:1 v/v, 2:3 v/v and 3:2 
v/v.  The reaction mixtures were subsequently analysed directly by GCMS and 
peak areas recorded. The results are shown in Table 8-2. 
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Table  8-2: Relative peak areas for OPs, DAPs and IS at different reagent compositions*. 
50 µl of (MTBSTFA+1%TBDMCS:EtOAc) at 40°C for 30 
min 
COMPOUND 
(1:1) (2:3) (3:2) 
DMP 1.00 1.05 1.11 
DEP 1.00 0.97 1.05 
DETP 1.00 1.02 1.02 
DICHLORVOS 1.00 1.12 0.51 
CHLORPYRIFOS 1.00 1.34 1.39 
DIAZINON 1.00 1.04 0.86 
PARATHION 1.00 1.43 0.95 
PARAOXON 1.00 1.02 0.96 
Diazinon-D10 1.00 1.02 0.97 
*Relative to the area obtained with the reagent with a 1:1 v/v ratio. 
Table 8-2 demonstrates that the highest peak intensity for most analytes was 
produced with MBSTFA+1%TDM:EtOAc 2:3 v/v. Additionally, there was no 
significant enhancement in the sensitivity of DAPs when using more than 20 µl of 
the derivatising agent in the derivatising mixture, while OPs decreased when 
EtOAc was less than the derivatising agent, especially for dichlorvos. This ratio 
was selected for analyte reconstitution and derivatisation. In order to optimise 
the derivatisation reaction time for OPs and DAPs and enhance the response of 
DAPs without affecting OPs compounds, the derivatisation process was repeated 
in duplicate using three different reaction times at 30, 60, and 90 minutes. The 
results are presented in Table 8-3. 
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Table  8-3: Peak area at different incubation times 
Incubation time (minutes) 
COMPOUND 
30 min. 60 min. 90 min. 
DMP 1.00 1.18 1.14 
DEP 1.00 1.11 1.10 
DETP 1.00 0.96 0.94 
DICHLORVOS 1.00 0.99 0.92 
CHLORPYROFOS 1.00 0.82 0.79 
DIAZINON 1.00 0.98 0.97 
PARATHION 1.00 0.92 0.86 
PARAOXON 1.00 1.05 1.01 
Diazinon-D10 1.00 0.93 0.91 
 
As shown in Table 8-3, the highest peak areas for DMP and DEP were obtained 
with a reaction time of 60 minutes, while for DETP at the optimum was 30 
minutes. However, beyond 1 hour, all DAP peak areas decreased. Furthermore, 
the OP and diazinon-d10 areas decreased as the incubation time increased. The 
optimal reaction time for all compounds was 30 minutes and this was 
subsequently used for analyte derivatisation. Additionally, the antioxidant 
sodium metabisulfite (SOD) which was used to prevent conversion of DETP to DEP 
by oxidation, as described by Ueyama et al. was not added to the samples in this 
study to avoid introducing unwanted side-effects which might affect the stability 
of OPs, as, for example, resulted when NaF was added to samples containing 
these compounds.88,101  
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The final procedure adopted was as follows: the eluate obtained by SPE was 
evaporated to dryness at room temperature under a stream of nitrogen, the 
residue was derivatised using 50 µl of MTBSTFA+1%TBDMCS: EtOAc (2:3 v/v) in a 
sealed vial, which was vortexed and placed in a 40⁰C heating block for 30 
minutes; 1 µl was injected for analysis by GCMS. 
8.2.6 Optimisation of extraction method 
Most of the methods described in the literature for the extraction of OPs or DAPs 
were based on LLE, column clean-up, lyophilisation, azotropic distillation, and 
SPE using SAX columns.219,222,224-226,232,234-236,240,241 However, because SPE has 
advantages over LLE, a new SPE method was developed to provide an efficient 
method to extract OPs and their alkyl phosphate metabolites which would be 
simple and robust enough for routine application. Three literature methods for 
the extraction of acidic compounds were selected to determine which could 
provide the highest recoveries for OPs and DAPs from blood samples. The 
procedures are listed in Table 8-4.242-244 
Table  8-4: Procedures for three extraction methods used for comparison 
Method Extraction procedure 
A242 
Bond Elut C18 
  
• 2ml methanol, 2ml 0.04M phosphate buffer pH2 
• apply sample  
• 2ml 0.04M phosphate buffer pH2 
• dry 
• elute with 3ml DCM/EtOAc (1:1 v/v) 
 
B243 
Bond Elut Certify®  
 
• 2ml methanol, 2ml distilled water, 2ml 0.1M phosphate buffer 
pH 6,  
• load sample 
• 2ml 0.1M phosphate buffer pH 6, 2ml 1M acetic acid 
• elute with 3ml DCM/EtOAc (4:1 v/v) 
 
C244 
Bond Elut Certify® II 
 
• 2ml methanol, 2ml 0.1M sodium acetate buffer pH 7 with 5% 
methanol 
• add sample 
• 1ml 0.1 M sodium acetate buffer pH 7 with 5% methanol 
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• dry 
• elute with 3ml hexane/EtOAc (95:5 v/v) 
 
 
Method evaluation was carried out by extracting 1ml blood containing 50 ng of 
each standard in duplicate. 50 ng of internal standard was added after 
extraction. An unextracted 50 ng standard containing 50ng of internal standard 
was also prepared in duplicate. The unextracted and extracted standards were 
derivatised and analysed by GCMS and recoveries were calculated by comparing 
the peak area ratios of the extracted and unextracted standards (Table 8-5). 
Table  8-5: Mean recoveries for analytes, using three different methods 
Average recovery % (n=2) 
COMPOUND 
Method A Method B Method C 
DMP 43.6 17.1 59.5 
DEP 53.8 8.8 65.8 
DETP 42.4 18.8 64.3 
DICHLORVOS 57.8 59.4 83.6 
CHLORPYRIFOS 35.8 31.2 79.5 
DIAZINON 31.5 16.7 87.6 
PARATHION 26.7 14.2 79.6 
PARAOXON 25.9 22.6 92.5 
 
As shown in Table 8-5, the highest recoveries were obtained using method C and 
this method was used subsequently. However, the method was modified to 
improve the recoveries of DAP analytes, which showed the lowest recoveries 
obtained by this procedure.   
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8.2.6.1 Comparison of elution solvents  
The sorbent in the Certify II column has strong anion (quaternary amine) 
exchange residues, which are always positively charged, while the analyte 
contains a negative charge at pH 7. Thus, the interaction will be between the 
negative charge of the analyte and the positive charge on the sorbent. 
Furthermore, the presence of a hydrophobic sorbent enables an extra 
mechanism of attraction of analytes to the cartridge. Since DAPs have a high 
polarity and acidity, these compounds required strong polar, acidified solvents 
to neutralise the acidic compounds and elute them. 
The results in Table 8.5 show that DAPs have low recoveries compared to OPs 
and further investigation was conducted to improve this. The previous procedure 
was repeated using a different elution solvent containing ethyl acetate with a 
high concentration of formic acid (98:2 v/v). Each extraction was carried out in 
duplicate. The results are shown in Table 8-6. 
Table  8-6: Average recoveries obtained for OPs and DAPs using different elution solvents 
Average recovery % (n=2) 
Compound 
Hexane/EtOAc (95:5) EtOAc:Formic Acid (98:2 v/v) 
DMP 58.2 72.1 
DEP 62.6 83.2 
DETP 71.1 89.0 
DICHLORVOS 81.8 91.7 
CHLORPYRIFOS 86.4 83.9 
DIAZINON 87.5 92.9 
PARATHION 74.3 97.5 
PARAOXON 82.7 102.3 
 
As shown in Table 8-6, acidification of the elution solvent gave improved 
recoveries compared to hexane/EtOAc. This acidified elution solvent reduced 
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the ionisation of the acidic compounds, which allowed them to be eluted with 
the strong elution solvent. However, DMP showed a low recovery because it is a 
very strong acid with a pKa around 2 which would need a more acidic elution 
solvent. The final procedure used to extract OPs and DAPs is listed in Table 8-7. 
Table  8-7: Optimised extraction and derivatisation method for OPs and DAPs. 
Step Procedure 
Sample 
preparation 
• 1ml of blood added to 2ml of 0.1M sodium acetate 
buffer pH 7 with 5 % methanol 
• 100 µl of internal standard added 
• Vortex for 5 minutes 
• Centrifuge at 2500rpm for 5 minutes. 
Conditioning 
• 2ml methanol  
• 2ml 0.1 M sodium acetate buffer pH7 with 5% methanol 
• Add sample.  
Washing 
• 1ml 0.1 M sodium acetate buffer pH7 with 5% methanol 
Elution 
• 2ml EtOAc:Formic Acid (98:2 v/v) 
Derivatisation 
• Evaporate to dryness under stream of nitrogen 
• Vortex mix with 50µl of (2:3) MBSTFA+1%TDM:EtOAc in a 
sealed vial  
• Place in a 40 °C heating block for 30 minutes 
• 1µl injected for analysis by GCMS. 
 
The optimised method summarised in table 8-7 was used in method validation 
and stability studies. However, for DBS samples the spots were cut from the 
sheet with scissors, transferred to extraction tubes and 3.5 ml extraction buffer 
were added.  The tube was vortex-mixed and placed in an ultrasonic bath for 
one hour to extract the drugs from the paper. The paper was discarded then the 
extract was centrifuged at 2500 RPM for 5 minutes. 
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8.2.7 Method validation 
The validation parameters applied in this study were similar to parameters in 
Table 4-1 except that the recovery and precision were determined at two 
concentrations, 50 ng and 100 ng/ml. 
8.2.7.1 Linearity  
The relationships between analyte concentrations and peak area ratios were 
linear over the range 10-400 ng/ml, and the linear correlation coefficients (r2) 
were better than 0.99 for all analytes, as shown in Table 8-8.  
8.2.7.2 LODs and LLOQs  
LOD values for all analytes were 2.30-7.10 ng/ml blood and LLOQ values were 
7.50-23.70 ng/ml blood. The results are shown in Table 8-8. The high LOD and 
LLOQ values obtained for analytes in this study compared to those obtained in 
the literature are attributed to the sensitivity of the GCMS instrument used in 
this experiment.  
Table  8-8: Linear correlation coefficients, LODs and LLOQs of DAPs and OPs in blood. 
Compound 
Linear correlation 
coefficients (r2) 
LOD 
ng/ml 
LLOQ 
ng/ml 
DMP 0.991 5.80 19.40 
DEP 0.993 4.60 15.30 
DETP 0.992 5.40 18.00 
DICHLORVOS 0.998 2.60 8.60 
CHLOPYRIFOS 0.999 7.10 23.70 
DIAZINON 0.994 2.30 7.50 
PARATHION 0.992 5.20 17.40 
PARAOXON 0.997 6.00 20.00 
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8.2.7.3 Recoveries 
Recoveries of analytes were determined at two concentrations above the LLOQs 
(50 ng and 100 ng/ml, n=5). The recoveries for all analytes were in the range of 
75-101%, as shown in Table 8-9. 
Table  8-9: Recoveries of DAPs and OPs. 
MEAN RECOVERY % (RSD%, n=5) 
COMPOUND 
50ng/ml 100ng/ml 
DMP 75 (9) 78 (8) 
DEP 85 (11) 82 (5) 
DETP 81 (13) 86 (7) 
DICHLORVOS 98 (14) 93 (11) 
CHLOPYRIFOS 90 (7) 95 (5) 
DIAZINON 97 (6) 101 (6) 
PARATHION 90 (7) 95 (5) 
PARAOXON 99 (13) 97 (5) 
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8.2.7.4 Intraday and interday precision  
The precision obtained by this method was good, and the relative standard 
deviations (RSD %) for intra- and interday precisions were in the ranges 0.9-9.8 
and 1.1-10.8%, respectively, which are considered acceptable, as shown in Table 
8-10. 
Table  8-10: Intraday and interday precision results. 
Intraday mean (RSD%, n=5) Interday mean (RSD%, n=5) 
Compound 
50ng/ml 100ng/ml 50ng/ml 100ng/ml 
DMP 51(5.5) 103(1.6) 50(10.2) 104(2.8) 
DEP 50(9.8) 90(2.6) 50(10.8) 98(3.1) 
DETP 48(4.2) 99(1.3) 46(5.4) 96(4.5) 
DICHLORVOS 50(4.5) 101(2.9) 50(5.5) 101(2.7) 
CHLOPYRIFOS 49(5.6) 101(4.5) 48(5.9) 97(6.7) 
DIAZINON 52(2.7) 101(1.3) 53(2.6) 101(1.1) 
PARATHION 48(5.0) 100(3.9) 47 (7.2) 100(4.1) 
PARAOXON 49(1.8) 100(0.9) 47(4.2) 99(1.7) 
 
 
 
210 
8.2.8 Stability study  
8.2.8.1 Stabilisation study using NaF 
It has previously been reported that the addition of NaF to blood samples 
accelerates the degradation of dichlorvos and chlorpyrofos. A similar experiment 
was done here to assess the degradation of five OPs and to quantify their 
degradation products (DAPs). 
Blank blood (100 ml, pH 7.2) was divided into 5 x 20ml portions. Portions 1, 2, 3, 
4, and 5 were spiked with dichlorvous, chlorpyrifos, diazinon, parathion, and 
paraoxon, respectively, to produce a final concentration of 1000 ng/ml. Each 
portion was vortex mixed for 30 minutes on roller, then extracted in duplicate, 
and these concentrations were designated as the time zero concentrations. The 
rest of the prepared samples were spiked with NaF to give a final concentration 
of 2% (w/v) for each portion, which were then stored at room temperature. The 
prepared samples were analysed after 5 and 15 minutes, and 3, 15, 24, 48, and 
72 hours in duplicate. The pH value was measured after addition of NaF and 
before each analysis using a pH meter.   
8.2.8.2 Stabilisation in DBS 
Blank blood (10 ml) was divided into 5 x 2ml portions and each portion was 
spiked with a single OP, dichlorvous, chlorpyrifos, diazinon, parathion and 
paraxon at 1000 ng/ml. The prepared samples were vortex mixed for 30 minutes 
on roller then 100 µl of each spiked preparation was spotted on five separate 
sheets of paper to produce 20 spots, each containing 100 ng of the compound. 
The samples were analysed in duplicate at time zero, after 5 and 15 minutes, 
and 3, 15, 24, 48, and 72 hours. These results were compared with those of the 
previous experiment involving NaF. The papers holding the prepared samples 
were stored at room temperature in sealed plastic bags. 
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8.3 Results 
8.3.1 Dichlorvos  
Dichlorvos rapidly decomposed after the addition of NaF to the sample, and only 
a small amount of the compound was detected after 5 minutes, which was less 
than 3% of the original concentration. It then completely disappeared after 15 
minutes. Its degradation product, DMP, was detected 5 minutes after the 
addition of NaF to the blood and then decomposed gradually to 260 ng/ml after 
72 hours. The pH value of the sample dropped from pH 7.8 after addition of NaF 
to pH 6.5 at the end of the study. On the other hand, the degradation of 
dichlorvos in DBS was much slower than in the aliquots containing NaF, and 
approximately 75% of the parent compound could be detected after 72 hours. 
Very little DMP was detected after 24 hours of spotting, increasing gradually to 
11ng/spot. The stability results are shown in Tables 8-11 and 8-12. 
Table  8-11: Stability of dichlorvos in blood samples preserved with 2% (w/v) NaF 
DICHLORVOS 
(RSD%, n=2) 
DMP 
(RSD%, n=2) 
Total 
TIME 
ng/ml ng/ml ng/ml 
pH 
Zero 
983 
(1.3) 
0 
(0.0) 
983 7.8 
5 MINS 
30 
(6.7) 
426 
(2.1) 
456 7.5 
15 MINS 
0 
(0.0) 
395 
(1.4) 
395 7.4 
3 HOURS 
0 
(0.0) 
368 
(2.5) 
368 7.2 
15 HOURS 
0 
(0.0) 
336 
(1.3) 
336 7.1 
24 HOURS 
0 
(0.0) 
298 
(2.2) 
298 6.8 
48 HOURS 
0 
(0.0) 
281 
(1.3) 
281 6.7 
72 HOURS 
0 
(0.0) 
260 
(2.8) 
260 6.5 
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Table  8-12: Stability of dichlorvos in dried blood spots stored on filter paper 
DICHLORVOS 
(RSD%, n=2) 
DMP 
(RSD%, n=2) 
Total 
TIME 
ng/spot ng/spot ng/spot 
Zero 
101 
(2.0) 
0 
(0.0) 
101 
5 MINS 
101 
(1.4) 
0 
(0.0) 
101 
15 MINS 
102 
(2.7) 
0 
(0.0) 
102 
3 HOURS 
100 
(1.3) 
0 
(0.0) 
100 
15 HOURS 
98 
(1.5) 
0 
(0.0) 
98 
24 HOURS 
89 
(2.2) 
6 
(12.8) 
95 
48 HOURS 
81 
(1.2) 
9 
(8.3) 
90 
72 HOURS 
76 
(1.3) 
11 
(6.1) 
87 
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8.3.2 Chlorpyrifos  
After the addition of NaF to the sample containing chlorpyrifos, the 
concentration of the compound decreased gradually and lost more than 62% of 
the day zero concentration. DETP appeared after 15 minutes and the 
concentration increased gradually during the observation period. The pH of the 
sample dropped from pH 7.6 at time of adding the NaF to pH 6.6 at the end of 
study.In DBS, the degradation of chlorpyrifos was very slow and the remaining 
content of the parent compound was more than 80% of the starting 
concentration, while DETP was detected in small concentrations after 72 hours. 
The stability results are shown in Tables 8-13 and 8-14. 
Table  8-13: Stability of chlorpyrifos in blood samples preserved with 2% (w/v) NaF. 
CHLORPYRIFOS 
(RSD%, n=2) 
DETP 
(RSD%, n=2) 
Total  
TIME 
ng/ml ng/ml ng/ml 
pH 
Zero 
1009 
(0.5) 
0 
(0.0) 
1009 7.6 
5 MINS 
941 
(0.4) 
0 
(0.0) 
941 7.6 
15 MINS 
928 
(1.5) 
25 
(3.1) 
953 7.5 
3 HOURS 
821 
(2.3) 
82 
(1.7) 
903 7.3 
15 HOURS 
626 
(2.3) 
184 
(1.1) 
810 7.2 
24 HOURS 
517 
(2.5) 
216 
(1.6) 
733 6.9 
48 HOURS 
462 
(2.7) 
230 
(2.4) 
692 6.8 
72 HOURS 
381 
(1.8) 
264 
(1.0) 
645 6.6 
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Table  8-14: Stability of chlorpyrifos in dried blood spots stored on filter paper. 
CHLORPYRIfOS 
(RSD%, n=2) 
DETP 
(RSD%, n=2) 
Total  
TIME 
ng/spot ng/spot ng/spot 
Zero 
101 
(0.6) 
0 
(0.0) 
101 
5 MINS 
98 
(1.5) 
0 
(0.0) 
98 
15 MINS 
93 
(0.8) 
0 
(0.0) 
93 
3 HOURS 
96 
(1.2) 
0 
(0.0) 
96 
15 HOURS 
92 
(0.8) 
0 
(0.0) 
92 
24 HOURS 
91 
(0.9) 
4 
(5.5) 
95 
48 HOURS 
89 
(1.2) 
5 
(6.7) 
94 
72 HOURS 
87 
(1.9) 
6 
(8.1) 
93 
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8.3.3 Diazinon  
The diazinon concentration decreased gradually after the addition of NaF to the 
sample and approximately 43% of the original concentration was detected after 
72 hours, while DETP started to appear 3 hours after the start time and 
continuously increased throughout the observation time. The pH dropped from 
pH 7.6 to pH 6.8. In DBS, the diazinon concentration decreased very slowly, and 
approximately 81% of the original concentration was detected after 72 hours. A 
small amount of DETP was detected after 15 hours and increased to a small 
amount at the end of the study. The stability results are shown in Tables 8-15 
and 8-16. 
Table  8-15: Stability of diazinon in blood samples preserved with 2% (w/v) NaF. 
DIAZINON 
(RSD%, n=2) 
DETP 
(RSD%, n=2) 
Total  
TIME 
ng/ml ng/ml ng/ml 
pH 
Zero 
1002 
(1.5) 
0 
(0.0) 
1002 7.7 
5 MINS 
956 
(0.9) 
0 
(0.0) 
956 7.6 
15 MINS 
944 
(0.4) 
0 
(0.0) 
944 7.6 
3 HOURS 
845 
(0.9) 
47 
(3.1) 
892 7.2 
15 HOURS 
682 
(0.8) 
121 
(3.9) 
803 7.1 
24 HOURS 
594 
(1.9) 
163 
(1.8) 
757 6.9 
48 HOURS 
464 
(1.5) 
225 
(1.9) 
689 6.8 
72 HOURS 
431 
(1.8) 
238 
(1.2) 
669 6.8 
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Table  8-16: Stability of diazinon in dried blood spots stored on filter paper 
DIAZINON 
(RSD%, n=2) 
DETP 
(RSD%, n=2) 
Total  
TIME 
ng/spot ng/spot ng/spot 
Zero 
98 
(0.6) 
0 
(0.0) 
98 
5 MINS 
99 
(1.1) 
0 
(0.0) 
99 
15 MINS 
100 
(0.4) 
0 
(0.0) 
100 
3 HOURS 
93 
(1.3) 
0 
(0.0) 
93 
15 HOURS 
84 
(0.9) 
7 
(9.4) 
91 
24 HOURS 
82 
(1.7) 
8 
(5.2) 
90 
48 HOURS 
79 
(1.3) 
8 
(3.9) 
87 
72 HOURS 
80 
(1.9) 
8 
(2.8) 
88 
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8.3.4 Parathion  
Degradation of parathion was observed after the addition of NaF to the blood 
samples and the remaining content after 72 hours was approximately 15% of the 
original concentration. The degradation product of parathion was detected after 
5 minutes and increased gradually until the end of the experiment. During the 
degradation of parathion and the increase of DETP, the pH value of the sample 
dropped from pH 7.8 to pH 6.6 at the end of the study. In DBS, the parathion 
concentration decreased slowly and more than 82% of the parent compound 
could be detected at the end of study. The degradation product was 
detectedable after 15 hours. The stability results are shown in Tables 8-17 and 
8-18. 
Table  8-17: Stability of parathion in blood samples stored with 2% (w/v) NaF. 
PARATHION 
(RSD%, n=2) 
DETP 
(RSD%, n=2) 
Total  
TIME 
ng/ml ng/ml ng/ml 
pH 
Zero 
1000 
(0.6) 
0 
(0.0) 
1000 7.8 
5 MINS. 
833 
(0.3) 
75 
(4.9) 
908 7.7 
15 MINS. 
727 
(0.9) 
112 
(3.7) 
839 7.5 
3 HOURS 
580 
(1.8) 
137 
(2.1) 
717 7.2 
15 HOURS 
414 
(2.8) 
217 
(1.9) 
631 7.1 
24 HOURS 
366 
(3.4) 
243 
(1.2) 
609 6.9 
48 HOURS 
245 
(4.7) 
290 
(3.6) 
535 6.8 
72 HOURS 
154 
(4.9) 
325 
(2.3) 
479 6.6 
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Table  8-18: Stability of parathion in dried blood spots stored on filter paper. 
PARATHION 
(RSD%, n=2) 
DETP 
(RSD%, n=2) 
Total  
TIME 
ng/spot ng/spot ng/spot 
Zero 
96 
(0.2) 
0 
(0.0) 
96 
5 MINS. 
93 
(0.8) 
0 
(0.0) 
93 
15 MINS. 
93 
(0.6) 
0 
(0.0) 
93 
3 HOURS 
90 
(0.3) 
0 
(0.0) 
90 
15 HOURS 
83 
(0.9) 
5 
(3.4) 
88 
24 HOURS 
82 
(1.6) 
6 
(3.4) 
88 
48 HOURS 
79 
(2.2) 
8 
(4.6) 
87 
72 HOURS 
79 
(2.4) 
8 
(6.2) 
87 
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8.3.5 Paraoxon  
Paraoxon decomposed gradually 5 minutes after the addition of NaF and 
completely disappeared after 24 hours, while its degradation product DEP was 
detected after 5 minutes and increased gradually during the degradation of the 
parent compound. It then decreased gradually after 15 hours and continued to 
decrease until the end of the study. The sample pH value decreased from pH 7.9 
after the addition of NaF to pH 6.9 at the end of the study. Paraoxon in DBS 
decreased slowly during the study and approximately 76% of the original 
concentration was recovered at the end. DEP was detected in a small amount 
after 24 hours and at the end of the study. The stability results are given in the 
table 8-19 and 8-20. 
Table  8-19: Stability of paraoxon in blood sample preserved with 2% (w/v) NaF. 
PARAOXON 
(RSD%, n=2) 
DEP 
(RSD%, n=2) 
Total  
TIME 
ng/ml ng/ml ng/ml 
pH 
Zero 
999 
(0.2) 
0 
(0.0) 
999 7.9 
5 MINS. 
790 
(0.1) 
89 
(3.2) 
879 7.9 
15 MINS. 
625 
(0.4) 
115 
(1.3) 
740 7.7 
3 HOURS 
107 
(3.4) 
308 
(1.2) 
415 7.6 
15 HOURS 
56 
(5.2) 
315 
(0.9) 
371 7.5 
24 HOURS 
0 
(0.0) 
203 
(1.7) 
203 7.3 
48 HOURS 
0 
(0.0) 
191 
(1.5) 
191 7.1 
72 HOURS 
0 
(0.0) 
188 
(3.1) 
188 6.9 
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Table  8-20: Stability of paraoxon in dried blood spot stored on filter paper. 
PARAOXON 
(RSD%, n=2) 
DEP 
(RSD%, n=2) 
Total  
TIME 
ng/spot ng/spot ng/spot 
Zero 
102 
(1.4) 
0 
(0.0) 
102 
5 MINS. 
101 
(2.1) 
0 
(0.0) 
101 
15 MINS. 
101 
(1.1) 
0 
(0.0) 
101 
3 HOURS 
99 
(0.2) 
0 
(0.0) 
99 
15 HOURS 
97 
(0.8) 
0 
(0.0) 
97 
24 HOURS 
85 
(0.7) 
6 
(10.8) 
91 
48 HOURS 
83 
(0.9) 
7 
(5.5) 
90 
72 HOURS 
78 
(1.8) 
9 
(6.5) 
87 
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8.3.6 Summary of pesticides stability using different 
preservative methods 
Summary of pesticides stability after 3 days using 2% (W/V) NAF or DBS as 
stabilizing method is shown in Table 8-21. 
Table  8-21: Summary of pesticides stability in DBS or using 2% (W/V) NAF 
Compound Conditions Results Comment 
2% (W/V) NAF, 3 days 
100% decrease 
after 15 minutes 
Dichlorvos 
DBS, 3 days 25% decrease  
2% (W/V) NAF, 3 days 62% decrease  
Chlorpyrifos 
DBS, 3 days 13% decrease  
2% (W/V) NAF, 3 days 57% decrease  
Diazinon 
DBS, 3 days 18% decrease  
2% (W/V) NAF, 3 days 85% decrease  
Parathion 
DBS, 3 days 18% decrease  
2% (W/V) NAF, 3 days 
100% decrease 
after 24 hours 
Paraoxon 
DBS, 3 days 24% decrease  
• DAP 
concentration 
increased as 
parent 
compound 
concentration 
decreased 
• Stability 
increased 
when using 
filter paper 
instead of NAF 
• NAF 
accelerated 
formation of 
degradation 
compounds  
• NAF must not 
be used as a 
preservative 
for OPs 
compounds 
• The extent of 
degradation is 
different from 
compound to 
compound and 
is related to 
the chemical 
structure  
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8.4 Discussion 
OPs were found to be unstable under different storage temperatures as reported 
previously.87 The presence of ester functional groups in the OPs made them 
prone to hydrolysis reactions, which accelerated under alkaline or acidic 
conditions to produce acidic and phenolic compounds as degradation products.  
Esterases metabolise OPs through hydrolysis to produce dialkylphosphates and a 
leaving group. These enzymes are divided into three groups: A, B, and C. The 
classification is based on their activity toward phosphate triesters. Esterase 
activity is known to continue a short time after death and some of these 
enzymes can hydrolyse OPs, such as A-esterase (paroxygenase), while others are 
inhibited by OPs, such as AChE. The addition of an anti-enzymatic compound is 
essential to preserve the OPs against the activity of these enzymes.202 
NaF is the most common preservative, usually used in forensic toxicology to 
preserve the analyte from decomposition by enzymes or bacterial activity that 
may take place in the sample and may influence compound stability. Although 
NaF can inhibit the enzyme that hydrolyses OPs, its addition to the blood sample 
was found to accelerate the degradation of these compounds, as reported 
previously and shown again in this study.88,99 The blood pH became more alkaline 
during hydrolysis of the OPs and the degradation can be attributed to an 
autocatalytic alkaline hydrolysis. Hydrolysis of OPs yields DAPs as major 
degradation products and their detection in a sample usually indicates OP 
exposure. However, these markers are common to several OPs and are not 
specific for a particular starting compound. They are generally analysed to 
assess OP exposure. According to the chemical structure of the compound, each 
OP is hydrolysed to yield a single DAP. For example, dichlorvos is hydrolysed to 
produce DMP, while chlorpyrifos, diazinon, and parathion are hydrolysed to 
produce DETP and paraoxon is hydrolysed to produce DEP. Therefore, the 
detection of DAP can indicate the presence of a specific OP. All compounds were 
sensitive to NaF and the pH increased after the addition of this preservative to 
the sample. The decomposition rates of the compounds were not the same 
because of differences in structure.  
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Dichlorvos and paraoxon were found to be less stable than chlorpyrifos, diazinon, 
and parathion. They also decomposed very quickly, which may be because both 
compounds are derivatives of orthophphoric acid whereas the other compounds 
are derivatives of thiophosphoric acid. Oxygen is more electronegative than 
sulphur and thiophosphates exhibit more resistance to hydrolysis than dichlorvos 
and paraoxon. Furthermore, diazinon showed greater stability than chlorpyrifos 
and parathion, possibly because there was no electron withdrawing substituent 
in the leaving group of diazinon, unlike chlorpyrifos, which has 3 chlorine atoms 
in its structure and parathion, which has a nitro group that could accelerate the 
hydrolysis process. 
The role of NaF may not only be to increase the pH of the sample to alkaline, 
but also to supply fluoride anion to act as a nucleophile, which attacks the 
positively charged phosphorus atom, thereby accelerating the decomposition 
process. 
The findings of the current study are in agreement with the results of Moriya et 
al. who reported that dichlorvos completely disappeared within 15 minutes of 
the addition of NaF to the blood sample while chlorpyrifos was found to be very 
unstable under these conditions.88 In the present study, all compounds showed 
poor stability after the addition of NaF.  
The drop in pH during the study is attributed to the acidity of DAPs, produced 
when the parent compound decomposed while the loss in the concentration was 
decreased in acidic pH. The parent OPs decomposed more rapidly than the DAP 
products, which may degrade further to monoalkyl phosphates and then to 
inorganic phosphate. The advantages of detection of DAPs in addition to the 
parent OPs, are that they can be detected even when the parent compounds 
have completely disappeared. 
Storing OPs in DBS minimised the hydrolysis degradation of all compounds 
compared to the addition of NaF, and all compounds could be detected after 3 
days. Furthermore, DAPs were detected in small levels. Therefore, the 
degradation of OPs at room temperature or during transportation at a high 
temperature should be considered and preserving these compounds on filter 
paper would help to minimise their degradation. A practical approach to the use 
of DBS would be to collect blood at autopsy as usual and spot an aliquot on 
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paper, allow it to dry and then seal in a plastic or paper bag, the latter being 
used for wet DNA samples. 
The initial blood pH ranged from 7.2 to 7.4 and, as observed in this study, OPs 
were found to decompose continuously. Acidification of the sample with EDTA/K 
or heparin/lithium reduced the degradation of OPs, as reported by Asri.99 Alos in 
this study and under acidic conditions, OPs were noted to decrease slower than 
in an alkaline pH. Furthermore, these additives are anticoagulants and don’t 
inhibit esterase, which may be present in the blood sample. Therefore, 
dehydration of the sample in filter paper is a promising preservation method to 
minimise the enzymatic and chemical hydrolysis of these compounds. 
The total amount of OPs and their DAP metabolites can be used to indicate the 
original OP concentration. Further studies seem to be necessary in order to 
assumption of the OP and its specific leaving group product (if they are available 
commercially), in addition to the specific DAP and its further degradation 
products in order to give the original OP concentration.   
Decomposition of OP after death may result from the continuous activity of the 
esterase enzyme and the concentration of OP in a suspected poisoning case is 
lower than at the time of death. Detection of the degradation products may help 
forensic toxicologists estimate the concentration of OPs that may have caused 
the death.  
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8.5 Conclusions 
In conclusion, NaF should not be added as a preservative to blood samples 
containing OPs as it may act as a catalyst for their hydrolysis. The rate of 
decomposition can be reduced when blood samples are stored in filter paper, 
which was found to be a promising alternative method to preserving OPs against 
degradation. The concentrations of degradation products for each OP can be 
added to those of the parent compounds to estimate the original concentration. 
Dehydration of the sample stored in paper, in addition to the assumption of 
degradation products to the parent compound, could help to preserve and 
indicate the original concentration of the parent compound at the time of 
sampling. Furthermore, storing the DBS samples in a cold place, such as the 
freezer, will enhance the stability, as described earlier in the previous chapters 
of this thesis. 
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9 Conclusions and Future Work 
The possibility of a decrease in concentration of an analyte in biological 
specimens during storage should be considered, even if samples are stored at 
-20ºC. Under the same storage conditions different compounds exhibit different 
stabilities according to their chemical structures. Drugs containing ester or 
amide groups are prone to degradation by hydrolysis reactions, and this should 
be carefully considered when they are being transported or stored and during 
the interpretation of results. Although oxazepam, lorazepam, alprazolam and 
estazolam belong to the same drug class, they exhibit different stabilities that 
can be attributed to the presence of an amide group in oxazepam and lorazepam 
which make these compounds more sensitive to degradation by hydrolysis 
reactions, leading to a decrease in their concentration during storage, whereas 
alprazolam and estazolam exhibit more stability due to the presence of a 
triazolo ring instead of an amide group that make these compounds more 
resistant to this degradation process and more stable for long time periods. 
Addition of preservatives and anticoagulants to samples containing 
benzodiazepines showed little enhancement of stability without a possible loss 
of concentration by preservatives used NaF while anticoagulant should be added 
to blood samples to prevent them from coagulating, which makes sample 
analysis difficult. High and low concentrations of the same drug showed different 
stabilities: high concentrations can be detected for a long time in comparison to 
low concentrations, and this should be considered in the interpretation of 
samples with either therapeutic or toxic concentrations of drugs.  
 
The opiate glucuronides M3G, M6G and C6G exhibited different stabilities under 
different storage conditions and in different matrices. These metabolites showed 
more stability when stored at negative temperatures however even then 
significant losses were observed and these could influence the interpretation. 
Samples should be stored in a freezer at -20 °C or less in order to preserve the 
compounds for a long period, while additives should be added even if they result 
in only a small improvement in stability as this may be greater in post-mortem 
samples, which are known to contain bacteria that may accelerate the 
decomposition of these compounds and limit their detection. C6G was more 
stable than M3G and M6G which can be explained on the basis of differences in 
their chemical structures. M3G and M6G may undergo both hydrolysis and 
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oxidation reactions because of the presence of a phenolic moiety in their 
structures while in C6G this group is alkylated, so further study is suggested on 
the use of antioxidant substances, such as ascorbic acid or sodium metabisulfite 
to examine their effects on the stability of morphine metabolites with respect to 
oxidation. Storage conditions were not the only factor influencing the stability of 
these metabolites, but the nature of the biological matrix also had an effect: 
they are more stable in blood than urine, which should be considered in 
interpretation of results. 
 
An assessment was made of the degradation of diazepam, temazepam, 
chlordiazepoxide and oxazepam stored in blood and urine for one month at a 
high temperature of 80 °C under alkaline and acidic conditions. Under all 
conditions, the degradation of diazepam and temazepam in blood and urine 
produced MACB as the main hydrolysis product, while degradation of oxazepam 
and chlordiazepoxide produced ACB as the main hydrolysis product. The rate of 
degradation is accelerated most by alkaline conditions, then by high 
temperature then by acidic conditions. Similar to opiate glucuronides, the 
degradation of benzodiazepines in urine is faster than in blood. The pH of the 
matrix and lack of protective protein binding in urine may explain this. The 
degradation product MACB was found to be degraded further into ACB. A 
validated method was applied to case samples of blood and urine and the 
degradation products MACB and ACB were detected in all urine samples but not 
in blood. That may have been because these compounds were influenced by 
urine matrix or affected by enzymes used in the sample preparation step of the 
analysis to cleave the glucuronides. MACB and ACB concentrations increased as 
the degradation of the drugs proceeded and they could be detected when the 
parent drugs had completely disappeared. MACB and ACB can be reliably 
detected in whole blood and urine and can be used to correct for losses of 
parent drugs. They can also indicate the original presence of these compounds if 
case samples were suspected to have contained benzodiazepines and the parent 
compounds were not detected.  
A new method was developed and validated to determine OPs and their 
degradation product DAPs by SPE followed by GCMS analysis after suitable 
derivatization. Addition of preservatives to the blood samples containing OPs 
elevated the pH value of the samples, thereby accelerating the degradation of 
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these compounds. However, during this degradation process DAP compounds 
were produced and these increased in concentration as the parent compounds 
decreased. Esters of orthophosphoric acid are degraded faster than those of 
thiophosphoric acid because the electronigativity of oxygen is higher than 
sulphur. Storage of blood samples containing OPs in filter paper showed 
enhancement of their stability compared to the use of preservatives and the 
compounds were detected for longer time periods. The DBS technique has been 
shown to be useful in reducing the enzymatic and chemical hydrolysis of these 
compounds.  
For benzodiazepines and cocaine a validated method was developed which can 
be used for the quantitative analysis of drugs in small volumes of blood 
contained in dry blood spots. The DBS technique provides a suitable procedure 
for the storage and analysis of samples in forensic toxicology because they are 
easy to handle, transport and to store in the laboratory, even in the absence of 
refrigeration, which can be a problem in some countries. It permits the analysis 
of a small volume of sample and, as a result, frequent collection of blood 
samples from living donors is possible. In addition, the test analytes chosen for 
this study were drugs which are known to be rapidly degraded in biological 
samples and these were preserved when stored on paper, instead of adding the 
usual preservatives and anticoagulants. For some substances the addition of 
preservatives is not recommended as they may accelerate degradation, for 
example, organophosphorus pesticides, while anticoagulants are not 
recommended for other drugs as they can increase their concentrations, for 
example morphine. The DBS technique is therefore recommended as an 
additional procedure to be used in conjunction with conventional methods for 
preserving unstable drugs from decomposition and for avoiding potential errors 
in interpretation of analytical results resulting from the addition or absence of 
preservatives and anticoagulants.  
 
The water present in blood samples plays a very important role in hydrolysis 
reactions as an active agent which cleaves drug molecules. The use of filter 
paper to store samples resulted in enhancement of drug stability due to the 
dehydration of the sample and consequent minimalisation of enzymatic and 
chemical hydrolysis of the drugs and hydrolycally labile compounds. Degradation 
of drugs in DBS at all storage conditions was less than for the corresponding 
liquid blood samples stored under similar conditions.  
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Interpretation of results obtained from samples stored long-term should be 
carefully interpreted to avoid serious errors.  Ideally, analyses should be 
performed as soon as sample received and the samples should be stored at 
-20 °C or lower to keep the drug stable for a long time. The preservative should 
be carefully selected according to the analyte while NaF should not be added to 
samples containing OP compounds. 
Extended transportation time and increased environmental temperature may 
affect the pH of the sample, for example the pH of urine samples may exceed 
pH 9 within 2 days, destroying drugs and giving false negative results. 
Degradation products are promising compounds as markers that can indicate the 
former presence of specific drugs in cases in which the parent drug has been lost 
due to poor storage conditions. Further preservation of the sample in filter 
paper can keep the drug stable for a longer period of time. Stabilization of drugs 
using filter paper in addition to quantification of degradation products can help 
in estimating the original concentrations of compounds at the time of sampling.  
The DBS technique also needs to be validated and used for other groups of drugs 
to assess their stability using this technique in comparison to liquid samples. In 
some countries, including Saudi Arabia, urine samples are usually transported 
from distant places and that may take 1 or 2 days before they arrive in the 
central screening lab. Most of the samples are negative despite the suspected 
presence of drugs, and that may be as a result of poor storage conditions during 
transportation under high temperature. Stabilization of samples using the DBS 
technique may present an inexpensive, practical method to stabilize drugs of 
interest during transportation. 
Further studies should be carried out to determine the degradation products of 
other benzodiazepines such as ANB, ADB and MNFB which produced from 
degradation of nitrazepam, lorazepam and flunitazepam respectively. Similarly, 
further work would permit the determination of degradation products of other 
OPs, in particular DAPs and their leaving groups.  
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Stability of alprazolam, estazolam, lorazepam and oxazepam in 
whole blood at different storage conditions 
 
 
Alfazil A.A and Anderson R.A.  
Department of Forensic Medicine and Science, University of Glasgow, Glasgow 
G12 8QQ, UK 
 
This study has been undertaken to investigate the stability over one year of four 
drugs, all within the benzodiazepines class. For these tests, blank blood was 
spiked at low and high concentrations and stored in tubes containing no 
preservative or else containing fluoride-oxalate at -20° C, 4°C and room 
temperature. The times selected for analysis were, the first (day zero), second 
and fourth days, one week, two weeks, one month, two months, three months, 
six months and one year. Solid phase extraction was used for extracting the 
samples while the analysis was performed using liquid chromatography-tandem 
mass spectrometry.  Alprazolam and estazolam were stable at -20° C and 4° C, 
however a decrease of almost 10% in the concentration was observed at room 
temperature for both drugs at low and high concentrations. Lorazepam and 
oxazepam were stable at -20°C.  However, at 4° C lorazepam decreased by 50% 
and 28% for low and high concentrations respectively, while oxazepam decreased 
by 31% and 26% for low and high concentration respectively. At room 
temperature, both oxazepam and lorazepam decreased by 100% at low and high 
concentration. The addition of sodium fluoride enhanced the stability of the 
drugs by 10% in comparison with unpreserved samples. The long-term stability of 
alprazolam and estazolam is attributed to the presence of the trizolo ring in 
their structures, which makes the compounds more resistant to hydrolysis 
reactions, which of the most like degradation reactions affecting the stability of 
benzodiazepines drugs. 
 
Key words: stability, benzodiazepines, storage condition, blood. 
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STABILITY OF BENZODIAZEPINES AND COCAINE IN BLOOD SPOTS 
STORED ON FILTER PAPER. 
 
Alfazil A.A and Anderson R.A. 
Forensic Medicine and Science, Faculty of Medicine, University of Glasgow, 
Glasgow G12 8QQ, United Kingdom. 
 
 
Previous studies have shown that drug concentrations in blood can change during 
storage, especially at room temperature, but even labile drugs such as cocaine 
may be stable in dried blood spots (DBS).  A new method has been developed for 
the analysis of hydrolytically-labile drugs in blood spots on filter paper in order 
to assess their degradation during a storage period of one month.  
  
The drugs selected included flunitrazepam, temazepam, oxazepam, lorazepam, 
nitrazepam, diazepam and cocaine.  A Guthrie card 903 was spotted with 100 µl 
of blood containing the drugs at concentrations of 1000ng/ml and left overnight 
to dry at room temperature.  The filter paper was suspended in extraction buffer 
for 1 hour with ultrasonication.  Drugs were then extracted from the buffer by 
solid phase extraction using Clean Screen® columns and analysed by liquid 
chromatography-tandem mass spectrometry.  Method validation showed that all 
calibration curves were linear over the concentration range 5-200 ng/spot with 
correlation coefficients of 0.994-0.999.  Inter-day and intra-day precisions at 
three concentrations (10, 50 and 100ng/spot) were 1.6-18.3% and 2.8-14.7% 
respectively. Limits of detection were 0.29-0.74 ng/spot while lower limits of 
quantitation were 0.99-2.46 ng/spot. Recoveries of all analytes were in the 
range 81-106%. 
 
DBS were stored in duplicate at room temperature, 4°C and -20°C for up to one 
month.  Degradation of the drugs in DBS at all storage conditions was less than 
for the corresponding liquid blood samples stored under similar conditions and 
more than 80% of each analyte could be recovered from the samples. 
 
Key words: dried blood spots, filter paper, drug stability, blood analysis. 
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Correction for drug loss during storage: decomposition of diazepam and temazepam 
in whole blood under different storage conditions 
 
A.ALFAZIL, R.A.ANDERSON 
Forensic Medicine and Science, Faculty of Medicine, University of Glasgow, Glasgow 
G12 8QQ, UK 
 
Introduction:  Loss of analyte from biological samples during the post-mortem interval or 
during storage has potentially serious implications in forensic toxicology, and it would be 
of value to make corrections for these losses. This initial study evaluated one approach to 
this problem based on measurement of the main hydrolysis decomposition product of 
diazepam and temazepam, 2-methylamino 5-chlorobenzophenone (MACB).  Previous 
studies have reported on the instability of diazepam and temazepam under different storage 
conditions. The aims of this study were to determine MACB in whole blood as an indicator 
of the extent of analyte degradation as well to investigate the effects of temperature and pH 
on the stability of diazepam and temazepam for one month. 
Method: Blank blood was spiked with diazepam and temazepam to produce final 
concentrations of 1000 ng/ml of each. It is known from previous work that these drugs are 
stable for long periods of time, therefore, for the purposes of this study, degradation of the 
drugs was accelerated by storing aliquots of blood at high temperature (80°C) and under 
acidic (pH 2) and basic (pH 12) conditions at room temperature for one month. The 
samples were analyzed in duplicate at days 1, 2, 4, 7, 14 and 30. Samples were extracted 
by solid phase extraction and extracts were analysed by liquid chromatography-tandem 
mass spectrometry.  
Results: Recoveries of all analytes were between 85-102%. The linear correlation 
coefficients for all three analytes were better than 0.99. Limits of detection and lower 
limits of quantitation were 0.1-2 ng/ml and 0.4-7 ng/ml respectively. Intra-day and inter-
day precisions were found to be 4-17% and 4-18% respectively. After one month, the 
diazepam concentration at 80 °C, pH 2 and pH 12 had decreased from the original 
concentration by 30, 25 and 49 % respectively whereas temazepam decreased by 100%, 
77% and 100% respectively. Under all sets of conditions the MACB concentration was 
observed to increase as degradation of the drugs proceeded and it could be detected when 
the parent drugs concentration were completely disappeared.  However, MACB itself was 
found to be further degraded under some of the conditions used. Diazepam and temazepam 
are more sensitive to alkaline pH than to acidic pH or high temperature. Diazepam was 
noted to be more stable than temazepam. 
Conclusion: Degradation of diazepam and temazepam in the blood under different 
conditions will produce MACB as the main hydrolysis product. MACB can be reliably 
detected in whole blood and can be used to correct for losses of diazepam and temazepam 
and to indicate the original diazepam concentration.  MACB can also be used to confirm 
the presence of these drugs in samples, especially when the drug has decomposed due to 
poor or prolonged storage conditions.  
 
KEYWORDS: benzodiazepines, degradation, whole blood, MACB. 
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Correction for Drug Loss During Storage: Decomposition of Chlorodiazepoxide and 
Oxazepam in Whole Blood Under Different Storage Conditions 
 
Abdulkareem.A.Alfazil* and Robert.A.Anderson 
Forensic Medicine and Science, Faculty of Medicine, University of Glasgow, Glasgow 
G12 8QQ, UK 
 
Introduction:  Decomposition of analytes in biological samples during the post-mortem 
interval or during storage has been reported in the previous studies which leading to loss of 
the original concentration thus it would be of value to make corrections for these losses. 
This initial study evaluated one approach to this problem based on measurement of the 
main hydrolysis decomposition product of chlorodiazepoxide and oxazepam, 2-amino 5-
chlorobenzophenone (ACB).  Previous studies have reported on the instability of 
chlorodiazepoxide and oxazepam under different storage conditions. The aims of this study 
were to determine ACB in whole blood as an indicator of the extent of analyte degradation 
as well to investigate the effects of temperature and pH on the stability of 
chlorodiazepoxide and oxazepam for one month using the same method of our work in 
TIAFT2008 to correct the loss of diazepam and temazepam in whole blood. 
Method: Blank blood was spiked with chlorodiazepoxide and oxazepam to produce final 
concentrations of 1000 ng/ml of each. It is known from previous work that these drugs are 
stable for more than one month, therefore, for the purposes of this study, degradation of the 
drugs was accelerated by storing aliquots of blood at high temperature (80°C) and under 
acidic (pH 2) and basic (pH 12) conditions at room temperature for one month. The 
samples were analyzed in duplicate at days 1, 2, 4, 7, 14 and 30. Samples were extracted 
by solid phase extraction and extracts were analysed by liquid chromatography-tandem 
mass spectrometry.  
Results: Recoveries of all analytes were between 83-97%. The linear correlation 
coefficients for all three analytes were better than 0.99. Limits of detection and lower 
limits of quantitation were 0.46-2.3 ng/ml and 1.5-7.5 ng/ml respectively. Intra-day and 
inter-day precisions were found to be 1-13% and 2-18% respectively. After one month, the 
chlorodiazepoxide concentration at 80 °C, pH 2 and pH 12 had decreased from the original 
concentration by 62, 51 and 100 % respectively whereas oxazepam decreased by 100%, 
99.7% and 100% respectively. Under all sets of conditions the ACB concentration was 
observed to increase as degradation of the drugs proceeded and it could be detected when 
the parent drugs concentration were completely disappeared. However, ACB itself was 
found to be further degraded under some of the conditions used. Chlorodiazepoxide and 
oxazepam are more sensitive to alkaline pH than to acidic pH or high temperature. 
Chlorodiazepoxide was noted to be more stable than oxazepam. 
Conclusion: Degradation of chlorodiazepoxide and oxazepam in the blood under different 
conditions will produce ACB as the main hydrolysis product. ACB can be reliably detected 
in whole blood and can be used to correct for losses of chlorodiazepoxide and oxazepam 
and to indicate the original drug concentration. ACB can also be used to confirm the 
presence of these drugs in samples, especially when the drug has decomposed due to poor 
or prolonged storage conditions.  
 
KEYWORDS: benzodiazepines, degradation, ACB. 
 
 
 
262 
12 Specimen Chromatograms  
RT: 2.00 - 11.00 SM: 15G
2 3 4 5 6 7 8 9 10 11
Time (min)
0
20
40
60
80
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
0
20
40
60
80
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
0
20
40
60
80
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
0
20
40
60
80
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
ESTAZOLAM
RT: 5.48
AA: 2478167988
OXAZEPAM
RT: 5.60
AA: 973745395
LORAZEPAM
RT: 6.46
AA: 1361912941
ALPRAZOLAM
RT: 6.45
AA: 1896729772
NL: 3.91E7
m/z= 266.5-267.5 F: 
+ c ESI Full ms2 
295.00@40.00 [ 
80.00-350.00]  MS  
ICIS TEST4
NL: 1.58E7
m/z= 268.5-269.5 F: 
+ c ESI Full ms2 
287.00@26.00 [ 
75.00-300.00]  MS  
ICIS TEST4
NL: 2.53E7
m/z= 302.5-303.5 F: 
+ c ESI Full ms2 
321.00@28.00 [ 
85.00-350.00]  MS  
ICIS TEST4
NL: 3.35E7
m/z= 280.5-281.5 F: 
+ c ESI Full ms2 
309.00@41.00 [ 
85.00-350.00]  MS  
ICIS TEST4
 
 
 
263 
RT: 2.50 - 4.35 SM: 11G
2.5 3.0 3.5 4.0
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
M3G
RT: 3.42
AA: 21319202
NL: 1.41E6
m/z= 285.5-286.5 F: 
+ c ESI Full ms2 
462.00@29.00 [ 
125.00-500.00]  MS  
ICIS TEST6
 
 
 
 
264 
RT: 5.50 - 7.10 SM: 11G
5.6 5.8 6.0 6.2 6.4 6.6 6.8 7.0
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
M6G
RT: 6.25
AA: 24113181
NL: 1.32E6
m/z= 285.5-286.5 F: 
+ c ESI Full ms2 
462.00@29.00 [ 
125.00-500.00]  MS  
ICIS TEST6
 
 
 
 
265 
RT: 10.00 - 12.30 SM: 11G
10.0 10.5 11.0 11.5 12.0
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
C6G
RT: 11.09
AA: 120980896
NL: 1.00E7
m/z= 299.5-300.5 F: 
+ c ESI Full ms2 
476.00@30.00 [ 
130.00-500.00]  MS  
ICIS TEST6
 
 
 
 
266 
RT: 0.00 - 20.00 SM: 15G
0 5 10 15 20
Time (min)
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100 COCAINE
RT: 4.02
AA: 1746143761
OXAZEPAM
RT: 5.47
AA: 279743114
LORAZEPAM
RT: 6.55
AA: 258935778
NITRAZEPAM
RT: 6.32
AA: 24631590
TEMAZEPAM
RT: 9.14
AA: 1048841891
FLUNITRAZEPAM
RT: 9.47
AA: 118397591
DIAZEPAM
RT: 11.74
AA: 187636141
NL: 1.38E7
m/z= 181.5-182.5 F: + c ESI 
Full ms2 304.00@32.00 [ 
80.00-350.00]  MS  ICIS 
TEST13
NL: 2.28E6
m/z= 268.5-269.5 F: + c ESI 
Full ms2 287.00@26.00 [ 
150.00-350.00]  MS  ICIS 
TEST13
NL: 2.10E6
m/z= 302.5-303.5 F: + c ESI 
Full ms2 321.00@28.00 [ 
150.00-350.00]  MS  ICIS 
TEST13
NL: 2.00E5
m/z= 253.5-254.5 F: + c ESI 
Full ms2 282.00@41.00 [ 
150.00-350.00]  MS  ICIS 
TEST13
NL: 8.43E6
m/z= 282.5-283.5 F: + c ESI 
Full ms2 301.00@28.00 [ 
150.00-350.00]  MS  ICIS 
TEST13
NL: 9.74E5
m/z= 285.5-286.5 F: + c ESI 
Full ms2 314.00@40.00 [ 
150.00-350.00]  MS  ICIS 
TEST13
NL: 1.50E6
m/z= 256.5-257.5 F: + c ESI 
Full ms2 285.00@40.00 [ 
150.00-350.00]  MS  ICIS 
TEST13
 
 
 
 
267 
RT: 0.00 - 19.00 SM: 15G
0 5 10 15
Time (min)
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100 OXAZEPAM
RT: 5.34
AA: 479039687
CHLORDIAZEPOXIDE
RT: 5.95
AA: 1061020827
TEMAZEPAM
RT: 8.79
AA: 1381861735
5.960.83 2.79 4.19
DIAZEPAM
RT: 11.53
AA: 1076420279
AB
RT: 12.36
AA: 38955753
ACB
RT: 14.11
AA: 2828954
MACB
RT: 15.89
AA: 84275763
10.59 11.86
NL: 8.88E6
m/z= 268.5-269.5 F: + c ESI 
Full ms2 287.00@26.00 [ 
150.00-350.00]  MS  ICIS 
TEST11
NL: 2.03E7
m/z= 282.5-283.5 F: + c ESI 
Full ms2 300.00@30.00 [ 
100.00-350.00]  MS  ICIS 
TEST11
NL: 2.55E7
m/z= 282.5-283.5 F: + c ESI 
Full ms2 301.00@28.00 [ 
80.00-350.00]  MS  ICIS 
TEST11
NL: 2.38E7
m/z= 256.5-257.5 F: + c ESI 
Full ms2 285.00@40.00 [ 
75.00-2000.00]  MS  ICIS 
TEST11
NL: 7.26E5
m/z= 119.5-120.5 F: + c ESI 
Full ms2 198.00@35.00 [ 
100.00-250.00]  MS  ICIS 
TEST11
NL: 5.74E4
m/z= 153.5-154.5 F: + c ESI 
Full ms2 232.00@36.00 [ 
100.00-300.00]  MS  ICIS 
TEST11
NL: 1.68E6
m/z= 227.5-228.5 F: + c ESI 
Full ms2 246.00@35.00 [ 
200.00-300.00]  MS  ICIS 
TEST11
 
 
 
 
268 
RT: 4.50 - 5.20 SM: 15G
4.5 4.6 4.7 4.8 4.9 5.0 5.1 5.2
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
DMP
RT: 4.90
AA: 18358699
NL: 2.36E6
m/z= 182.50-183.50 F: 
{0;0}  + c EI 
det=349.00 Full ms [ 
40.00-500.00]  MS  
ICIS TEST11
 
 
 
 
269 
RT: 5.80 - 6.30 SM: 15G
5.8 5.9 6.0 6.1 6.2 6.3
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
DEP
RT: 6.06
AA: 54204820
NL:
7.18E6
m/z= 
154.50-
155.50  MS 
 ICIS 
TEST11
 
 
 
 
270 
RT: 6.20 - 6.90 SM: 15G
6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
DETP
RT: 6.59
AA: 11479476
NL:
1.55E6
m/z= 
226.50-
227.50  MS 
 ICIS 
TEST7
 
 
 
 
271 
 
 
 
RT: 3.40 - 4.50 SM: 15G
3.4 3.6 3.8 4.0 4.2 4.4
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
DICHLORVOS
RT: 3.94
AA: 32887034
NL: 3.70E6
m/z= 108.50-109.50 
F: {0;0}  + c EI 
det=349.00 Full ms [ 
40.00-500.00]  MS  
ICIS TEST6
 
272 
 
 
 
RT: 12.60 - 13.10 SM: 15G
12.6 12.7 12.8 12.9 13.0 13.1
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
CHLORPYROFOS
RT: 12.88
AA: 13942111
NL: 1.83E6
m/z= 196.50-197.50 
F: {0;0}  + c EI 
det=349.00 Full ms [ 
40.00-500.00]  MS  
ICIS TEST3
 
273 
 
 
 
RT: 10.60 - 11.20 SM: 15G
10.6 10.7 10.8 10.9 11.0 11.1 11.2
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
DIAZINON
RT: 10.94
AA: 75648878
NL: 9.99E6
m/z= 178.50-179.50 
F: {0;0}  + c EI 
det=349.00 Full ms [ 
40.00-500.00]  MS  
ICIS TEST8
 
274 
 
 
 
RT: 12.50 - 13.30 SM: 15G
12.6 12.8 13.0 13.2
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
PARATHION
RT: 12.91
AA: 92171286
13.25
NL: 1.22E7
m/z= 96.50-97.50 F: 
{0;0}  + c EI 
det=349.00 Full ms [ 
40.00-500.00]  MS  
ICIS TEST12
 
275 
 
 
 
RT: 11.80 - 12.50 SM: 15G
11.8 11.9 12.0 12.1 12.2 12.3 12.4 12.5
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
PARAOXON
RT: 12.15
AA: 49818552
NL: 6.58E6
m/z= 108.50-109.50 F: 
{0;0}  + c EI 
det=349.00 Full ms [ 
40.00-500.00]  MS  
ICIS TEST16
 
276 
 
 
 
RT: 10.55 - 11.10 SM: 15G
10.6 10.7 10.8 10.9 11.0 11.1
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
tiv
e
 
Ab
u
n
da
n
ce
DIAZINON-D10
RT: 10.82
AA: 120435972
NL: 1.60E7
m/z= 137.50-138.50 
F: {0,0}  + c EI 
det=349.00 Full ms [ 
40.00-500.00]  MS  
ICIS TEST2
 
 
 
 
